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Abstract 
The key aim was to characterise Nuclear factor-κB (NF-κB) inhibitors in 
four multiple myeloma (MM) cell lines to evaluate their use as potential 
therapeutic agents in this incurable haematological malignancy. The NF-κB 
inhibitors were characterised in terms of their effects on cytotoxicity, nuclear 
NF-κB activity, global gene expression changes and the survival protein Mcl-1. 
Using this workflow, the following inhibitors were investigated: the 
commercial non-specific NF-κB inhibitor BAY 11-7082; a series of first-in-class 
putative IKKα inhibitors (SU compounds); and a novel putative NIK inhibitor 
(CW15337) in MM cell lines. 
BAY 11-7082, CW15337 and most of the SU compounds induced dose-
dependent cytotoxicity in the MM cell lines. For BAY 11-7082 and CW15337, 
cytotoxicity was associated with dose-dependent changes in NF-κB activity, 
although BAY 11-7082 inhibited both the canonical and the non-canonical NF-
κB pathway, whereas CW15337 specifically inhibited the non-canonical NF-κB 
activity. In addition, the apoptosis induced by CW15337 was accompanied by 
a dose-dependent decrease in Mcl-1 expression in all tested MM cell lines.  
In contrast, the cytotoxicity of the SU compounds did not correlate with 
the dose-dependent down-regulation of Mcl-1 expression or NF-κB activity, 
and could not be completely explained by the SU compounds IKKα, IKKβ and 
CDK9 inhibitory profiles. Microarray analysis indicated a large disparity 
between the numbers of genes differentially regulated by some of the SU 
compounds; the number altered and the magnitude of the changes was 
associated with their cytotoxicity. Therefore, it seems likely that the increased 
potency of some of the SU compounds was caused by off-target effects.  
Overall, this work supports the concept of NF-κB as a molecular target 
in MM and suggests that NIK inhibition may present the most promising 
therapeutic option for specific non-canonical NF-κB targeting in MM. 
However, a more detailed investigation of CW15337 across the kinome is 
merited. 
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Chapter 1- Introduction 
1.1. Multiple myeloma (MM) 
Multiple myeloma (MM) accounts for approximately 10% of 
haematological malignancies and is predominantly a disease of the elderly, 
where two thirds of newly diagnosed individuals are 65 years or more (CRUK 
2014; HMRN 2014). Overall, there are approximately 4,000 new cases of MM 
in the UK per year and the disease is more common in males relative to 
females, with a male:female ratio of 1.3:1 (CRUK 2014; HMRN 2014). Despite 
the recent advances in treatments for MM, the disease remains incurable, 
although patients are now predicted to live for approximately 5 years 
following diagnosis (Bergsagel et al. 2013).  
1.1.1. MM biology 
MM is a B-cell malignancy in which the accumulation and infiltration 
of malignant plasma cells in the bone marrow (BM) is the key characteristic 
(Kyle et al. 2003; Greipp et al. 2005). Plasma cells are terminally 
differentiated B-cells and these cells have a crucial role in the adaptive 
immune system because plasma cells are involved in the production of 
antibodies. B-cells are derived from haematopoietic stem cells and undergo 
immunoglobulin (Ig) rearrangement in their early stages to generate a large 
antigen recognition repertoire. B-cells differentiate to plasma cells in 
response to stimulation and activation by exogenous antigens through both 
T-cell independent and T-cell dependent pathways. The activation of B-cells 
triggers extensive somatic hypermutation of the variable region of 
immunoglobulin genes, which allows the production of antigen-specific 
antibodies. 
The resulting plasma cells then localise to the BM where they can 
survive as long-lived plasma cells (Brieva et al. 1991; Slifka et al. 1995; Manz 
et al. 1997). The process of bone marrow homing is prompted by the reduced 
expression of the CXC chemokine receptor 5 (CXCR5) and the increased 
expression of CXCR4, CXCR3, CXCR6 and α4β1-integrin on the surface of 
plasma cells (Hargreaves et al. 2001; Hauser et al. 2002; Kunkel a Butcher 
2003; Odendahl et al. 2005). The BM microenvironment (BMM) then 
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provides a supportive environment to promote the survival of long-lived 
plasma cells through interleukin-6 (IL-6), B-cell-activating factor (BAFF), IL-
5 and tumour-necrosis factor (TNF) secretion, and the expression of survival 
receptors such as CXCL12, CD44 ligand and CD40 ligand (Minges Wols et 
al. 2002; Cassese et al. 2003; O'Connor et al. 2004). 
The malignant plasma cells in MM retain many similarities with their 
long-lived normal counterparts in the respect that the cells retain a strong 
BM dependence, are positive for the surface antigens CD38 and CD138, and 
usually possess extensive somatic hypermutation of immunoglobulin genes 
(Ruiz-Argüelles a San Miguel 1994; Wijdenes et al. 1996; Kuehl a Bergsagel 
2012). However, unlike normal plasma cells, malignant plasma cells produce 
excess amounts of damaging proteins with no useful function in the place of 
normal monoclonal immunoglobulin (mIg), known as paraproteins. 
Furthermore, MM plasma cells retain the ability to proliferate at a low rate 
(Kuehl a Bergsagel 2012). Malignant plasma cells typically lack the 
expression of the B-cell associated antigen CD19, the CD27 antigen and 
CD45, and may also aberrantly express CD56 and CD28 (San Miguel et al. 
2002; Bianchi a Anderson 2014). As a result, myeloma plasma cells can be 
differentiated from normal plasma cells through a variety of diagnostic 
techniques, such a multi-parametric flow cytometry, to allow the MM 
disease to be diagnosed and its progression monitored. 
1.1.2. Symptoms 
The majority of MM symptoms are a consequence of the 
accumulation of malignant plasma cells within the BM and the presence of 
excess paraproteins. MM patients frequently present with symptoms such as 
bone pain, hypercalcaemia, anaemia and recurrent infections. In addition, 
the presence of end-organ failure is one of the main symptoms that is 
required for MM diagnosis and the specific symptoms required can be 
abbreviated to the CRAB acronym. These specifically include hypercalcemia 
(C), renal failure (R), anemia (A), and/or bone disease (B) in the form of 
osteolytic lesions (IMWG 2003).(Group 2003).  
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Hypercalcaemia, anaemia and recurrent infections arise due to 
osteolytic bone destruction and impaired haematopoiesis. This is a result of 
the localisation of the malignant plasma cells within the BM (Bommert et al. 
2006). Normal BM structure is maintained due a balance of osteoblast and 
osteoclast cell activity. In MM, the abundance of malignant plasma cells 
within the BM leads to an imbalance in the regulation of these cells, which 
ultimately results in decreased bone construction and increased bone 
destruction (Xi et al. 2016). Increased osteoclast activity is caused as a result 
of increased levels of tumour-associated cytokines, such as IL-6 and TNFα, 
and the interaction of MM cells with the BMM through pathways such as 
receptor activator of nuclear factor-κB (RANK) and its ligand (RANKL) (Xi 
et al. 2016).  
The excess paraprotein that is produced by malignant plasma cells in 
MM leads to symptoms such as kidney injury, which can then result in renal 
failure, and in some cases peripheral neuropathy and encephalopathy 
(Bianchi a Anderson 2014). 
1.1.3. Diagnosis 
Some patients present with a pre-malignant condition before they are 
diagnosed with symptomatic MM. Monoclonal gammopathy of 
undetermined significance (MGUS) is an asymptomatic condition that in 
most cases precedes the diagnosis of MM, although not all MGUS cases will 
progress to MM (Landgren et al. 2009; Weiss et al. 2009). Moreover, 
approximately 3-4% of the population over the age of 50 years have features 
of MGUS (Dispenzieri et al. 2010). MGUS is characterised by the presence of 
mIg in the serum (<30 g/L) but in the absence of the usual CRAB clinical 
signs of malignancy (Rajkumar et al. 2014). In addition, the percentage of 
clonal plasma cells within the BM is less than 10% (Rajkumar et al. 2014). 
Before MGUS transforms to symptomatic MM, it often progresses to 
an intermediate clinical stage of the disease known as smoldering MM (or 
asymptomatic myeloma). Smoldering MM is diagnosed if there is a high 
level of paraprotein detected in serum (≥ 30 g/L) and/or the BM contains ≥ 
10% plasma cells (Rajkumar et al. 2014). However, smoldering MM is not 
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classed as symptomatic MM because it is only diagnosed in the absence of 
the usual CRAB clinical symptoms of MM. As a result, many arguments 
exist as to whether treatment for MM should be initiated in the smoldering 
MM phase of the disease or to wait to see whether progression to 
symptomatic MM arises (Dispenzieri et al. 2013). 
The next stage of disease progression is symptomatic MM and this is 
usually detected based on the appearance of a variety of clinical symptoms. 
The diagnosis of MM is achieved if three criteria are met: 
1. There must be greater than 10% plasma cells found within the 
bone marrow aspirate. In addition, more than 90% of these 
plasma cells will present with a malignant phenotype. 
2. There are excess levels of paraproteins (≥ 30 g/L) within the 
serum and/or urine. 
3. There is evidence of all the CRAB symptoms of MM. 
A more advanced stage of MM may be observed and this is known as 
plasma cell leukemia or extramedullary MM. In this stage of the disease, 
malignant plasma cells leave the BMM and enter the peripheral blood where 
they can account for more than 20% of cells present in this fraction 
(Rajkumar et al. 2014). 
1.1.4. Prognosis 
The prognosis of MM is determined based on a variety of prognostic 
factors, including tumour burden, the age and relative fitness of the patient, 
and cytogenetics (Bianchi a Anderson 2014). In addition, patients with a 
previous diagnosis of MGUS preceding MM have a better survival outcome, 
which may be consequence of increased follow-up leading to earlier 
treatment once MGUS eventually progresses to MM (Sigurdardottir et al. 
2015). 
The International Staging System (ISS) can be used to assess the level 
of tumour burden in MM patients and used to categorise patients into three 
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separate groups (Table 1.1) (Greipp et al. 2005). The measurements used for 
the three-stage ISS are serum β2-microglobulin and serum albumin, both of 
which are measured easily and inexpensively using simple laboratory tests. 
As a result, the ISS provides a highly accessible and significantly relevant 
prognostic indicator of tumour burden (Greipp et al. 2005). 
Table 1.1 The International Staging System (ISS) 
The table shows the criteria used in respect to β2 microglobulin and serum albumin 
measurements for stratifying patients into the three stages of the ISS. The overall 
survival in months that is predicted by ISS is also provided. In summary, the higher 
the ISS stage of tumour burden, the worse the predicted outcome is for the patient 
at diagnosis. Adapted from (Greipp et al. 2005; Bianchi a Anderson 2014). 
 
Stage ISS criteria 
Overall survival 
according to ISS 
(months) 
I 
Serum β2-microglobulin <3.5 mg/dL 
AND serum albumin ≥3.5 g/dL 
62 
II 
Meets criteria for neither stage I nor stage 
III 
44 
III Serum β2-microglobulin ≥5.5 mg/dL 29 
 
The use of a combination of prognosis factors, such as tumour burden 
and cytogenetics, are then used to place patients into different risk 
categories, such as standard-risk patients and high-risk patients, which can 
help to decide what treatment regime they should receive. Patients 
diagnosed with standard-risk MM can survive for 10 years or more, whereas 
the median survival for a patient who presents with high-risk MM is less 
than 2 years (Chng et al. 2014). 
20% of cases of high-risk MM arise as a consequence of specific 
cytogenetic abnormalities (Egan et al. 2016). For this reason, a revised ISS (R-
ISS) is now used to assess prognosis using a combination of the original ISS 
criteria, cytogenetic evaluation and the measurement of serum lactate 
dehydrogenase (LDH) to provided a more reliable assessment of risk 
stratification for MM patients (Palumbo et al. 2015). Serum LDH has been 
shown to be a relevant biomarker in MM and increased levels of serum LDH 
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indicate increased disease aggressiveness and MM cell proliferation (Terpos 
et al. 2010). 
The chromosomal abnormalities that are frequently detected in MM 
can be separated into two main cytogenetic categories; translocations 
involving the Ig heavy-chain (IgH) locus and genomic imbalances (Bergsagel 
et al. 2013). Table 1.2 shows the most common cytogenetic abnormalities that 
are detected in MM along with whether they are associated with a high-risk 
prognosis. The majority of these primary genetic abnormalities lead to 
deregulation of cyclin D genes (chromosome 14), which results in 
uncontrolled MM plasma cell proliferation (Bergsagel et al. 2005). 
Interestingly, these genetic abnormalities have been found to arise before the 
MGUS stage of disease and increase in number throughout MM disease 
progression, indicating their importance in tumour progression (Walker et 
al. 2014). 
Table 1.2 The most common cytogenetic abnormalities in MM and their 
association with MM prognosis. 
The cytogenetic abnormalities can be separated into two main cytogenetic 
categories; IgH translocations and genomic imbalances. Those shown in red are 
associated with a worse prognosis and can stratify MM patients into the high-risk 
category. The most commonly observed high-risk genetic abnormalities in MM are 
the t(4;14) translocation and 17p deletion. Adapted from (Bergsagel et al. 2013). 
 
IgH translocations Genomic  imbalances 
t(4;14) 
t(14;16) 
t(14;20) 
t(11;14) 
t(6;14) 
Hyperdiploid 
Non-hyperdiploid 
1q gains 
Monosomy 13 
17p deletions 
 
The cytogenetic evaluation used in the R-ISS evaluates deletions of 
chromosome 13 and 17p deletion, and IGH translocations. Based on the new 
R-ISS criteria, cytogenetic detection of deletion of 17p, translocation t(4;14) 
and/or translocation t(14;16) are considered to stratify a patient as high-risk 
(Palumbo et al. 2015). The R-ISS criteria can be found in Table 1.3 and is now 
used to assess prognosis in newly diagnosed MM patients. 
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Table 1.3 The Revised International Staging System (R-ISS) 
The table shows the criteria used in respect to original ISS criteria (see Table 1.1), 
cytogenetic evaluation and serum LDH measurement for stratifying patients into 
three stages of prognosis. Cytogenetic detection of deletion of 17p, translocation 
t(4;14) and/or translocation t(14;16) are considered to stratify a patient as high-risk. 
Adapted from (Palumbo et al. 2015). 
 
Stage R-ISS criteria 
I 
ISS stage I, standard-risk cytogenetics, and serum 
LDH < the upper limit of normal 
II Meets R-ISS criteria for neither stage I nor stage III 
III 
ISS stage III, high-risk cytogenetics, and serum LDH > the 
upper limit of normal 
 
In addition, patients may accumulate new cytogenetic abnormalities 
over time due to genomic instability and these secondary genetic events 
usually relate to pathways that drive tumour progression, such as 
proliferation and survival (Brioli et al. 2014b). The acquirement of new 
mutations as the disease progresses is known as clonal evolution and leads 
to different tumour sub-clones arising and becoming dominant at any one 
time (Brioli et al. 2014a; Paíno et al. 2015). This creates an even more complex 
level of heterogeneity in MM because the change in tumour cytogenetic 
profile can impact on a patients prognosis and response to individual 
treatments. For example, a treatment that may have previously reduced the 
tumour burden previously, may not be successful a second time due to a 
different sub-clone gaining dominance. 
1.1.5. Current therapies 
As mentioned previously, MM remains an incurable disease. 
Therefore, the main aim of current MM treatment is to achieve and then 
maintain a complete remission (CR), which should result in an increase the 
disease free survival of the MM patient. The recent increase in our 
understanding of the biology of MM has led to an increase in the treatments 
available for this disease.  
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The treatment of MM involves three main therapy steps: induction, 
consolidation and maintenance (Moreau et al. 2015). The induction stage of 
treatment aims to reduce the main bulk of the tumour burden, whereas 
consolidation therapy aims to eliminate all remaining tumour cells, 
including sub-clones that may have risen through clonal evolution. Finally, 
maintenance therapy acts to pressure the tumour cell selection process so 
that less aggressive malignant plasma cells are selected, to prevent or delay 
relapse. 
The current therapy for MM involves using pharmaceutical agents 
alongside autologous stem cell transplantation (ASCT). However, ASCT is 
limited to MM patients that have a good fitness score and are usually less 
than 65 years old due to the intensity of this treatment option. Therefore, for 
most MM patients, comparatively less intensive drug therapies may be the 
only available treatment option. The current therapies for MM include 
cytotoxic agents, immunomodulatory agents (IMiDs), proteasome inhibitors 
and corticosteroids, all of which may be used as a monotherapy or in 
combination. Over the last decade, a handful of novel frontline agents have 
been approved for use in MM treatment and these include the IMiDs 
thalidomide, lenalidomide and pomalidomide, and the proteasome 
inhibitors bortezomib and carfilzomib. These agents are regularly used for 
both transplant and non-transplant eligible MM patients. However, MM 
patients with high-risk disease often have a poor prognosis even with the 
conventional therapies and are frequently enrolled on clinical trials at 
diagnosis to improve their outcome (Naymagon a Abdul-Hay 2016). 
 Immunomodulatory agents 1.1.5.1.
Thalidomide and its derivative lenalidomide are two of the IMiDs 
that are used as frontline therapy for the treatment of MM. These have 
been found to be highly effective against MM, especially when used in 
combination with bortezomib and dexamethasone, and their use has 
resulted in a 50% improvement in median MM survival (Kumar et al. 2008; 
Stewart et al. 2009). Preclinical studies suggest that these agents induce cell 
cycle arrest and apoptosis in MM cells as well as interrupting the 
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interaction of malignant plasma cells with the BMM (Davies a Baz 2010). 
The immunomodulatory action of these agents involves increasing tumour 
cell killing through activation of CD8+ T cells and increasing the expression 
of death effector molecules on natural killer cells (Davies a Baz 2010). 
Despite this, the two agents possess some mechanistic differences, for 
example lenalidomide possesses greater immunomodulatory properties 
when compared to thalidomide (Davies a Baz 2010). For this reason, 
lenalidomide can be used as a second line treatment for MM regardless of 
prior response to thalidomide.  
Pomalidomide, a next generation thalidomide derivative, was 
granted accelerated approval for use in MM in 2013 and this is currently 
used a third line treatment option after the MM disease becomes resistant 
to precursor IMiDs and bortezomib (McCurdy a Lacy 2013). Pomalidomide 
has been found the be the most potent of the IMiDs and is predicted to 
have 100 times and 10 times the potency of thalidomide and lenalidomide, 
respectively (Gertz 2013). 
 Proteasome inhibitors 1.1.5.2.
Bortezomib was the first proteasome inhibitor used for the 
treatment of MM and today remains a crucial frontline agent in the 
treatment of MM. Bortezomib is mainly a reversible inhibitor of the 26S 
proteasome, which is responsible for the degradation of a wide range of 
proteins (Boccadoro et al. 2005). As a result, 26S proteasome inhibition can 
lead to apoptosis, an unfolded protein response, a heat-shock response and 
cell cycle arrest in MM cells due to the accumulation of misfolded, 
ubiquitinated and pro-apoptotic proteins (Hideshima et al. 2002; Obeng et 
al. 2006). Malignant cells on average display a higher level of proteasome 
activity so are more sensitive to the negative effects caused by proteasome 
inhibition (Dou a Li 1999). Moreover, bortezomib may also indirectly 
disrupt MM cell survival and drug resistance through inhibiting the 
interaction of MM cells with the BMM (Reddy a Czuczman 2010; Zangari 
et al. 2012). One of the main adverse events that are observed with 
bortezomib is the development of peripheral neuropathy in some patients 
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(Richardson et al. 2012). This is thought to be due to the lack of inhibitory 
specificity of bortezomib because this agent can reversibly inhibit a wide 
range of other serine proteases.  
Carfilzomib is a second-generation proteasome inhibitor that is also 
approved for the treatment of MM, although at present only as a third-line 
therapy following the use bortezomib and IMiDs (Perel et al. 2016). It is 
approved for use either as a monotherapy or in combination with 
dexamethasone (a corticosteroid) and lenalidomide (Perel et al. 2016). 
Carfilzomib is an irreversible inhibitor of the 20S proteolytic core of the 26S 
proteasome and this activity has been shown to promote apoptosis, cell 
cycle arrest and inhibition of tumourigenesis in MM cells (Kortuem a 
Stewart 2013). In addition, this proteasome inhibitor provides a more 
specific alternative to bortezomib and less adverse events relating to 
neuropathy (Dimopoulos et al. 2016). As a result, carfilzomib can be used 
as a proteasome inhibitor alternative in those patients who cannot tolerate 
bortezomib due to the development of neuropathy. Moreover, the 
difference in the molecular targeting of carfilzomib also means that this 
agent may still successfully treat MM even after the development of 
bortezomib resistance (Siegel et al. 2012). 
1.1.6. The future of MM treatment 
Despite the recent increase in novel agents for the treatment of MM 
over the last decade, the disease still remains incurable and progression-free 
survival is limited, especially in the high-risk MM patient group (Kumar et 
al. 2008; Naymagon a Abdul-Hay 2016). A limiting factor is the emergence of 
treatment resistant sub-clonal populations in MM, which leads to patient 
relapse and refractory MM (Egan et al. 2012; Magrangeas et al. 2013). At this 
point, the treatment options are limited as the frontline therapies are 
exhausted. 
As a result, targeted therapies have become an interesting alternative 
to the current therapies that exist for MM and may provide a more beneficial 
form of treatment that can remain effective even in refractory patients. Their 
clinical use in MM is further favoured due to advances in cytogenetic 
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screening and the understanding of the relevance of specific cytogenetic 
abnormalities in disease progression and risk stratification. In the future, this 
may encourage the use of more specific agents earlier in the treatment 
regime based on the outcome of patient cytogenetic screening. In addition, 
targeted therapies may also help to reduce the adverse effects of treatment, 
which would be particularly beneficial for MM patients due to their 
relatively high mean age at diagnosis and comorbidities associated with 
ageing. 
Many novel agents are currently in development for MM and these 
are targeting a wide a range of tumour mitigating factors in MM (Table 1.4). 
These include, but are not limited to, CD138 and CD38 targeting mAbs, 
cyclin-dependent kinase inhibitors, Bcl-2 inhibitors, IL-6 inhibitors, and 
BAFF and APRIL inhibitors, which are all factors that have been shown to be 
essential for malignant plasma cells so are frequently dysregulated in MM 
(Naymagon a Abdul-Hay 2016). In addition, as proteasome inhibitors are 
still used as efficacious treatments in MM, substantial effort is going into 
producing the next generation of improved proteasome inhibitors that may 
overcome bortezomib resistance (Table 1.4). 
Another example of a tumour-promoting genetic abnormality that is 
commonly expressed in MM patients involves deregulation of the nuclear 
factor-κB signalling pathways (Annunziata et al. 2007; Keats et al. 2007; 
Chapman et al. 2011). These pathways have been shown to be highly 
relevant in MM disease progression due to their role in supporting the 
growth, survival and proliferation of malignant plasma cells within the 
BMM (Hideshima et al. 2002). Moreover, there is much evidence that 
targeting this signalling pathway may provide a potential therapeutic option 
due to some of the existing MM treatments imparting some of their anti-
tumour activity through inhibition of nuclear factor-κB signalling pathways. 
 
11
	  Table 1
.4
 A
 li
st
 o
f 
so
m
e 
of
 th
e 
n
ex
t g
en
er
at
io
n
 n
ov
el
 a
ge
n
ts
 th
at
 a
re
 c
u
rr
en
tl
y 
in
 d
ev
el
op
m
en
t f
or
 th
e 
tr
ea
tm
en
t o
f 
M
M
. 
A
d
ap
te
d
 fr
om
 (H
en
ge
ve
ld
 a
 K
er
st
en
 2
01
5;
 N
ay
m
ag
on
 a
 A
bd
ul
-H
ay
 2
01
6)
. 
 
N
am
e 
T
yp
e 
T
ar
ge
t 
P
ro
gr
es
s 
Ix
az
om
ib
 
PI
 
20
S 
pr
ot
ea
so
m
e 
Ix
az
om
ib
 i
s 
th
e 
fi
rs
t 
or
al
 P
I 
to
 e
nt
er
 c
lin
ic
al
 t
ri
al
s 
an
d
 i
s 
ef
fe
ct
iv
e 
in
 B
T
Z
 r
es
is
ta
nt
 M
M
 c
el
ls
, 
in
d
uc
es
 a
 
no
ti
ce
ab
le
 i
m
pr
ov
em
en
t 
in
 P
FS
 i
n 
bo
th
 s
ta
nd
ar
d
 a
nd
 h
ig
h 
ri
sk
 p
at
ie
nt
 g
ro
up
s,
 a
nd
 s
ho
w
s 
a 
go
od
 t
ox
ic
it
y 
pr
of
ile
 w
it
h 
an
 a
cc
ep
ta
bl
e 
in
ci
d
en
ce
 o
f 
ne
ur
op
at
hi
es
. A
pp
ro
ve
d
 b
y 
th
e 
FD
A
 i
n 
20
15
 f
or
 u
se
 i
n 
co
m
bi
na
ti
on
 
w
it
h 
L
en
 a
nd
 D
ex
 to
 tr
ea
t M
M
 p
at
ie
nt
s 
th
at
 h
av
e 
re
ce
iv
ed
 o
ne
 p
re
vi
ou
s 
th
er
ap
eu
ti
c 
ag
en
t. 
M
ar
iz
om
ib
 
PI
 
20
S 
pr
ot
ea
so
m
e 
T
hi
s 
in
ve
st
ig
at
io
na
l 
ag
en
t 
d
is
pl
ay
s 
in
cr
ea
se
d
 c
yt
ot
ox
ic
it
y 
an
d
 d
ur
at
io
n 
of
 a
ct
io
n,
 e
ve
n 
in
 B
T
Z
 r
es
is
ta
nt
 M
M
 
ce
lls
. P
ha
se
 I
 s
tu
d
ie
s 
sh
ow
 t
ha
t 
A
E
’s
 a
re
 li
m
it
ed
 a
nd
 d
o 
no
t 
in
cl
ud
e 
ne
ur
op
at
hi
es
 . 
In
 v
it
ro
 s
yn
er
gy
 h
as
 b
ee
n 
ob
se
rv
ed
 w
it
h 
IM
iD
s 
an
d
 m
ar
iz
om
ib
 c
ou
ld
 b
e 
us
ed
 i
n 
co
m
bi
na
ti
on
 w
it
h 
B
T
Z
 d
ue
 t
o 
th
e 
d
if
fe
re
nc
e 
in
 
ap
op
to
si
s 
re
la
te
d
 M
O
A
. 
D
ar
at
u
m
u
m
ab
 
m
A
b 
C
D
38
 
D
ue
 to
 th
e 
hi
gh
 C
D
38
 e
xp
re
ss
io
n 
on
 M
M
 c
el
ls
, t
hi
s 
m
A
b 
ha
s 
be
en
 s
ho
w
n 
to
 m
ed
ia
te
 th
e 
ph
ag
oc
yt
os
is
 o
f M
M
 
ce
lls
 b
y 
m
ac
ro
ph
ag
es
. 
Ph
as
e 
I/
II
 t
ri
al
s 
sh
ow
ed
 h
ig
h 
ef
fi
ca
cy
 w
he
n 
us
ed
 i
n 
co
m
bi
na
ti
on
 w
it
h 
L
en
 a
nd
 
su
bs
eq
ue
nt
 t
ri
al
s 
al
so
 d
em
on
st
ra
te
d
 a
n 
en
co
ur
ag
in
g 
ef
fi
ca
cy
 w
he
n 
us
ed
 a
s 
a 
m
on
ot
he
ra
py
 in
 r
ef
ra
ct
or
y 
M
M
 
pa
ti
en
ts
 w
ho
 h
ad
 r
ec
ei
ve
d
 a
 m
ed
ia
n 
of
 f
iv
e 
pr
io
r 
tr
ea
tm
en
ts
. 
In
 2
01
5,
 t
he
 F
D
A
 a
pp
ro
ve
d
 i
ts
 u
se
 a
s 
a 
M
M
 
th
er
ap
y 
in
 p
at
ie
nt
s 
th
at
 h
ad
 r
ec
ei
ve
d
 th
re
e 
pr
io
r 
tr
ea
tm
en
ts
 a
nd
 it
 w
as
 a
pp
ro
ve
d
 b
y 
th
e 
E
M
A
 in
 2
01
6 
fo
r 
M
M
 
pa
ti
en
ts
 r
es
is
ta
nt
 to
 IM
iD
s 
an
d
 P
I’
s.
  
In
d
at
u
xi
m
ab
 
m
A
b 
C
D
13
8 
In
d
at
ux
im
ab
 is
 a
 c
hi
m
er
is
ed
 a
nt
i-
C
D
13
8 
m
A
b 
co
nj
ug
at
ed
 to
 D
M
4,
 w
hi
ch
 is
 a
 p
ot
en
t i
nh
ib
it
or
 o
f m
ic
ro
tu
bu
le
 
as
se
m
bl
y.
 A
s 
C
D
13
8 
is
 a
 p
la
sm
a 
ce
ll 
sp
ec
if
ic
 a
nt
ig
en
, t
hi
s 
al
lo
w
s 
sp
ec
if
ic
 t
ar
ge
ti
ng
 o
f 
th
is
 a
ge
nt
 t
o 
M
M
 c
el
ls
 
an
d
 i
nt
er
na
liz
at
io
n 
of
 D
M
4 
re
su
lt
in
g 
in
 M
M
 c
el
l 
d
ea
th
. 
Pr
ec
lin
ic
al
 r
es
ul
ts
 d
em
on
st
ra
te
d
 s
yn
er
gy
 w
it
h 
L
en
 
an
d
 a
 p
ha
se
 I
/I
Ia
 s
tu
d
y 
ha
s 
sh
ow
n 
hi
gh
 e
ff
ic
ac
y 
w
he
n 
us
ed
 in
 c
om
bi
na
ti
on
 w
it
h 
L
en
 a
nd
 D
ex
 in
 r
ef
ra
ct
or
y 
M
M
 p
at
ie
nt
s,
 w
he
re
 e
ve
n 
no
n-
re
sp
on
d
er
s 
st
ill
 a
ch
ie
ve
d
 d
is
ea
se
 s
ta
bi
lis
at
io
n.
 
A
B
T
-1
99
 
SM
I 
B
cl
-2
 
B
cl
-2
 is
 a
n 
im
po
rt
an
t a
nt
i-
ap
op
to
ti
c 
re
gu
la
to
ry
 p
ro
te
in
 in
 a
 n
um
be
r 
of
 h
ae
m
at
ol
og
ic
al
 m
al
ig
na
nc
ie
s 
an
d
 B
cl
-2
 
SM
I’
s 
ha
ve
 b
ee
n 
sh
ow
n 
to
 i
nd
uc
e 
tu
m
ou
r 
ce
ll 
ap
op
to
si
s.
 A
B
T-
19
9 
is
 t
he
 f
ir
st
 o
ra
lly
 b
io
av
ai
la
bl
e 
B
cl
-2
 
in
hi
bi
to
r 
an
d
 p
re
lim
in
ar
ily
 in
ve
st
ig
at
io
ns
 in
 M
M
 s
ho
w
 th
at
 it
 is
 h
ig
hl
y 
ef
fe
ct
iv
e 
at
 in
d
uc
in
g 
ce
ll 
d
ea
th
 in
 c
el
ls
 
th
at
 a
re
 d
ep
en
d
en
t 
on
 B
cl
-2
 e
xp
re
ss
io
n 
fo
r 
su
rv
iv
al
. 
T
hi
s 
in
d
ic
at
es
 t
ha
t 
th
is
 a
ge
nt
 m
ay
 b
e 
th
er
ap
eu
ti
ca
lly
 
re
le
va
nt
 in
 c
er
ta
in
 M
M
 p
at
ie
nt
 g
ro
up
s 
as
 a
 ta
rg
et
ed
 th
er
ap
y 
an
d
 th
is
 is
 fu
rt
he
r 
su
pp
or
te
d
 b
y 
th
e 
ef
fe
ct
iv
en
es
s 
of
 A
B
T
-1
99
 in
 M
M
 c
el
l l
in
es
 th
at
 p
os
se
ss
 th
e 
t(
11
;1
4)
 c
yt
og
en
et
ic
 M
M
 p
he
no
ty
pe
. A
B
T
-1
99
 h
as
 d
em
on
st
ra
te
d
 
ex
 v
iv
o 
sy
ne
rg
y 
w
it
h 
ca
rf
ilz
om
ib
 b
ut
 s
o 
fa
r 
th
e 
sa
fe
ty
 p
ro
fi
le
 o
f 
th
is
 s
pe
ci
fi
c 
ag
en
t 
is
 f
la
w
ed
 w
it
h 
T
L
S 
pr
es
en
ti
ng
 a
s 
a 
co
m
m
on
 fe
at
ur
e.
 
12
	   
T
ab
le
 1
.4
 c
on
ti
n
u
ed
 
D
in
ac
ic
li
b
 
SM
I 
C
D
K
 
C
D
K
s 
ar
e 
pr
ot
ei
n 
ki
na
se
s 
th
at
 a
re
 e
ss
en
ti
al
s 
in
 t
he
 r
eg
ul
at
io
n 
of
 t
he
 c
el
l 
cy
cl
e.
 D
in
ac
ic
lib
 i
s 
an
 i
nh
ib
it
or
 o
f 
C
D
K
1,
 C
D
K
2,
 C
D
K
5 
an
d
 C
D
K
9.
 I
ts
 u
se
 a
s 
a 
si
ng
le
 a
ge
nt
 i
n 
re
la
ps
ed
/r
ef
ra
ct
or
y 
M
M
 i
n 
a 
ph
as
e 
I 
tr
ia
l 
ha
s 
in
d
ic
at
ed
 it
 h
as
 m
od
er
at
e 
ef
fi
ca
cy
. A
 tr
ia
l i
nv
es
ti
ga
ti
ng
 th
e 
us
e 
of
 D
in
ac
ic
lib
 in
 c
om
bi
na
ti
on
 w
it
h 
B
T
Z
 in
 M
M
 
is
 a
 fu
tu
re
 p
os
si
bi
lit
y 
d
ue
 to
 e
vi
d
en
ce
 s
ug
ge
st
in
g 
th
at
 C
D
K
5 
in
hi
bi
ti
on
 m
ay
 e
nh
an
ce
 th
e 
ac
ti
vi
ty
 o
f P
I’
s.
 
S
il
tu
xi
m
ab
 
m
A
b 
IL
-6
 
Si
lt
ux
im
ab
 i
s 
a 
ch
im
er
ic
 m
A
b 
ta
rg
et
in
g 
IL
-6
, 
w
hi
ch
 i
s 
a 
m
aj
or
 B
M
M
 f
ac
to
r 
th
at
 s
up
po
rt
s 
th
e 
su
rv
iv
al
 o
f 
m
al
ig
na
nt
 M
M
 c
el
ls
. P
ha
se
 II
 tr
ia
ls
 h
av
e 
so
 fa
r 
fa
ile
d
 to
 s
ho
w
 in
cr
ea
se
d
 e
ff
ic
ac
y 
or
 P
FS
 w
he
n 
co
m
pa
re
d
 to
 th
e 
cu
rr
en
t 
re
gi
m
es
 u
se
d
 t
o 
tr
ea
t 
M
M
 o
r 
ev
en
 w
he
n 
th
e 
IL
-6
 i
nh
ib
it
or
 i
s 
us
ed
 i
n 
co
m
bi
na
ti
on
 w
it
h 
B
T
Z
. 
H
ow
ev
er
, 
it
 i
s 
pr
es
en
tl
y 
be
in
g 
in
ve
st
ig
at
ed
 f
or
 u
se
 i
n 
hi
gh
-r
is
k 
SM
M
 d
ue
 t
o 
th
e 
as
so
ci
at
io
n 
of
 I
L
-6
 
co
nc
en
tr
at
io
n 
w
it
h 
M
M
 d
is
ea
se
 s
ta
ge
. 
A
ta
ci
ce
p
t  
R
FP
 
B
A
FF
 &
 
A
PR
IL
 
A
ta
ci
ce
pt
 i
s 
a 
R
FP
 c
on
si
st
in
g 
of
 t
he
 F
c 
re
gi
on
 o
f 
hu
m
an
 I
gG
 a
nd
 t
he
 b
in
d
in
g 
d
om
ai
n 
of
 t
he
 T
A
C
I 
re
ce
pt
or
. 
T
he
re
fo
re
, 
it
 c
an
 b
in
d
 b
ot
h 
B
A
FF
 a
nd
 A
PR
IL
, 
pr
ev
en
ti
ng
 t
he
ir
 i
nt
er
ac
ti
on
 w
it
h 
th
ei
r 
re
ce
pt
or
s.
 B
A
FF
 a
nd
 
A
PR
IL
 a
re
 t
w
o 
fa
ct
or
s 
th
at
 h
av
e 
be
en
 s
ho
w
n 
to
 b
e 
hi
gh
ly
 r
el
ev
an
t 
to
 M
M
 d
is
ea
se
 p
ro
gr
es
si
on
 a
nd
 m
ed
ia
te
 
so
m
e 
of
 t
hi
s 
ac
ti
on
 t
hr
ou
gh
 N
F-
κB
 s
ig
na
lli
ng
. I
n 
a 
hu
m
an
 m
ou
se
 m
od
el
 o
f 
M
M
 a
nd
 i
n 
m
ye
lo
m
a 
ce
ll 
lin
es
, 
A
ta
ci
ce
pt
 w
as
 s
ho
w
n 
to
 p
ro
m
ot
e 
an
ti
-m
ye
lo
m
a 
ac
ti
vi
ty
, 
es
pe
ci
al
ly
 i
n 
th
os
e 
ce
lls
 t
ha
t 
po
ss
es
se
d
 h
ig
h 
ex
pr
es
si
on
 o
f 
T
A
C
I. 
A
 p
ha
se
 I
 s
tu
d
y 
sh
ow
ed
 f
ur
th
er
 c
lin
ic
al
 e
ff
ic
ac
y 
in
 M
M
 t
hr
ou
gh
 s
ta
bi
lis
at
io
n 
or
 
re
d
uc
ti
on
 i
n 
th
e 
nu
m
be
r 
of
 B
M
 p
la
sm
a 
ce
lls
 w
it
h 
5/
11
 p
at
ie
nt
s 
ac
hi
ev
in
g 
PF
S 
fo
llo
w
in
g 
1 
cy
cl
e.
 H
ow
ev
er
, 
fu
rt
he
r 
pr
og
re
ss
 h
as
 b
ee
n 
st
al
le
d
 d
ue
 to
 th
e 
im
m
un
os
up
pr
es
si
on
 a
ri
si
ng
. 
T
ab
al
u
m
ab
 
m
A
b 
B
A
FF
 
T
ab
al
um
ab
 is
 a
 h
um
an
 m
A
b 
th
at
 h
as
 n
eu
tr
al
is
in
g 
ac
ti
vi
ty
 a
ga
in
st
 b
ot
h 
so
lu
bl
e 
an
d
 r
ec
ep
to
r-
bo
un
d
 B
A
FF
. I
n 
m
ur
in
e 
xe
no
gr
af
t 
m
od
el
s,
 t
he
 a
ge
nt
 h
as
 s
ho
w
n 
pr
om
is
in
g 
an
ti
-M
M
 e
ff
ec
ts
, i
nc
lu
d
in
g 
os
te
oc
la
st
og
en
es
is
. A
 
ph
as
e 
I 
st
ud
y 
sh
ow
ed
 t
ha
t 
w
he
n 
T
ab
al
um
ab
 i
s 
us
ed
 i
n 
co
m
bi
na
ti
on
 w
it
h 
B
T
Z
, 
it
 i
s 
w
el
l 
to
le
ra
te
d
 a
nd
 
in
d
uc
ed
 a
 P
R
 o
r 
C
R
 i
n 
~5
0%
 o
f 
pa
ti
en
ts
. O
th
er
 p
ha
se
 I
 s
tu
d
ie
s 
in
 r
ef
ra
ct
or
y 
M
M
 p
at
ie
nt
s 
ha
ve
 s
ho
w
n 
th
at
 
T
ab
al
um
ab
 h
as
 a
n 
ac
ce
pt
ab
le
 s
af
et
y 
pr
of
ile
 a
nd
 c
an
 b
e 
us
ed
 i
n 
co
m
bi
na
ti
on
 w
it
h 
D
ex
 a
nd
 B
T
Z
 t
o 
im
pr
ov
e 
re
sp
on
se
 r
at
es
. H
ow
ev
er
, a
 r
ec
en
t p
ha
se
 I
I 
tr
ia
l f
ai
le
d
 to
 s
ho
w
 a
n 
im
pr
ov
em
en
t i
n 
PF
S 
w
he
n 
T
ab
al
um
ab
 w
as
 
us
ed
 in
 c
om
bi
na
ti
on
 w
it
h 
D
ex
 a
nd
 B
T
Z
, c
om
pa
re
d
 t
o 
tr
ea
tm
en
t 
w
it
h 
D
ex
 a
nd
 B
T
Z
 in
 r
el
ap
se
d
 o
r 
re
fr
ac
to
ry
 
M
M
. 
 A
E
 =
 a
dv
er
se
 e
ve
nt
, A
P
R
IL
 =
 a
 p
ro
lif
er
at
io
n-
in
du
ci
ng
 li
ga
nd
, B
A
FF
 =
 B
-c
el
l a
ct
iv
at
in
g 
fa
ct
or
, B
T
Z
 =
 b
or
te
zo
m
ib
, C
D
K
 =
 c
yc
lin
-d
ep
en
de
nt
 k
in
as
es
, C
R
 =
 c
om
pl
et
e 
re
sp
on
se
, 
D
ex
 =
 D
ex
am
et
ha
so
ne
, 
E
M
A
 =
 E
ur
op
ea
n 
M
ed
ic
in
es
 A
ge
nc
y,
 F
c 
= 
fr
ag
m
en
t 
cr
ys
ta
lli
sa
bl
e,
 F
D
A
 =
 t
he
 U
S 
Fo
od
 a
nd
 D
ru
g 
A
dm
in
is
tr
at
io
n,
 I
M
iD
s 
= 
im
m
un
om
od
ul
at
or
y 
ag
en
ts
, L
en
 =
 L
en
al
id
om
id
e,
 m
A
b
 =
 m
on
oc
lo
na
l 
an
ti
bo
dy
, M
M
 =
 m
ul
ti
pl
e 
m
ye
lo
m
a,
 M
O
A
 =
 m
ec
ha
ni
sm
 o
f 
ac
ti
on
, P
FS
 =
 p
ro
gr
es
si
on
-f
re
e 
su
rv
iv
al
, P
I 
= 
pr
ot
ea
so
m
e 
in
hi
bi
to
r,
 P
R
= 
pa
rt
ia
l 
re
sp
on
se
, R
FP
 =
 r
ec
om
bi
na
nt
 f
us
io
n 
pr
ot
ei
n,
 S
M
I 
= 
sm
al
l 
m
ol
ec
ul
e 
in
hi
bi
to
r,
 S
M
M
 =
 s
m
ol
de
ri
ng
 M
M
, T
A
C
I 
= 
tr
an
sm
em
br
an
e 
ac
ti
va
to
r 
an
d 
C
A
M
L 
in
te
ra
ct
or
, T
L
S
 =
tu
m
ou
r 
ly
si
s 
sy
nd
ro
m
e.
  
13
	  1.2. Nuclear factor-κB (NF-κB) 
Nuclear factor-κB (NF-κB) was first discovered as a transcription factor 
that transcriptionally enhances the regulation of the immunoglobulin κ light 
chain gene by binding to a highly conserved DNA sequence known as the κB 
element (Sen a Baltimore 1986). NF-κB was at first thought to be a B-cell-
specific nuclear protein but has since been found to be expressed in a number 
of cells due to its important regulatory role in a number of processes, 
including immunity and inflammation (Lawrence 2009; Hayden a Ghosh 
2011). In normal B-cells, NF-κB is required for the regulation of genes relating 
to B-cell proliferation, differentiation, activation and survival (Gasparini et al. 
2014). 
1.2.1. NF-κB subunits 
NF-κB exists as either homodimers or heterodimers of its five 
subunits; p65, p50, c-Rel, p52 and RelB. The structures of the five NF-κB 
subunits are shown in Figure 1.1. The subunits all contain the same highly 
conversed 300 amino acid region called the Rel homology domain (RHD) at 
their N-terminals and it is this region that allows subunit dimerisation, 
dimer nuclear localisation and DNA κB element binding (Zheng et al. 2011). 
The N-terminal of the RHD in NF-κB subunits interacts with DNA at the 
consensus sequence of NF-κB target genes corresponding to 5’-
GGGRNYYYCC-3’ (R = purine, Y = pyrimidine and N = any nucleotide) 
(Chen a Ghosh 1999). The nuclear localisation signals (NLS) in each NF-κB 
subunit is located at the C-terminal end of the RHD (Zheng et al. 2011).  
Although all NF-κB subunit dimers bind to DNA κB sites to 
transcriptionally regulate target genes, the different dimer combinations can 
act as transcriptional activators or repressors. One reason for this is that the 
transcription activation domain (TAD), which is required for positive 
regulation of NF-κB target genes, is expressed in only the p65, c-Rel and 
RelB subunits (Ghosh et al. 2012). Therefore, NF-κB homodimers of p50 or 
p52 are thought to act as inhibitors or repressors of target genes due to the 
absence of a TAD (Figure 1.1), although they can become transcriptional 
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activators through interaction with nuclear IκB proteins (Ghosh et al. 2012; 
Hinz et al. 2012). 
 
 
Figure 1.1 The structures of the NF-κB subunits p65, RelB, c-Rel, p105/p50 and 
p100/p52.  
The structures of the five NF-κB subunits p65, RelB, c-Rel, p50 and p52 are shown 
alongside the precursor subunits p105 and p100. The N- and C-terminals of each 
subunit protein are indicated using N and C, respectively, and the length of each 
subunit protein in amino acids (aa) is provided. On the p105 and p100 precursor 
subunits, the arrow indicates the position of cleavage to the active NF-κB subunits p50 
and p52, respectively. Adapted from (Chen a Greene 2004; Hayden a Ghosh 2012). 
ARD = ankyrin repeat domain, DD = death domain, GRR = glycine rich region, NLS = 
nuclear localisation signal, LZ = leucine zipper, RHD = Rel homology domain and 
TAD = transcription activation domain.  
 
The NF-κB subunits can be divided into two categories; subunits that 
are synthesised in their mature form and those subunits that are synthesised 
in a precursor form and require further processing. The p65, c-Rel and RelB 
subunits are synthesised in their mature forms whereas the p50 and p52 NF-
κB subunits are synthesised as precursor molecules p105 and p100, 
respectively (Hayden a Ghosh 2008; Zheng et al. 2011).  
p65 
RelB 
c-Rel 
p105 
p50 
p100 
p52 
LZ 
RHD 
RHD 
RHD 
RHD 
RHD 
RHD 
RHD 
TAD 
TAD 
TAD 
NLS 
NLS 
NLS 
N 
N 
N 
N 
N 
N 
N 
C 
C 
C 
C 
C 
C 
C 
NLS 
NLS 
NLS 
NLS 
GRR 
GRR 
GRR 
GRR 
433 
447 
DD 
DD 
551 aa 
557 aa 
619 aa 
969 aa 
898 aa 
433 aa 
447 aa 
ARD 
ARD 
15
	   
Each NF-κB subunit is expressed to varying extents in different cell 
types, although all five subunits are expressed in B-cells where they have 
been found to be highly relevant in modulating the differentiation, 
proliferation, survival and activation of B-cells (Gasparini et al. 2014). 
1.2.2. Inhibitory protein of NF-κB (IκB proteins) 
In unstimulated cells, NF-κB is held inactive in the cytoplasm as a 
result of interaction with inhibitory proteins of NF-κB (IκB proteins). The IκB 
proteins include the classical IκB proteins IκBα, IκBβ and IκBε, the nuclear 
IκB proteins, Bcl-3 and IκBζ, and the precursor proteins p100 and p105 (Hinz 
et al. 2012). The structures of the classical and nuclear IκB proteins are 
shown in Figure 1.2. The IκB proteins characteristically contain six to seven 
ankyrin-repeat motifs that interact with the RHD on the NF-κB subunits to 
mask the NLS and help regulate NF-κB activity by restricting it to the 
cytoplasm of the cell (Chen a Greene 2004; Zheng et al. 2011).  
For NF-κB to become activated, the IκB proteins must undergo 
phosphorylation at specific serine residues (see Figure 1.2), which 
subsequently leads to ubiquitin-dependent proteasomal degradation 
(Kanarek et al. 2010; Hinz a Scheidereit 2014). The IκB proteins are 
polyubiquitinated at specific lysine residues (see Figure 1.2) that are located 
in their N-terminal regulatory domains and the polyubiquitinated IκB 
proteins are selectively degraded by the 26S proteasome (Chen et al. 1995; 
Karin et al. 2002).  
In the case of the precursor proteins p100 and p105, the C-terminal 
protein domains are post-translationally cleaved to the smaller p52 and p50 
subunits to remove the ankyrin-repeat regions that mask the NLS (Henkel et 
al. 1992). The structure of the p105 and p100 precursor subunits also 
contains a glycine-rich domain that follows the conventional RHD (see 
Figure 1.1). The glycine-rich region (GRR) in both the p105 and p100 subunit 
prevents complete protein degradation to allow the release of the active p50 
and p52 subunits, respectively (Lin a Ghosh 1996; Heusch et al. 1999; Orian 
et al. 1999). The p105 protein is constitutively processed to the p50 subunit 
whereas p100 processing is a more closely regulated process in unstimulated 
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cells (Xiao et al. 2001). Constitutive processing of p105 and p100 is prevented 
by a C-terminal death domain downstream of the ankyrin repeat domain, 
which acts as a processing inhibitory domain (Xiao et al. 2001).  
 
 
Figure 1.2 The structures of the IκB proteins IκBα, IκBβ, IκBε, IκBζ, and BCL-3. 
The structures of the three classical IκB proteins, IκBα, IκBβ and IκBε, are shown 
alongside the atypical, nuclear IκB proteins, IκBζ, and BCL-3. The N- and C-terminals 
of each subunit protein are indicated using N and C, respectively, and the length of 
each subunit protein in amino acids (aa) is provided. The specific serine residues that 
are required for IKK phosphorylation and specific lysine residue(s) that are essential 
for ubiquitination are indicated for each classical IκB protein. The PEST regions on the 
C-terminal of IκBα and IκBβ are also indicated. The nuclear IκB protein BCL-3 can 
interact with nuclear p50 and p52 proteins to function as a transcriptional co-activator. 
Adapted from (Huxford a Ghosh 2009; Vallabhapurapu a Karin 2009; Hayden a Ghosh 
2012). ARD = ankyrin repeat domain, K = lysine residue, S = serine residue, PEST = 
proline (P), glutamic acid (E), serine (S), and threonine (T) domains are indicated as 
PEST. 
 
Each IκB protein displays a selective binding preference towards the 
NF-κB subunits. For example, IκBα favours interactions with heterodimers 
that contain the p50, p65 and c-Rel subunits whereas the IκBβ and IκBε 
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cytoplasm (Hinz et al. 2012). Interestingly, the classical IκB proteins do not 
interact with the RelB subunit and it is the precursor protein, p100, that 
displays the highest affinity for RelB (Dobrzanski et al. 1994). 
The IκB proteins Bcl-3 and IκBζ migrate to the nucleus when they 
become overexpressed and, once localised in the nucleus, they possess 
binding specificity towards p52 and p50 homodimers (Hinz et al. 2012). 
Through interaction with the p50 and p52 homodimers, the nuclear proteins 
Bcl-3 and IκBζ can function as transcriptional co-activators (Ghosh et al. 
2012).  
1.2.3. The IκB kinase (IKK) complex  
Upon activation of NF-κB signalling, the IκBα, IκBβ or IκBε proteins 
undergo phosphorylation by the IκB kinase (IKK) complex. This is a 
complex that is composed of three proteins called IKKα, IKKβ and NF-κB 
essential modulator (NEMO), which is also known as IKKγ (Liu et al. 2012). 
Figure 1.3 shows the structures of the three IKK proteins.  
The IKKα and IKKβ proteins share approximately 51% sequence 
homology, which includes an N-terminal kinase domain consisting of two 
serine residues and a NEMO-binding domain (NBD) at the C-terminals. On 
the other hand, NEMO is structurally different from the IKKα and IKKβ 
proteins (Figure 1.3) and does not include the kinase domain that is found in 
the other IKK proteins (Liu et al. 2012; Hinz a Scheidereit 2014). For this 
reason, the NEMO protein acts as a regulatory subunit within the IKK 
complex and allows the IKK complex to interact with upstream activators 
through its C-terminal zinc finger motif (Ghosh a Karin 2002). Moreover, in 
the absence of NEMO, the IKKα and IKKβ cannot become activated through 
normal NF-κB stimulation, which indicates that NEMO is essential in NF-κB 
regulation (Yamaoka et al. 1998).  
The IKK complex is suggested to comprise of an IKKα and IKKβ 
heterodimer that binds to dimers of NEMO using the NBDs on each 
respective IKK (Rothwarf a Karin 1999; Miller a Zandi 2001). The IKKα and 
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IKKβ proteins dimerise using their leucine zipper domains and helix-loop-
helix regions (Jost a Ruland 2007; Huxford a Ghosh 2009). 
 
 
 
Figure 1.3 The structures of the IKK complex proteins IKKα, IKKβ and IKKγ 
(NEMO). 
The structures of the three IKK proteins, IKKα, IKKβ and IKKγ, also known as NEMO, 
are shown. The N- and C-terminals of each subunit protein are indicated using N and 
C, respectively, and the length of each subunit protein in amino acids (aa) is provided. 
The specific serine residues within the kinase domain are indicated for IKKα and 
IKKβ, along with the position of the leucine zipper domains and helix-loop-helix 
regions that are required for subunit dimerisation. The location of other structural 
domains such as the NBD, ubiquitin-like domain, zinc-finger domain and predicted 
coiled-coil motifs are also shown on the schematic above. Adapted from (Hayden a 
Ghosh 2004; Huxford a Ghosh 2009).  
CC1/2 = coiled-coil motifs, KD = kinase domain, HLH = helix-loop-helix, LZ = leucine 
zipper, NBD = NEMO binding domain, S =serine residue, U = ubiquitin-like domain 
and ZF = zinc-finger domain. 
 
The IKK complex is activated through phosphorylation of the IKKα 
and IKKβ proteins at two specific serine residues, which induces a 
conformational change that activates the catalytic kinase domain (Mercurio 
et al. 1997; Ling et al. 1998; Delhase et al. 1999). However, the mechanism 
through which the IKK complex is phosphorylated remains unconfirmed, 
although two general mechanisms have been suggested; transauto-
phosphorylation or specific IKK kinases (IKKK) (Liu et al. 2012; Hinz a 
Scheidereit 2014). The IKKKs recruited may differ based on the specific 
stimuli that initially induces the NF-κB activity. 
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1.2.4. NF-κB signalling 
Bringing together the above information, the activation of NF-κB is 
generally described as occurring through two pathways; the canonical and 
non-canonical NF-κB signalling pathways. 
 The canonical signalling pathway  1.2.4.1.
Examples of cellular stimuli that can directly activate the canonical 
pathway include the pro-inflammatory cytokines TNFα and IL-1, the B-cell 
agonists, RANKL and CD40; and the danger signals provided by toll-like 
receptors and lipopolysaccharide. The antigen receptors such as the B-cell 
receptor can also activate NF-κB (Siebenlist et al. 2005; Vallabhapurapu a 
Karin 2009).  
The p65, p50 and c-Rel NF-κB subunits are typically associated with 
canonical NF-κB signalling. The IκB proteins act to sequester the canonical 
subunits in the cytoplasm and each IκB protein displays specific binding 
preferences towards the individual subunits.  
In the canonical signalling pathway, the IKK complex is predicted to 
be phosphorylated by IKKKs, such as Transforming growth factor beta-
activated kinase 1 (TAK1) (Wang et al. 2001). Activation of the IL-1 
receptor is followed by the activation of the E3 ligase TNF receptor-
associated factor 6 (TRAF6), which then facilitates the formation of Lys63-
linked polyubiquitination (K63-pUb) chains in the presence of the dimeric 
ubiquitin-conjugating Ubc13-Uev1A (Deng et al. 2000; Wang et al. 2001). 
Similarly, TNFα stimulation induces the polyubiquitination of RIP1 by 
activated cIAPs or TRAF2, allowing RIP1 to act as a scaffold for the 
recruitment of TAK1 and the IKK complex to the TNF receptor (Ea et al. 
2006; Newton et al. 2008). In both scenarios, TAK1 is then activated 
through interaction with either TRAF6 formed K63-pUb chains or K63-pUb 
chains on RIP1, which induces autophosphorylation of TAK1 (Wang et al. 
2001; Xia et al. 2009). The binding of K63-pUb chains to the NEMO domain 
of the IKK complex facilitates the activation of the IKKβ components by 
TAK1 phosphorylation (Ea et al. 2006; Wu et al. 2006). On the other hand, it 
has also been demonstrated that K63-pUb chains and linear pUb chains are 
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capable of directly activating the IKK complex through interaction with 
NEMO (Xia et al. 2009; Walczak et al. 2012).  
In the canonical NF-κB pathway, the classical IκBs are mainly 
phosphorylated by activated IKKβ, although it has also been suggested that 
IKKα may also be capable of carrying out this phosphorylation, although 
less efficiently (Adli et al. 2010). IKKβ phosphorylates IκBα at serines 32 
and 36; IκBβ at serines 19 and 23, and IκBε at serines 18 and 22 
(Vallabhapurapu a Karin 2009). The phosphorylated IκB then undergoes 
polyubiquitination by a ubiquitin ligase related to SCF and is consequently 
degraded by the proteasome (Kanarek a Ben-Neriah 2012).  
Following the degradation of IκB, the NLS is exposed on the NF-κB 
subunits and so they are no longer sequestered in the cytoplasm. However, 
IκBα is not fully effective at masking the NLS on NF-κB dimers so NF-κB-
IκBα complexes can translocate to the nucleus in the absence of canonical 
pathway stimuli (Carlotti et al. 2000; Malek et al. 2001). The existence of a 
nuclear export sequence (NES) on IκBα results in the oscillation of these 
complexes between the nucleus and cytoplasm, with nuclear export being 
dominant so as to localise the complexes mainly in the cytoplasm (Johnson 
et al. 1999; Huang et al. 2000). As a result, the degradation of IκBα shifts 
this balance to favour the nuclear localistaion of NF-κB dimers (Hayden a 
Ghosh 2008). 
In the nucleus, NF-κB subunits bind to DNA κB elements to 
transcriptionally regulate genes. During nuclear translocation, the 
canonical NF-κB subunit p65 can undergo phosphorylation by cyclic AMP-
dependent protein kinase or casein kinase II. The purpose of 
phosphorylation of p65 appears to allow the NF-κB subunit to bind DNA 
with a greater affinity than its unphosphorylated form (Ghosh a Karin 
2002).  
Figure 1.4 provides a schematic overview of the canonical NF-κB 
signalling pathway. 
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Figure 1.4 The canonical NF-κB signalling pathway. 
The canonical signalling pathway is activated through a variety of stimuli, which 
activates IKKK’s, such as TAK1. IKKK’s phosphorylate and activate IKKβ and IKKβ 
phosphorylates the IκB protein at the residues 18 and 22. The IκB protein is 
subsequently ubiquitinated by a SCF-family ubiquitin ligase and undergoes 
degradation by the 26S proteasome. The free NF-κB dimers translocate to the nucleus 
where they bind to DNA κB elements to regulate gene transcription. Adapted from 
(Jost a Ruland 2007; Hayden a Ghosh 2012). 
BCR = B-cell receptor, IκB = Inhibitor of κB, IKK = IκB kinase, IKKK’s = IKK kinases, 
LPS = lipopolysaccharide, P = phosphorylate, RANK = receptor activator of NF-κB, 
RANKL = RANK ligand, TLR = toll-like receptor, TNFα = Tumour necrosis factor α, 
TNFR = TNF receptor, U = ubiquitin.  
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   Non-canonical signalling pathway 1.2.4.2.
The non-canonical pathway can be activated by some of the same 
and some different cell stimuli, including BAFF, lymphotoxin β, RANK and 
CD40 ligand (Vallabhapurapu a Karin 2009; Kaileh a Sen 2012).  
Before it is processed to p52, the IκB-like protein p100 can inhibit the 
nuclear translocation of the RelB subunit through interaction with the RHD 
of RelB (Solan et al. 2002). Therefore, the conversion of p100 activates non-
canonical NF-κB signalling by allowing the nuclear translocation of p52 
and RelB dimers. However, under normal cellular conditions the 
generation of p52 is tightly regulated and can only occur following 
stimulation of the non-canonical pathway (Heusch et al. 1999).  
NF-κB inducing kinase (NIK) is a MAP3K-related protein kinase 
that activates NF-κB mainly through the phosphorylation of IKKα, which 
predominantly results in non-canonical NF-κB pathway signalling (Malinin 
et al. 1997; Ling et al. 1998). NIK is also capable of phosphorylating IKKβ to 
activate the canonical pathway but NIK has less affinity for this IKK so 
IKKα is the preferred substrate (Ling et al. 1998; Senftleben et al. 2001).  
In unstimulated cells, NIK undergoes constant proteasomal 
degradation due to interaction with TRAF3. Upon cellular stimulation of 
the non-canonical NF-κB pathway, the ubiquitin ligase complex TRAF2-
cIAP1/2 is recruited to TRAF3 and TRAF2 becomes activated 
(Vallabhapurapu et al. 2008). TRAF2 then carries out the ubiquitination of 
cIAP1/2, which enhances its ubiquitin ligase activity and TRAF3 in turn 
become ubiquitinated. The ubiquitinated TRAF3 dissociates from NIK and 
undergoes proteasomal degradation. Once dissociated, NIK is stabilised 
and can undergo activation through autophosphorylation (Vallabhapurapu 
et al. 2008). 
Once activated, IKKα phosphorylates the p100 precursor subunit to 
the active p52 subunit. The processing of p100 to the active p52 subunit has 
been shown to be dependent on IKKα phosphorylation and can occur in 
the absence of IKKβ and IKKγ (NEMO) (Senftleben et al. 2001). 
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Phosphorylation of p100 promotes β-TrCP binding to the IκB 
phosphopeptide region, which in turn allows polyubiquitination and 
subsequent proteasomal degradation of the multiple ankyrin repeats 
(Yaron et al. 1998; Fong a Sun 2002).  
RelB does not associate with any other IκB proteins other than the 
p100 precursor protein (Solan et al. 2002). Therefore, proteasomal 
degradation of the ankyrin-repeat domain of p100 exposes the NLS on the 
RelB and p52 subunits. RelB cannot homodimerise and commonly forms a 
heterodimer with the p52 subunit, although it may also heterodimerise 
with the p50 subunit (Ryseck et al. 1992; Dobrzanski et al. 1994). Exposure 
of the NLS allows the RelB-p52 dimer to translocate to the nucleus to bind 
to DNA κB elements and regulate gene expression. Please refer to Figure 
1.5 for a schematic summary of the non-canonical NF-κB signalling 
pathway.
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Figure 1.5 The non-canonical NF-κB signalling pathway. 
(A) In unstimulated cells, NIK undergoes constant proteasomal degradation through 
interaction with TRAF3. (B) Following cellular stimuli, TRAF2/cIAP1/2 is recruited to 
the receptor and this induces TRAF2 dependent ubiquitination of cIAP1/2. cIAP1/2 
then ubiquitinates TRAF3 and TRAF3 undergoes proteasomal degradation. Activated 
NIK mainly phosphorylates IKKα but to a lesser extent can phosphorylate IKKβ to 
activate the canonical signalling pathway. Activated IKKα phosphorylates p100 to 
promote ubiquitination and degradation of the IκB region to free activated p52. The 
p52/RelB dimers then translocate to the nucleus where they bind DNA κB elements. 
Adapted from (Jost a Ruland 2007; Hayden a Ghosh 2012). 
BAFF = B-cell activating factor, BAFF-R = BAFF receptor, cIAP1/2 = c inhibitors of 
apoptosis proteins 1/2, IKK = IκB kinase, NIK = NF-κB inducing kinase, P = 
phosphorylate, RANK = receptor activator of NF-κB, RANKL = RANK ligand, TRAF = 
TNF receptor-associated factor, U = ubiquitin. 
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  1.2.5 Downstream NF-κB gene regulation 
Many genomic studies have identified DNA binding κB sites within a 
huge number of genes, which indicates that NF-κB is capable of regulating a 
large number of biological processes (Wang et al. 2012). In addition, changes 
in the base pairs that construct a target gene’s individual DNA κB site can 
alter the binding preferences of specific NF-κB subunit dimers and define 
whether the target gene is up- or down-regulated (Leung et al. 2004). As a 
result, activation of the canonical or non-canonical signalling pathways can 
regulate different target genes. Two of the main cellular processes that NF-
κB signalling is responsible for governing are cell proliferation and 
apoptosis. 
1.2.5.1. Cell proliferation 
In B-cells deletion of either the c-Rel, p65 or p105 subunit all result 
in proliferative defects (Joyce et al. 2001). This indicates that NF-κB 
signalling is important in cell proliferation and growth and in B-cells this is 
likely a consequence of activation of the canonical signalling pathway. 
More specifically, NF-κB can directly up-regulate the transcription 
of cyclin D1, which is associated with the progression into the S phase of 
the cell cycle, due to the existence of a DNA κB binding site that is present 
within the cyclin D1 promoter (Guttridge et al. 1999; Hinz et al. 1999). In 
addition, NF-κB can regulate the expression of a number of cytokines that 
can support cell growth and proliferation, including IL-6, Granulocyte-
macrophage colony-stimulating factor (GM-CSF) and BAFF (Hideshima et 
al. 2002; Fuchs 2013). In MM, IL-6 has been shown to be an essential 
growth factor and most MM cells cannot survive in its absence (Kawano et 
al. 1988; Hirata et al. 2003). Moreover, the cytokine GM-CSF can 
synergistically increase MM cell growth with IL-6 (Zhang et al. 1990; 
Villunger et al. 1998). BAFF is also important in MM cell proliferation, 
survival and BMM cell adhesion (Novak et al. 2004; Fuchs 2013).  
1.2.5.2. Cell survival and anti-apoptotic proteins 
The importance of NF-κB in the regulation of apoptosis was shown 
through several knockout experiments. For example, B-cells that lack 
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expression of the NF-κB subunits c-Rel, p65 or p50, or the protein IKKβ 
experience increased cell death (Grossmann et al. 2000; Pasparakis et al. 
2002). Moreover, in vivo mouse models show that when the canonical-
related NF-κB proteins, such as p65, IκBα and IKKβ, are deleted, cells 
undergo rapid apoptosis (Gasparini et al. 2014). In addition, constitutive 
RelB activation is observed in approximately 40% of MM cases and the 
phenotypic advantage of this is to promote MM cell survival by increasing 
the expression of anti-apoptotic NF-κB target genes such as cIAP2 (Cormier 
et al. 2013). Overall, this indicates that both the canonical and non-
canonical NF-κB pathways are critically involved in cell survival and anti-
apoptosis in MM. 
Apoptosis can be induced through two main pathways; the extrinsic 
and intrinsic pathways (Millimouno et al. 2014). The extrinsic pathway 
involves the activation of death receptors, while molecules that are released 
from the mitochondria mediate the intrinsic pathway (Ichim a Tait 2016). 
Both pathways activate caspases, which are cysteine proteases that initiate 
apoptosis or programmed cell death through the cleavage of cellular 
proteins. NF-κB can directly increase cell survival by protecting cells from 
apoptosis induced by TNF activation of the extrinsic pathway. For 
example, NF-κB induces transcriptional activation of TRAF1/2 and 
inhibitors of apoptosis proteins (IAPs) such as c-IAP1, cIAP2 and XIAP, all 
of which block caspase activation and apoptosis (Wang et al. 1998). Other 
anti-apoptotic NF-κB target genes include X-linked IAP (XIAP) and Bcl-2 
and its homologues, such as Bcl-XL and Mcl-1 (Grossmann et al. 2000; Li et 
al. 2008).  
1.2.5.3. The role of NF-κB in the progression of malignancies 
As outlined previously, NF-κB is responsible for regulating 
increased proliferation and increased cell survival. Further to this, NF-κB 
can be intrinsic to other tumourgenic processes such as metastasis, 
replicative immortality and the development of drug resistance. For 
example, tumours that possess constitutive NF-κB activity usually display 
more resistance to chemotherapy so it has been suggested that NF-κB 
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pathway activation may induce multidrug resistance through the increased 
expression of P-glycoprotein (Dolcet et al. 2005). In addition, increased NF-
κB activity in MM cells has been shown to contribute to cell adhesion 
mediated drug resistance (CAM-DR) following adhesion of MM cells with 
fibronectin within the BMM (Landowski et al. 2003). Immortality of 
malignant plasma cells may arise through increased NF-κB activation 
because NF-κB is a regulator of telomerase, which is the enzyme 
responsible for maintaining telomere length (Yin et al. 2000). 
Therefore, NF-κB is responsible for regulating several of the 
established hallmarks of cancer (Hanahan a Weinberg 2000, 2011). For this 
reason, this transcription factor is frequently dysregulated in a number of 
human cancers. 
 
1.3. Activation of NF-κB in MM 
The name of the transcription factor, NF-κB, is related to its discovery 
in B-cells and its role in enhancing immunoglobulin-κ light chain (Matthews 
et al. 2016). Therefore, NF-κB also possesses important roles in non-malignant 
plasma cells, which are fully differentiated B-cells, in terms of the production 
of antibodies. Moreover, malignant MM plasma cells express relatively high 
levels of NF-κB, which contributes to the progression and pathophysiology of 
this haematological malignancy (Annunziata et al. 2007; Keats et al. 2007; 
Demchenko et al. 2010; Chapman et al. 2011).  
1.3.1 Mutation based activation 
Deregulation of NF-κB signalling can arise as a consequence of 
overexpression or gain-of-function mutations in positive regulators of NF-κB 
and loss-of-function mutations in negative regulators (Annunziata et al. 
2007; Keats et al. 2007). Overall, genetic abnormalities leading to constitutive 
NF-κB activity have been found in approximately 20% of MM patients and 
40% of MM cell lines (Annunziata et al. 2007; Keats et al. 2007; Demchenko 
et al. 2010).  
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Frequent genetic abnormalities relating to NF-κB pathway 
deregulation in MM include aberrant expression of NIK, CD40, TRAF2, 
TRAF3, transmembrane activator and CAML interactor (TACI) and cIAP1/2 
(Annunziata et al. 2007; Keats et al. 2007). In these studies, the majority of 
MM cases possessed overexpression of the positive NF-κB regulators NIK, 
TACI and CD40, or reduced or silenced activity of the negative NF-κB 
regulators TRAF2, TRAF3 and cIAP1/2. All of these phenotypes contribute 
to increased NF-κB signalling, with a preference towards non-canonical NF-
κB signalling (Keats et al. 2007; Demchenko et al. 2010). In addition, other 
less common genetic abnormalities that also lead to constitutive NF-κB 
signalling in MM were identified. These included high expression of the 
NFKB1 gene (p105) and abnormalities within the NFKB2 gene (p100), which 
results in increased canonical and non-canonical NF-κB signalling, 
respectively (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 
2010). 
1.3.2 Bone marrow microenvironmental activation 
Although a large number of genetic abnormalities have been 
described that explain the high NF-κB activity in some MM cell lines and 
patient samples, it is likely that a substantial portion of the NF-κB signalling 
in MM cells arises as a consequence of the BM microenvironment (BMM) (Li 
et al. 2008; Demchenko et al. 2010).  
One mechanism by which NF-κB can be activated in the BMM in MM 
is through CD40-CD40L interactions (Coope et al. 2002; Tai et al. 2003; 
Hauer et al. 2005). CD40 is a cell surface marker that is not usually expressed 
on normal plasma cells but has been shown to be present in the early stages 
of MM (Tong et al. 2000; Perez-Andres et al. 2009). CD40 is abundant in the 
BMM and is involved in the cell homing of MM cells to the BM. Moreover, 
CD40 expression is frequently increased on MM cells and blocking the 
interaction of CD40 with CD40L decreases NF-κB activation (Richardson et 
al. 2004; Annunziata et al. 2007). This results in the inhibition of IL-6 and 
vascular endothelial growth factor (VEGF) secretion, which leads to growth 
arrest and cell death of MM cells (Richardson et al. 2004). In addition, 
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inhibition of canonical and non-canonical NF-κB signalling can abolish 
CD40-induced MM cell migration (Fuchs 2013). This indicates the 
importance of the CD40-CD40L pathway in both NF-κB activation and 
subsequent MM pathogenesis. 
Furthermore, the bone marrow stromal cells (BMSC) found in the 
MM tumour microenvironment have also been found to possess high levels 
of NF-κB activation that helps to support the proliferation, survival and 
drug resistance of malignant plasma cells within the BMM (Chauhan et al. 
1995; Chauhan et al. 1996; McMillin et al. 2013). Adherence of MM cells to 
BMSCs induces NF-κB-dependent cytokine transcription and secretion of 
TNFα, IL-6, VEGF, RANKL and BAFF, to promote MM cell survival and 
growth through MM cell NF-κB activation (Chauhan et al. 1996; Landowski 
et al. 2003; Bommert et al. 2006). The production of IL-6 is one of the main 
NF-κB regulated factors that induces these effects to help to produce and 
support the malignant plasma cell population in MM (Chauhan et al. 1996). 
RANKL binds to RANK, which is usually expressed on osteoclasts. 
Although normal plasma cells do not usually express RANKL, in MM 
malignant plasma cells can gain the expression of RANKL (Sezer et al. 2002). 
Activation of, RANKL-RANK signalling in osteoclasts through interaction 
with MM cells, mediates cell differentiation and activation through 
activation of NF-κB (Xi et al. 2016). Inhibition of NF-κB signalling blocks 
osteoclastogenesis, which indicates the role of NF-κB in the RANKL-RANK 
signalling pathway and consequently the role that this transcription factor 
plays in establishing the BMM and the bone destruction that occurs in MM 
(Dai et al. 2004a; Feng et al. 2007).  
NF-κB activation in plasma cells within the BMM can also result from 
BAFF and a proliferation-inducing ligand (APRIL). For example, 
interference with BAFF signalling significantly reduces plasma cell numbers, 
which suggests that activation of NF-κB by BAFF contributes to the survival 
of plasma cells found in the BMM (O'Connor et al. 2004). The expression of 
BAFF and its receptor, BAFF-R, are essential for mature B-cell survival and 
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this is partially due to both canonical and non-canonical NF-κB activation 
(Mackay a Schneider 2008; Sasaki a Iwai 2016). In addition, BAFF, itself, is a 
target gene of NF-κB, which creates a positive feedback loop to further 
increase the activation of both molecules in MM to promote tumour cell 
survival (Novak et al. 2004). 
Normal plasma cells and MM cells highly express two receptors to 
both BAFF and APRIL, which are B-cell maturation antigen (BCMA) and 
TACI (Moreaux et al. 2005). BCMA and TACI are both overexpressed in 
MM, which indicates their importance in the pathogenesis of the disease and 
in tumour cell survival (Claudio et al. 2002b; Tarte et al. 2002; Keats et al. 
2007). However, low TACI expression on malignant plasma cells produces a 
more aggressive phenotype that leads to a worse overall prognosis in MM 
(Moreaux et al. 2005). This is predicted to indicate that MM tumour cells that 
lose expression of BAFF and APRIL receptors become independent of BMM 
activation perhaps as a result of acquiring NF-κB genetic abnormalities. 
In conclusion, the NF-κB signalling pathway plays a highly relevant 
role in many aspects of MM pathogenesis, both as a consequence of MM cell 
mediated NF-κB activity through genetic abnormalities and through NF-κB 
activation within the BMM and as a consequence of the BMM. 
1.4. NF-κB as a therapeutic target in MM 
Over more than two decades there has been increased interest in 
designing therapeutic agents that target specific signalling pathways. 
Targeting NF-κB may provide a promising therapeutic strategy for the 
treatment of MM due to the important reliance the disease has on NF-κB 
activation, as outlined above. Moreover, inhibiting NF-κB signalling through 
targeting specific proteins within the NF-κB signalling pathway would likely 
reduce overall NF-κB activity regardless of whether it was generated as a 
consequence of NF-κB genetic abnormalities or BMM activation.  
Inhibiting both canonical and non-canonical NF-κB signalling has been 
shown to reduce MM cell growth, induce cell cycle arrest and promote 
apoptosis (Ni et al. 2001; Hideshima et al. 2002; Mitsiades et al. 2002b; Bharti 
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et al. 2003). Moreover, several of the current treatments for MM impart some 
of their therapeutic activity through the inhibition of NF-κB signalling 
pathways.  
Bortezomib has been shown to induce some of its therapeutic activity 
in MM through the inhibition of the canonical NF-κB signalling pathway due 
to preventing the 26S proteasomal degradation of the IκB protein (Hideshima 
et al. 2001; Hideshima et al. 2002). NF-κB inhibition by bortezomib has been 
shown to induce cell cycle arrest and apoptosis, and reduce the expression of 
the NF-κB target genes such as IL-6 and vascular cell adhesion protein 1 
(VCAM-1) (Palombella et al. 1998; Hideshima et al. 2001; Hideshima et al. 
2002). The reduction in VCAM-1 expression interferes with the MM cell 
interaction with the BMM, which acts to further reduce overall NF-κB 
activation (Hideshima et al. 2001). 
Additionally, the success of IMiDs in MM may also be partially a 
consequence of these agents targeting NF-κB. Thalidomide has been shown to 
inhibit the DNA-binding activity of NF-κB by reducing the activity of IKK 
(Keifer et al. 2001; Mitsiades et al. 2002c). As a result, thalidomide can reduce 
the expression of NF-κB-regulated genes such as TRAF1, TRAF2 and c-IAP2, 
which likely contributes to the overall cell apoptosis that this agent induces. 
Furthermore, dexamethasone, a corticosteroid that is frequently used in 
combination with proteasome inhibitors and IMiDs in MM, also reduces NF-
κB activity (Mitsiades et al. 2002c). 
Moreover, it has been speculated that combining a specific NF-κB 
inhibitor with current therapies used for MM, such as dexamethasone or 
bortezomib, may act synergistically to induce anti-cancer effects (Mitsiades et 
al. 2002a). This may be a consequence of the overcoming the drug resistance 
that constitutive NF-κB activation often imparts in MM cells. 
In summary, NF-κB represents a prominent transcription factor that is 
critical in MM disease progression and pathogenesis. Therefore, specific 
inhibitors targeting the NF-κB signalling pathway may be of benefit as a 
future treatment for this haematological malignancy. However, as NF-κB is 
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involved in the regulation of a number of biological processes including 
inflammation, immunity, survival and proliferation, global inhibition of NF-
κB signalling gives rise to a number of toxicities related to immune 
suppression and inflammation (DiDonato et al. 2012). Therefore, the 
development NF-κB inhibitors that selectively target specific components of 
the NF-κB pathway should minimise the serious toxicities that are associated 
with global inhibition. 
1.5. Aims and objectives 
The NF-κB pathway can be specifically inhibited at several points; 
prevention of IκB protein degradation, inhibition of IKK activation and 
blockage of NF-κB DNA-binding (Godwin et al. 2013). Due to the crucial roles 
that IKK plays in the regulation of NF-κB activity, both through canonical and 
non-canonical pathway activation, inhibition of IKK activation may be a 
promising therapeutic strategy.  
Multiple IKKβ inhibitors have been evaluated in MM, but concerns 
over the their safety profiles has prevented further development. For 
example, complete ablation of the canonical pathway activity through IKKβ 
inhibition is likely to impair the function of the adaptive and innate immune 
system, lead to IL-1β induced neutrophilia and inflammation and may also 
lead to hepatic toxicity (Li et al. 1999a; Li et al. 1999b; Tanaka et al. 1999; 
Greten et al. 2007; Vallabhapurapu a Karin 2009; Hsu et al. 2011).  
This thesis investigates the use of a series of first-in-class IKKα 
inhibitors and a novel NIK inhibitor as therapeutic agents in four MM cell 
lines. The main hypothesis of this work was that specific inhibitors of IKK 
activation would induce apoptotic responses in MM cells and this would be a 
consequence of inhibition of NF-κB activation.  
The aims of this study were as follows; 
1. Characterisation of the four MM cell lines in terms of growth 
characteristics, cell surface phenotype, and overall NF-κB activity at 
baseline and in response to NF-κB stimulation or inhibition. 
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2. Characterisation of a selection of novel putative IKKα inhibitors in 
the MM cell lines by investigating cytotoxicity and effects on NF-κB 
activity and gene expression. 
3. Characterisation of the use of a novel putative NIK inhibitor in the 
MM cell lines by investigating cytotoxicity and effects on NF-κB 
activity and gene expression. 
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Chapter 2 - Materials and methods 
2.1. Cell culture 
2.1.1. Cell viability analysis and cell counting 
A Vi-CELL XR Cell Viability Analyser (Beckman-Coulter) was used 
to assess cell viability and count cells to ensure cell lines were maintained at 
a suitable cell density and viability. 500µL of each multiple myeloma (MM) 
cell line was as counted twice weekly in a Vi-CELL sample cup. In some 
scenarios, cells were counted at a 1:10 dilution in which 50µL of each cell line 
was diluted in 450µL phosphate buffered saline (PBS) in a Vi-CELL sample 
cup. Viability analysis was assessed using the trypan blue dye exclusion 
method. 
2.1.2. Culture of MM cell lines 
NCI-H929 (H929), U266B1 and RPMI8226 cell lines were cultured in 
Roswell Park Memorial Institute (RPMI-1640) culture medium 
supplemented with 10% foetal bovine serum (FBS), 1% L-glutamine and 2% 
penicillin/streptomycin while the JJN3 cell line was cultured in Dulbecco's 
Modified Eagle's medium (DMEM) supplemented with 20% FBS, 1% 
pyruvate, 1% non-essential amino acids and 2% penicillin/ streptomycin. 
All cells were cultured at 37ºC with 5% CO2 and were maintained at cell 
densities between 3×105 and 1×106 cells/mL and at a viability exceeding 
85%. 
The MM cell lines used were chosen because they each represent 
different clinical features of MM (Drexler a Matsuo 2000; Annunziata et al. 
2007; Keats et al. 2007). For example, H929 was chosen because it possesses 
no known genetic abnormalities in the NF-κB pathway. On the other hand, 
U266B1, RPMI8226 and JJN3 possess activating mutations affecting the NF-
κB pathway (Annunziata et al. 2007; Keats et al. 2007). U266B1 and 
RPMI8226 possess inactivating TRAF3 mutations while JJN3 possesses an 
activating mutation in NIK. 
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2.1.3. Culture of CD40 ligand (CD40L) transfected and non-transfected 
ligand (NTL) fibroblast cell lines 
CD40L and NTL transfected fibroblast cell lines were cultured in 
DMEM culture medium supplemented with 10% FBS, 1% pyruvate and 2% 
penicillin/ streptomycin. Fibroblast cells were sustained at 37ºC with 5% 
CO2 in 15mL of culture medium within T75 culture flasks. When the 
adherent fibroblast cell layer became confluent, cell lines were passaged. 
This involved discarding used culture medium and then washing the 
adherent fibroblast cells with 8mL PBS. PBS was used to wash the cell layer 
before addition of trypsin because the FBS in the media can affect the 
enzyme reaction. Adherent cells were removed from flasks by incubation 
with 5mL of trypsin at 37ºC with 5% CO2 for 8-10 minutes. Once adherent 
cells were in suspension, the 5mL of trypsin was removed (containing 
suspended fibroblast cells) and diluted in 5mL culture medium in a 15mL 
falcon tube to stop the enzyme reaction. Cells were subsequently centrifuged 
at 300 × g for 5 minutes and the remaining pellet resuspended in 1mL of 
culture medium. 200μL fibroblasts were reseeded into new T75 flasks with 
15mL of fresh culture media. If required for experiments, the remaining 
fibroblasts were prepared for co-culture with the MM cell lines.  
2.1.4. Co-culture of MM cell lines with CD40L and NTL transfected 
fibroblasts 
The MM cell lines were co-cultured with CD40L transfected and non-
transfected fibroblast cell lines to investigate the impact of CD40L on MM 
cell line phenotype, growth, survival and NF-κB activation. Prior to co-
culture with MM cell lines, the CD40L and NTL transfected cells were 
irradiated at 75 Grays (30 minutes in the presence of Caesium-137). 
Irradiation prevents the fibroblasts from replicating but does not affect their 
viability or biological activity, including the expression of the transfected 
CD40L. Post-irradiated fibroblasts were counted and 2.5×105 cells were 
plated into each well of a 12-well plate with 2mL of culture medium. The 
cells were left to adhere to the plate overnight at 37ºC with 5% CO2. 
 The next day, the old fibroblast media was discarded, along with any 
cells that had not adhered, and replaced with 3mL of fresh MM cell line 
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culture medium. 1×106 MM cells were added to each well of the 12-well 
plate to give an optimal ratio of 1 fibroblast cell to every 4 MM cells. MM 
cells were then co-cultured with transfected and non-transfected fibroblasts 
for 24h.  
Subsequently, the media containing the non-adhering MM cells was 
carefully removed from the 12-well plates and used as appropriate in 
experiments. The adherent fibroblast cells remaining in the 12-well plates 
were then discarded. Where more than 1×106 cells were required for 
experiments, plate wells for the same co-culture condition were combined to 
produce the correct number of cells. 
 
2.2. Flow cytometry 
All flow cytometric analysis was carried out using an Accuri C6 flow 
cytometer (BD Biosciences). The flow cytometer was maintained as per 
manufacturer’s recommendations to keep the flow cytometer free of debris 
and the fluidics system free from air bubbles. The majority of flow cytometric 
data was analysed using Cflow Plus software and the Prism 6.0 statistical 
package (Graphpad Software), unless otherwise specified. 
2.2.1. Cell cycle analysis using propidium iodide (PI) 
PI is a fluorescent dye that is commonly used for cell cycle analysis. 
PI intercalates to the major groove of double stranded DNA in a 
stoichiometric manner facilitating the identification of the proportion of cells 
in each stage of the cell cycle and allowing assessment of the replicative 
capability of cell populations.  
MM cells were harvested and washed twice in PBS. The resulting cell 
pellet was resuspended in cold 70% ethanol at a cell density of 1×105 
cells/mL. To avoid clumping and cell loss due to incomplete fixation, the 
ethanol was added forcefully by dispelling from a pipette and then 
vortexing. Cells were fixed in ethanol for at least 1 hour at −20°C. Following 
this, cells were washed twice in an equal volume of PBS. At this stage of 
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ethanol fixation the cells can become more buoyant so a higher centrifuge 
speed of 700 × g for 5 minutes was used. Cells were treated with 50µL of 
10µg/mL ribonuclease A solution at 37°C for 45 minutes. This is necessary 
because PI is also capable of binding to ribonucleic acid (RNA) so digesting 
the RNA present in the samples means that specific labelling of DNA can be 
achieved. Cells were stained immediately with 500µL PI solution for 10 
minutes at 37°C before flow cytometric analysis on 20,000 events. 
2.2.1.1. Interpreting PI cell cycle analysis flow cytometric data 
For this flow cytometric measurement FlowJo V.10.1 software was 
used to analyse the data. This software will plot a computer based model of 
the cell cycle profile that relates to the collected data. Analysis of PI cell 
cycle data was carried out after first gating cells to exclude debris based on 
FSC-A and SSC-A profiles (Figure 2.1). Cells gated in P1 were used to 
create a scatter plot of FSC-H against FSC-A profile to allow a second level 
of gating to include only singlet cells (Figure 2.2). This allows exclusion of 
doublets and clumped cells that if included in analysis would give false 
results for the proportion of cells in certain regions of the cell cycle. For 
example, if a doublet occurs between two cells that are both in the G0/G1 
phase of cell cycle, then this will produce the same readout as a single cell 
that is in G2/M phase. This is a consequence of the PI binding the same 
amount of DNA in both scenarios because in the G0/G1 phase only one 
copy of DNA is present within the nucleus while at G2/M phase the DNA 
has been duplicated in preparation for cell division. 
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A histogram of the amount of PI staining in cells gated by P2 (P1 in 
all) was plotted and a gate was applied to this graph to exclude the sub G0 
phase (Figure 2.3A) to result in the final profile that the FlowJo software 
could then fit a cell cycle model to (Figure 2.3B). An example of the final 
plot produced is shown in Figure 2.4. The first peak in the histogram 
represents the cells in G0/G1 phase of the cell cycle because these cells 
possess diploid chromosome content. The last peak represents cells in 
G2/M phase because PI staining reveals that these cells have double 
diploid chromosome content. Cells in between the two prominent peaks 
are in S phase because these cells are in the transition of single to double  
 
 
Figure 2.1 The gating (P1) used to exclude debris and select cells based on their 
forward scatter-area (FSC-A) and side scatter-area (SSC-A) profiles for PI cell 
cycle flow cytometric data. 
 
 
 
Figure 2.2 The gating (P2) used to exclude doublets and clumps based on their 
FSC-A profile and forward scatter-height (FSC-H) parameter for PI cell cycle 
flow cytometric data. 
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diploid chromosome content. The FlowJo software will give an output of the 
percentages of cells in each phase of the cell cycle, which can then be input 
into Graphpad Prism 6.0 software for statistical analysis. 
 
 
A B 
  
  
Figure 2.3 An example of a histogram plot used to apply the cell cycle profile model 
to in FlowJo after gating cells using P2 (P1 in all).  
(A) A historgam of PI (area) was plotted for the cells gated by P2 (P1 in all) and a gate 
was applied to this graph to exclude the sub G0 phase. (B) The resultant PI cell cycle 
profile for the FlowJo software to fit a cell cycle model. 
 
 
 
 
Figure 2.4 The final PI cell cycle profile after FlowJo has fitted a model to calculate 
the percentage of cells in each phase of the cell cycle.  
The FlowJo software uses the Watson pragmatic model to create the Gaussian 
distributions that result in final fitted cell cycle model. The gates G1 and G2 are 
manually applied to suggest to the software the areas in which it should begin to base 
its model. The cell cycle model is then plotted for the data as shown and the software 
calculate the percentage of cells in each phase of the cell cycle. The complete model is 
the sum of the three phases. 
G2/M phase 
S phase 
G0/G1 phase 
Sum of model 
G1 G2
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2.2.2. Annexin V/ propidium iodide apoptosis assay 
Apoptosis was assessed in MM cells by dual staining with fluorescein 
isothiocyanate (FITC)-labelled Annexin V and propidium iodide (PI) (BD 
Biosciences). Briefly, 2.5×105 cells were washed in 1mL of PBS. After 
removing supernatant, cells were incubated in darkness for 10 minutes with 
190µL a 1:4 dilution of binding buffer diluted in autoclaved deionized H2O 
containing 4µL of Annexin V-FITC. Before flow cytometric analysis, 
10µg/mL of PI was added and then flow cytometric data on 25,000 events 
was collected.  
2.2.2.1. Interpreting Annexin V/PI flow cytometric data 
Annexin V/PI flow cytometric data was analysed after first gating 
cell populations to exclude debris and select cells based on forward scatter 
(FSC-A) and side scatter (SSC-A) profiles (Figure 2.5). The cells gated in P1 
were used to generate a scatter plot of Annexin V-FITC area (-A) against 
PI-A positivity and the plot was split into quadrants. Figure 2.6 illustrates 
one of the scatter plots used to calculate Annexin V/PI positivity. 
A                                                                    B 	  	  	  	  	  
	  	  
Figure 2.5 The gating (P1) used to exclude debris and select cells based on their 
forward scatter (FSC-A) and side scatter (SSC-A) profiles for Annexin V/PI flow 
cytometric data.  
(A) Untreated MM cells that have a high percentage of viabilty. (B) MM cells 
treated for 48h with a high concentration of a cytotoxic agent.  
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Annexin V binds to phosphatidylserine (PS), a phospholipid present 
on the cytosolic side of the plasma membrane in non-apoptotic cells. Upon 
initiation of apoptosis, PS translocates to the extracellular side of the 
plasma membrane allowing Annexin V-FITC to identify apoptotic cells 
(Andree et al. 1990; Fadok et al. 1992). PI is used in conjunction with 
Annexin V-FITC to differentiate late stage apoptotic cells from early stage 
apoptotic cells. PI is an indicator of late stage apoptotic cells because the 
cell membranes of apoptotic cells become damaged allowing PI to 
permeate cells (Vermes et al. 1995). 
Using this principle, the percentage of viable cells was calculated as 
the percentage of cells that were Annexin V- negative/ PI- negative (viable 
cell quadrant). For the example shown in Figure 2.6A, this equals 77.1%. In 
contrast, the percentage of apoptotic cells was quantified from the 
summation of the percentage of Annexin V- positive /PI- negative (early 
stage apoptotic cell quadrant) and Annexin V- positive/PI - positive (late 
stage apoptotic cell quadrant). For example, for the plot shown in Figure 
2.6B the total percentage of apoptotic cells in this population is 85.8% 
(65.3% + 20.5%). Scatter plots similar to that shown in Figure 2.6 were 
generated for each sample and the percentage of apoptotic and viable cells 
was calculated. 
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Figure 2.6 An example of the scatter plots used to calculate Annexin V/PI positivity 
with the quadrants labelled.  
Cells gated in P1 were then used to generate a scatter plot of Annexin V-FITC-H 
against propidium iodide–A (PI-H) positivity and the plot was split into quadrants to 
represent the differents stages of apoptosis that the staining identifies. (A) Untreated 
MM cells that have a higher percentage of viabilty. (B) MM cells treated for 48h with a 
high concentration of a cytotoxic agent. In this scatter plot, it is clear to see that more 
cells are appearing in the apoptotic regions. 
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2.2.3. Cell surface analysis 
2.2.3.1. CD38, CD138 and CD40 expression 
The expression of the cell surface markers CD38, CD138 and CD40 
was measured by labelling MM cells with monoclonal antibodies (mAb) 
raised against each specific antigen and conjugated to different 
fluorochromes to facilitate simultaneous analysis of multiple parameters. 
The mAbs used included CD38 mouse anti-human R-phycoerythrin (PE) 
conjugate (MHCD3804, Invitrogen), CD138 mouse anti-human 
allophycocyanin (APC) conjugate (356506, BioLegend UK Ltd) and CD40 
mouse anti-human mAb FITC conjugate (CD4001, Life Technologies), 
respectively.  
Duplicate samples of 2.5×105 MM cells were harvested and washed 
in 1mL of PBS by centrifuging at 300 × g for 5 minutes. After removing 
supernatant, one of the duplicates was incubated in darkness for 10 
minutes with 5µL of the desired mAbs while the other sample was left 
unstained to act as the negative control. 1mL of PBS was added to the 
samples and the cells were washed again to remove any unbound mAb 
that may interfere with flow cytometric measurements. The supernatant 
was aspirated and the cell pellet was re-suspended in 200µL of PBS. Flow 
cytometric analysis was then carried out and 20,000 events were collected 
for each sample after carrying out the gating shown in Figure 2.7. 
Representative histograms for a CD138-APC stained sample verses an 
unstained sample are also shown in Figure 2.7. 
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Figure 2.7 FSC-A and SSC-A scatter plots with their respective histograms to 
provide a representative demonstration of the gating strategy used for cell surface 
analysis.  
In this particular example, the top panel of graphs show an unstained sample 
whereas the bottom panel shows a sample that has been stained for cell surface 
analysis of CD138 using the CD138-APC mAb. The FSC-A and SSC-A scatter plots 
show the gating (P2) used to select a population of viable cells. 20,000 events are then 
recorded in the P2 viable cell gate and the results for CD138 expression are shown in 
the histograms that plot the level of CD138-APC-H staining against count. As can be 
seen, the unstained MM cells show minimal CD138 expression compared to MM cells 
stained with the CD138-APC mAb. An identical strategy is used for CD38 and CD40 
cell surface analysis, when cells are stained with the respective mAb. 
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2.2.4. Intracellular analysis 
2.2.4.1. Mcl-1 expression 
Mcl-1 is an intracellular protein that is a member of the Bcl-2 protein 
family and is essential for MM cell survival (Derenne et al. 2002; Zhang et 
al. 2002). As it is an intracellular protein, a FIX & PERM® Cell 
Permeabilization Kit (Invitrogen) was used to allow the anti-Mcl-1 mAb to 
access its intended target. The staining process outlined below is shown in 
Figure 2.4.  
Duplicate samples of 3×105 MM cells were harvested and washed in 
1mL of PBS by centrifuging at 300 × g for 5 minutes. After removing 
supernatant, samples were incubated for 10 minutes at room temperature 
in darkness with 60µL Reagent A. This is provided within the FIX & 
PERM® Cell Permeabilization Kit. Cells were then washed in 1mL PBS and 
the supernatant again aspirated. The cell pellets were re-suspended in 60µL 
Reagent B. Reagent B is also part of the FIX & PERM® Cell 
Permeabilization Kit. Additionally, 4µL of Mcl-1 mouse anti-human 
monoclonal IgG1 antibody (sc-12756, Santa Cruz Biotechnology) was added 
to one of the duplicate samples and the other was left unstained to act as 
the negative control. Samples were incubated in darkness for 10 minutes at 
room temperate after mixing with a vortex.  
Samples were again washed in 1mL PBS then incubated with 4µL 
goat anti-mouse IgG1 FITC-conjugated antibody (SC-2078, Insight 
Biotechnology) at room temperate for 5 minutes. The secondary antibody 
was conjugated to the fluorchrome thereby allowing fluorescence detection 
of Mcl-1 (Figure 2.8).  
Samples were washed a final time in 1mL PBS and finally re-
suspended in 200µL PBS. Flow cytometric analysis was then carried out on 
20,000 events after carrying out gating similar to that shown in Figure 2.5.  
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Figure 2.8 Intracellular analysis of Mcl-1 expression.  
(1) Cells are fixated and permeabilised using a FIX & PERM® Cell Permeabilization 
Kit. Fixation preserves cellular antigens and maintains natural cell configuration 
while permeabilisation allows the antibodies access to the intracellular proteins they 
are targeted to. (2-3) Once cells are fixed and permeabilised, the antibodies can be 
added. Mcl-1 mouse anti-human IgG1 mAb is added first and acts as the primary 
antibody in the reaction because it binds to human Mcl-1 intracellular protein in the 
MM cell lines. The secondary antibody, goat anti-mouse IgG1 antibody conjugated 
to FITC is then added. This is an isotype-specific antibody, meaning that it is 
targeted to the IgG1 mouse region of the primary antibody. The FITC-conjugated 
secondary antibody then allows detection of the protein complex formed by flow 
cytometric analysis. 
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2.3.  Analysis of NF-κB activity 
2.3.1. Preparation of nuclear extracts 
5-10×106 cells were washed in 1mL PBS and centrifuged at 16,000 × g 
for 1 minute. The supernatant was discarded to create a semi-dry pellet. 
Pellets were re-suspended in 100µL of lysis buffer (Table 2.1) for 10 minutes 
on ice after vortexing to ensure that they were completely re-suspended in 
the lysis buffer. The lysis buffer contains a detergent (NP-40) that is capable 
of breaking down the cytoplasmic membrane. The lysed samples were 
centrifuged for 5 minutes at 16,600 × g at 4ºC (Heraeus Biofuge) and the 
supernatant (cytoplasmic extract) was removed. The remaining pellets, 
mainly consisting of cell nuclei, were then re-suspended in 50µL of high salt 
buffer (Table 2.1) for 25 minutes on ice after vortexing. The high salt buffer 
breaks down the nuclear membrane and also releases the transcription 
factors bound to the DNA by disrupting their electrostatic interactions. 
Samples were centrifuged at 16,600 × g for 5 minutes at 4ºC and the 
supernatant (nuclear extract) was removed to be stored at -20ºC in a fresh 
tube.  
 
 
Table 2.1 Components of the nuclear extraction buffers.  
*These reagents were added to the buffers immediately before use. PMSF has a short 
half-life of 30 minutes in water. PMSF= phenylmethanesulfonylfluoride.  
Lysis buffer High salt buffer 
10mM Hepes pH 7.9 25% Glycerol 
1.5mM MgCl2 20mM Hepes pH 7.9 
10mM KCl 420mM NaCl 
*0.1% PMSF 1.5mM MgCl2 
*0.1% NP40 0.2mM EDTA 
 **0.1% PMSF 
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2.3.2. Nuclear extract protein quantification 
Protein concentration of all nuclear extracts was determined using a 
Bio-Rad Protein Assay (5000006, Bio-Rad), which quantifies protein using 
the Bradford method.  
Unknown nuclear extract protein was quantified using known 
protein concentrations of bovine serum albumin (BSA) solution at 
concentrations varying from 0–3.2µg/µL. 3µL of each BSA solution 
concentration was pipetted into triplicate wells of a 96-well microplate 
alongside 2.5µL/well of each nuclear extract sample. 200µL of the Bio-Rad 
protein assay dye reagent (prepared at a 1:5 dilution in H2O) was added to 
each well. This was left for approximately 5 minutes to develop at room 
temperature and then the absorbance was read at 595nm on a 
spectrophotometer. 
The absorbance readings for known concentrations of BSA solution 
was then used to plot a standard curve and the polynomial equation of the 
line was used to calculate the unknown protein concentrations of the nuclear 
extract samples (Figure 2.9). 
                           
Figure 2.9 Standard curve created with BSA solution standards for quantification of 
nuclear extracts using a Bio-Rad Protein Assay.  
A polynomial trendline was plotted which produced an equation of the line and an R2 
value using Microsoft Excel. The R2 value was used to assess linearity while the 
polynomial equation was used to calculate unknown nuclear extract protein 
concentrations.  
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2.3.3. Electrophoretic mobility shift assay (EMSA) 
EMSA is a semi-quantitative technique that can be used to investigate 
protein-DNA interactions. For the purpose of this thesis, EMSA was 
specifically used to characterise active NF-κB binding activity within cells. 
The technique relies on the principle that if a specific DNA-binding protein 
is present in the nucleus of cells, it will bind a corresponding radiolabelled 
DNA sequence. This DNA-protein complexes can then be electrophoretically 
separated because their electrophoretic mobility will be less than that of free 
radiolabelled DNA. 
2.3.3.1. Labelling NF-κB consensus oligonucleotides with 32P 
NF-κB consensus oligonucleotides were first radiolabelled with 32P. 
20µL of reaction mix was prepared as outlined in Table 2.2 and incubated 
for 30 minutes at 37°C. Subsequently, 1µL of 0.5M EDTA and 20µL of 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1) was added to the reaction 
mix followed by vortexing and centrifugation for 2 minutes at 1390 × g in a 
microcentrifuge. This resulted in an aqueous top layer that was transferred 
to a fresh tube and 1µL of 5M NaCl followed by 40µL of ice cold ethanol 
was added. The mix was then placed at -20°C for 30 minutes before 
centrifugation for 5 minutes at 1390 × g. This separated the 32P labelled NF-
κB consensus oligonucleotides from the ethanol so that the ethanol could 
consequently be discarded. Any remaining ethanol was eliminated by 
evaporation when the tube containing the resulting pellet was left at room 
temperature with the lid open for 10 minutes. The 32P labelled NF-κB 
consensus oligonucleotide pellet was then resuspended in 50µL Tris-EDTA 
and stored at 20°C. 
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Table 2.2 The components of 20µL of reaction mix.  
This was used for the preparation of the 32P labelled NF-κB consensus 
oligonucleotides. 
Component Source Volume 
dH2O  10µL 
10 × kinase buffer M4101, Promega 2µL 
NF-κB consensus oligonucleotides E3292, Promega 2µL 
T4 Polynucleotide kinase M4101, Promega 1µL 
ATP [γ-32P] NEG002A250UC, Perkin Elmer 5µL 
Total: 20µL 
 
2.3.3.2. EMSA 
2µg of nuclear extract protein was incubated at room temperature for 
30 minutes with 1µL 10× DNA binding buffer (Table 2.3), 2µL of 2µg/µL 
poly deoxyinosinic-deoxycytidylic acid (P4929, Sigma) and 1µL NF-κB 
consensus oligonucleotides labelled with 32P to allow the DNA-protein 
complexes to form. 2µL of Bromophenol Blue (B3269, Sigma) was then 
added to the reaction mix containing the DNA-protein complexes and the 
reaction mix was loaded onto a 6% DNA retardation gel (EC6365BOX, Life 
Technologies). The NF-κB DNA binding complexes within samples were 
then electrophoretically separated at 75V for 1h and 30 minutes. Once 
electrophoretically separated, the gel was transferred to filter paper and 
dried for approximately 30 minutes using a gel drier (165-1746, Bio-Rad). 
Once the gel was dried, it was placed into a cassette with a phosphor 
screen and left to develop for a minimum of 3 days. The protein DNA 
binding present on the phosphor screen was visualised by 
autoradiography using a Typhoon Biomolecular Imager (Amersham). 
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2.3.4. NF-κB family enzyme linked immunosorbent assay (ELISA) 
The quantity of subunit in 1µg of MM cell line nuclear extract was 
quantified with an NF-κB family ELISA kit (Active Motif) according to the 
manufacturer’s instructions. The kit contains 96-well plates to which an 
oligonucleotide containing the NF-κB consensus site (5’-GGGACTTTCC-3’) 
has been immobilised. This allows the active NF-κB dimers to bind to the 
immobilised oligonucleotide. The optical density reading of samples was 
performed at an absorbance of 450nm (OD450) on a spectrophotometer.  
Standard curves were generated using known quantities of 
recombinant p65 protein (R2 >0.99) so that the level of p65 subunit could be 
accurately quantified in the units of ng of subunit protein in 1µg of nuclear 
extract protein (Figure 2.10). Similarly, standard curves were generated 
using known quantities of recombinant p50 protein (R2 >0.96) so were used 
to accurately quantify p50 from OD450 values. Both recombinant p65 and p50 
proteins were used in duplicate at concentrations varying from 0.039-2.5ng. 
It was also necessary to use the recombinant p65 standard curves to 
approximate the quantities of the p52, RelB and c-Rel subunit proteins from 
mean OD450 values because recombinant protein for each of these proteins 
was not available. 
Plotting a standard curve created an equation of the line (y = 1.512x + 
0.036, in Figure 2.10), which was rearranged and used to quantify subunit 
Table 2.3 The components of 870µL of 10× DNA binding buffer.  
This was prepared and then aliquoted to allow storage at -20°C. DTT= Dithiothreitol 
Component Source Volume 
40% Glycerol  400µL 
10mg/mL Nuclease free BSA B2518, Sigma 100µL 
0.5M EDTA  20µL 
1M DTT 43816, Sigma 50µL 
5M NaCl  200µL 
1M Tris pH 7.5  100µL 
Total: 870µL 
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protein (the x value) based on the recorded absorbance (the y value). The 
plotted line also produced an R2 value, which was used to assess linearity. If 
R2 was calculated as >0.95 then the p65 or p50 standard lines were 
considered adequate to accurately quantify the respective subunit protein 
levels. 
 
2.3.5 Preparation of whole cell lysates 
3×106 cells were harvested and washed in 1mL ice cold PBS by 
centrifuging at 300 × g for 5 minutes at 4°C. The supernatant was discarded 
and samples were lysed by the addition of 200µL ice cold lysis buffer 
containing phosphatase and protease inhibitors. The lysis buffer was made 
fresh immediately before use (Table 2.4). After centrifugation at 16,000 × g at 
4°C for 20 minutes, the supernatants (whole cell lysates) were transferred to a 
fresh 500µL centrifuge tube to be stored at -20°C short term or -80°C long term. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 2.10 Standard curves were generated using known quantities of recombinant 
p65 or p50 protein and these were used to quantify NF-κB subunit expression in 
MM cell lines from OD450 values.  
The example above shows a standard curve that was generated by assaying known 
quantities of recombinant p65 protein (ng/well) in duplicate using a p65 protein 
monoclonal antibody. The plotted line, equation and R2 value were generated using 
Microsoft Excel. 
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Table 2.4 Components required to produce 10mL phospho-protein lysis buffer.  
This lysis buffer was made immediately before use because some of the reagents 
within the buffer are not stable in aqueous solution for more than 30 minutes. 
Phosphatase Inhibitor Cocktail 2 is optimised to inhibit tyrosine protein phosphatases 
while Phosphatase Inhibitor Cocktail 3 is designed to specifically inhibit alkaline and 
serine-threonine protein phosphatases. Similarly, the Protease Inhibitor Cocktail 
inhibits enzymes that break down proteins. All three of these reagents improve the 
yield of intact proteins from the whole cell lysates.  
Component Quantity 
HEPES 500µL 
NaF 2.1mg 
Iodoacetamide 9.25mg 
NaCl 43.83mg 
10% NP40 1mL 
Protease Inhibitor Cocktail  100µL 
Phosphatase Inhibitor Cocktail 2 (P5726, Sigma-Aldrich) 100µL 
Phosphatase Inhibitor Cocktail 3 (P0044, Sigma-Aldrich) 100µL 
Na3VO4 100µL 
PMSF 100µL 
H2O Make volume up 
to 10mL 
 
2.3.5.1 Whole cell lysate protein quantification 
The protein concentration of all whole cell lysates was measured using 
a BioRad DC protein assay kit (500-0116, Bio-Rad), which quantifies protein 
using the Lowry method. This is a different method to that used for the 
quantification of nuclear extracts because the whole cell lysate solution 
contains a detergent (10% NP40), which can interfere with the Bradford 
method of protein assay.  
The BioRad DC protein assay kit was used according to the 
manufacturer’s instructions. The kit contains three reagents; Reagent A (an 
alkaline copper tartrate solution), Reagent B (dilute Folin Reagent) and 
Reagent S (surfactant solution). For every 1mL of Reagent A used, 20µL of 
Reagent S must be added beforehand to created the Working Reagent A.   
BSA solution was used as a protein standard at concentrations varying 
from 0–5µg/µL. 5µL of each BSA solution concentration was pipette into 
triplicate wells of a 96-well microplate alongside 5µL/well of each whole cell 
lysate sample. 25µL of Working Reagent A followed by 200µL Reagent B to 
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each used well of the 96-well microplate. This was left to develop for 15 
minutes at room temperature before absorbance was read at 750nm on a 
spectrophotometer. 
The absorbance readings for known concentrations of BSA solution 
were then used to plot a standard curve and the polynomial equation of the 
line was used to calculate the unknown protein quantities of the whole cell 
lysate samples (Figure 2.11). 
                                   
Figure 2.11 Standard curve created with BSA solution standards for quantification 
of whole cell lysate using a Bio-Rad DC Protein Assay Kit.  
A polynomial trendline was plotted which produced an equation of the line and an R2 
vlaue in Microsoft Excel. The R2 value was used to assess linearity while the 
polynomial equation was used to calculate unknown whole cell lysate protein 
concentrations. Absorbance was carried out at 750nm 
 
2.3.6 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) is a technique that is used to separate charged proteins based on 
their molecular weight. The first step involves denaturing proteins using 
SDS. SDS is an anionic detergent that can be used to remove secondary and 
tertiary protein structures, which reduces a complex protein to a negatively 
charged polypeptide chain.  
Four micrograms of whole cell lysate were denatured by addition of 
7.5µL NuPAGE lithium dodecyl sulphate (LDS) Sample Buffer (Invitrogen) 
and 3µL NuPAGE Reducing Agent (Invitrogen), while ensuring that 
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samples were kept on ice. The Sample Buffer contained Coomassie G250 and 
Phenol Red tracking dyes that can be used to track the movement of 
polypeptides during electrophoresis. The tubes containing the whole cell 
lysates, Sample Buffer and Reducing Agent were then heated at 80°C for 10 
minutes on a pre-heated heating block before loading into pre-cast 12-well 
NuPage® Novex® 4-12% gel (Invitrogen).  
The 12-well NuPage® Novex® 4-12% gel was previously prepared by 
removing from packaging, and removing the insulating tape and the well 
comb carefully to avoid damaging the loading wells. The gel was then 
rinsed in deionised H2O before placing into the XCell SureLock Mini-Cell 
apparatus (Invitrogen). The electrophoresis running buffer was prepared by 
diluting 50mL NuPAGE MOPS SDS Running Buffer (Invitrogen) in 950mL-
deionised H2O and used to fill the central chamber of the electrophoresis 
apparatus, ensuring that the loading wells were completing submerged with 
no leaks. The first loading well was used to load 5µL of Novex SeeBlue Plus2 
Pre-stained Protein Standard (Invitrogen) to ascertain the molecular weight 
of the resolved proteins detected by western blotting. Following this, the 
previously prepared denatured whole cell lysate samples were loaded.  
The remaining running buffer was used to fill the external chamber of 
the electrophoresis apparatus and the denatured proteins within the 
samples were then electrophoretically separated at 200V for approximately 
55 minutes, or until the dye front had reached the ridge at the bottom of the 
gel. 
2.3.7 Western blotting 
While the SDS-PAGE was running, the reagents and materials for the 
western blotting were prepared. One litre of non-reduced transfer buffer 
was prepared by diluting 50mL NuPAGE Transfer Buffer (Invitrogen) in 
850mL deionised H2O and 100mL methanol. The prepared transfer buffer 
was then used to soak two pieces of filter paper and six blotting pads. The 
polyvinylidene difluoride (PVDF) membrane was pre-soaked in methanol to 
prevent unspecific binding and then also soaked in the non-reduced transfer 
buffer. 
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Following electrophoresis, the polyacrylamide gels were removed 
from cassettes and placed on top of the pre-soaked PVDF membrane. The 
gel and transfer membrane were then sandwiched between two pieces of 
pre-soaked filter paper while ensuring any air bubbles were removed. The 
assembly was then sandwiched between six pre-soaked blotting pads (three 
on either side) before being placed into an XCell II Blot Module apparatus 
(Invitrogen) with the gel layer closest to the cathode core. The blot module 
was inserted into an XCell SureLock Mini-Cell apparatus (Invitrogen) and 
the central chamber filled with transfer buffer until the gel/membrane 
assembly was completely submerged. The external buffer chambers were 
filled with deionised H2O to dissipate heat during transfer. The protein 
transfer was carried out at 30V for 1h and 30 minutes.  
2.3.8 Immunodetection 
Following transfer, the PVDF membrane was removed from the blot 
module and washed three times in PBS-Tween buffer. The membrane was 
blocked with 30mL I-Block Tween (IBT-Tween) solution (Table 2.5) for 1h at 
room temperature. The blocking agent prevents non-specific binding of 
primary and/or secondary antibodies to the membrane. 
Table 2.5 Components and method required to produce I-Block Tween (IBT-Tween) 
solution.  
The solution was prepared by placing PBS tablets into H2O with Tween-20. The PBS-
Tween was pre-heated to 80°C and then I-Block was added. The I-Block was dissolved 
in the heated PBS-Tween on a magnetic stirrer. The solution was cooled to room 
temperature and then sodium azide was added as a preservative. The IBT-Tween 
solution was stored at 4°C for up to 1 month. 
Component Quantity 
Phosphate buffered saline (PBS) tablets (Fisher Scientific) 10 tablets 
Distilled H2O 950mL 
Tween-20 (Sigma-Aldrich) 1mL 
I-Block solution (Invitrogen) 2g 
Sodium azide 4g 
 
Following blocking, the PVDF membrane was probed overnight at 
4°C on a roller with 10µL of primary antibodies (Table 2.6) diluted in 10mL 
of IBT-Tween blocking solution (1/1000). The blot was then removed from 
primary antibody solution and washed four times in PBS-Tween buffer, each 
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time for a period of 15 minutes on a rocking platform. This ensured that any 
unbound antibody was removed to decrease the likelihood of background 
staining. The blot was subsequently probed for 1h at room temperature on a 
roller with 1µL of the appropriate secondary antibody diluted in 10mL of 
IBT-Tween blocking solution (1/10,000). The blot was then removed from 
secondary antibody solution and washed four times in PBS-Tween buffer, 
each time for a period of 15 minutes on a rocking platform. 
Table 2.6 Primary antibodies used for immunodetection.  
For all western blots, anti-β-actin antibody was used as the control primary antibody.  
Target protein Source Product number 
Phospho-NF-κB2 p100 
(Ser866/870) 
Cell Signalling Technology 4810S 
IκBα Cell Signalling Technology 9242S 
Phospho-NF-κB p65 (Ser536)  Cell Signalling Technology 3031S 
NF-κB p100/p52  Merick Millipore 05-361 
β-Actin Cell Signalling Technology 3700S 
 
The PVDF membrane was washed with 10mL alkaline phosphatase 
buffer for 5 minutes before removing excess buffer and transferring the blot 
to a plastic sheet. The blot was incubated with 600µL of the substrate CDP-
Star (Invitrogen) for 5 minutes to enable detection of the protein bands 
probed for. Excess detection reagent was removed from plastic sheet and the 
plastic sheet was inserted into a film cassette case. In a darkroom, 
photographic film was exposed to the membranes for 15 minutes up to 2h. 
depending on the intensity of the bands obtained.  
 
2.4. Gene expression analysis 
2.4.1. Sample collection 
RPMI8226 cells were incubated with increasing concentrations of the 
NF-κB inhibiting agents at a density of 1×106 cells/mL of cell culture media/ 
well of a 24-well cell culture plate. At 4h, 2-4×106 cells were harvested on ice 
from untreated and 2.5µM wells only. To reach the required cell number, 
wells containing 1×106 cells were combined as appropriate. The cells were 
washed in 1mL ice cold PBS and centrifuged at 300 × g for 5 minutes. The 
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supernatant was discarded to leave a cell pellet that was thoroughly re-
suspended in 1mL of TRIzol® reagent (Invitrogen) to isolate total RNA. The 
TRIzol® lysates were stored at -80ºC. 
At 48h, cytotoxicity was assessed in the 24-well cell culture plates 
where TRIzol® lysate samples had been generated using Annexin V/PI 
positivity. This provided a way of ensuring that the NF-κB inhibiting agents 
used on RPMI8226 cells were having the desired cytotoxic effect thereby 
allowing me to assess the suitability of the collected samples. This helped to 
avoid processing inadequate samples especially when the gene expression 
analysis techniques used were time consuming and expensive. 
2.4.2. GeneChip® Human Transcriptome Array 2.0 
TRIzol® lysate samples were analysed using GeneChip® Human 
Transcriptome Array (HTA) 2.0 following RNA extraction. RNA extraction 
and GeneChip® Human Transcriptome Array (HTA) 2.0 procedures were 
both performed by Central Biotechnology Services (CBS) at Cardiff 
University.  
Briefly, the RNA was extracted from the samples and the quantity 
and quality was checked using an Agilent 2100 Bioanalyzer System (Agilent 
Technologies, Inc). 50-500ng of the resulting RNA samples was then 
analysed by GeneChip® Human Transcriptome Array 2.0 (Affymetrix, Santa 
Clara, CA) as per the manufacturers instructions. This Affymetrix 
GeneChip® is a high-resolution microarray that contains more than six 
million probes, 70% of which cover exons for coding transcripts whilst the 
remaining probes cover exon-exon splice junctions and non-coding 
transcripts. This allows complete coverage of all transcript isoforms to 
provide accurate and comprehensive gene expression profiling. 
2.4.3. Microarray data analysis 
The data from the Affymetrix GeneChip® HTA 2.0 analysis was 
returned by CBS in the form of a series of very large CEL files so all data 
analysis, calculations and statistics were carried out using the statistical 
software environment, R (R-Core-Team 2014). R is a highly versatile piece of 
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software that provides a variety of statistical and graphical techniques. The 
full R script for all of the data analysis performed throughout this thesis is 
available on request. The CEL files were imported into the R environment 
and opened using the ‘oligo’ package (Carvalho a Irizarry 2010). This 
produced a table of raw intensities of the perfect match (PM) probes. 
2.4.3.1. RMA normalisation 
The RMA normalisation, which is part of the ‘oligo’ package 
(Carvalho a Irizarry 2010), is a method that preforms three functions on the 
raw intensities PM probes: background correction, Log2 transformation 
and normalisation. The background correction eliminates ‘noise’ that has 
arisen in each microarray sample by correcting for spatial variation within 
the individual sample arrays. The Log2 transformation makes it easier to 
view the distribution and reduces skewing when visualising the data. The 
result of RMA normalisation should remove any ‘noise’ and improve the 
clarity of true biological variability between the individual sample arrays 
to allow meaningful conclusions to be drawn. 
2.4.3.2. Visualisation of differentially expressed probesets 
The individual array replicates were grouped into their respective 
treatment condition groups. The ‘limma’ package (Ritchie et al. 2015) was 
used in R Studio to fit linear models to the data to condense the Affymetrix 
HTA 2.0 probes to their corresponding probesets and calculate each 
probesets mean expression. The ‘limma’ package was then used to perform 
separate contrasts between the untreated (UT) group of arrays and each 
treatment condition group of arrays, which produced the Log2 (fold change 
(FC)) of each probeset for each contrast. Then, an empirical Bayes 
moderated t-statistics test was performed on each UT vs. treated group 
contrast to generate p values for each probeset in each UT vs. treated 
contrast. 
The results of the empirical Bayes moderated t-statistic test were 
sorted for each UT vs. treated contrast to only include only those probesets 
that experienced a significant (p ≤ 0.05) Log2 (FC) ≤ -1 or Log2 (FC) ≥ 1. This 
then became the definition for a differentially expressed (DE) probeset. 
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This was achieved using global multiple testing procedures followed by a 
Benjamini and Hochberg correction to adjust the p values generated using 
a function within the ‘limma’ package (Ritchie et al. 2015) in R Studio. This 
revealed a list of DE probesets for each of the UT vs. treated contrasts.  
2.4.3.3. Annotation of DE genes relating to DE probesets 
The identified DE probesets were converted to their respective genes 
and annotated. For this analysis, only the probesets matching human genes 
were used. The DE probesets of the UT vs. treated contrasts were 
annotated with the gene level information using the file ‘A-GEOD-
17586_comments.txt’ (Available from: 
https://www.ebi.ac.ukarrayexpress/files/A-GEOD-17586/A-GEOD-
17586_comments.txt) (Hubbard 2014), which was imported into R Studio 
using the ‘RCurl’ package (Lang a the.CRAN.team 2016). This .txt file 
contained the gene level information corresponding to all the probesets of 
the Affymetrix GeneChip® HTA 2.0 and allowed the annotation of the 
probesets based on their likelihood of an identified transcript cluster 
corresponding to a gene. 
Once the probesets were annotated with the transcript identity, the 
‘limma’ package (Ritchie et al. 2015) was then used again to locate only 
those transcripts that were DE (Log2 (FC) ≥ 1 in either direction and p ≤ 
0.05) in at least one of the UT vs. SU compound contrasts. This produced a 
list consisting of 1334 labelled DE transcripts. The majority of the 
transcripts within this list did not have a gene symbol and were either 
listed as ‘---‘, likely to be RNA transcripts, or ‘NA’ so were excluded from 
the study as it would be difficult to identify them.  
2.4.3.4. Selection of DE genes to be used for validation in qRT-PCR 
DE gene lists were generated for each UT vs. treatment condition 
group based on Log2 (FC) thresholds. The respective gene lists were then 
analysed to assess the Gene Ontology (GO) and pathway terms using the 
online tool Enrichr (http://amp.pharm.mssm.edu/Enrichr/) (Chen et al. 
2013; Kuleshov et al. 2016). Enrichr is an online tool that computes an 
enrichment analysis of a manually selected DE gene list and then provides 
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information on the gene lists based on accumulated knowledge of the 102 
gene-set libraries in the database based on the function of the DE genes. 
The enrichment analysis is carried out using three approaches; a Fisher 
exact test and a z-score that is computed based on rank and standard 
deviation, followed finally by a combined score which is formulated by the 
first two approaches. Unlike the majority of other enrichment analysis tools 
available, Enrichr provides enrichment analysis information on areas such 
as gene ontologies, transcription, signalling pathways and biological and 
pharmacological processes. This allows Enrichr to provide an in depth 
insight into the function of a selected list of DE genes. 
2.4.3.4.1. Enrichment analysis of biological Gene Ontology terms 
The enrichment analysis produced a list of biological GO terms for 
each treatment conditions DE gene list. The lists of GO terms were sorted 
into a selection of GO categories so that the lists of processes generated 
could be more readily assessed for each UT vs. treatment condition 
contrast. This was achieved using a manually designed code in R Studio 
that sorted the terms based on key words that were likely to be associated 
with a certain GO category.  
The six main GO categories used consisted of cell cycle, metabolic 
processes, development, regulation and detection/response to stimuli. 
Three additional GO sub-categories were also included (transcription, 
signalling and apoptosis) because these were areas that could be of 
particular interest in determining the mechanistic action of the SU 
compounds due to the ontologies association with NF-κB signalling. The 
designed method was thorough and successfully sorted >95% of the GO 
terms into the specified GO categories. Moreover, the small number of 
GO terms that remained unsorted belonged to GO categories not included 
in the analysis, such as sensory perception.  
2.4.3.4.2. Enrichment analysis of Pathway terms 
The enrichment analysis also produced pathway lists that each DE 
gene was responsible for regulating. The pathway information used was 
taken from a mixture of feedback from the WikiPathways 2015, BioCarta 
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2015 and Reactome 2015 gene-set libraries (Chen et al. 2013; Kuleshov et 
al. 2016) because each one produced a slightly different list of pathway 
terms that when combined gave much more detail about the DE genes 
pathway regulation. The mus muculus pathway terms were excluded so 
that only the homo sapien terms were included in the final analysis.  
2.4.3.4.3. Expression levels of the SU1438, SU1411 and SU1349 DE gene 
lists 
The list of selected DE genes was narrowed down further by 
investigating the specific Log2 expressions, Log2(FCs) and p values for 
each DE gene for its relevant treatment condition. If a DE gene was to be 
used in the qRT-PCR experiments to validate the microarray data, the DE 
gene must be expressed at a relatively high level in the RPMI8226 
myeloma cells and experience a substantially large and significant FC in 
response to the SU compound relative to UT. By adhering to these 
criteria, the qRT-PCR experiments would be more likely to successfully 
detect the DE gene and allow validation of the microarray.  
Therefore, DE genes were only selected if the Log2 expressions of 
the gene in UT RPMI8226 cells was relatively high and the respective DE 
genes experience a relatively large and highly significant down regulation 
in response to the relevant treatment condition. In addition, specific 
patterns of expression for each SU compounds regulatory profiles were 
considered. Ideally, the selected DE genes would reflect the patterns 
observed in unique DE genes and shared DE genes between the 
individual . 
2.4.4. Real-time quantitative polymerase chain reaction (qRT-PCR) 
The microarray analysis revealed a number of differentially expressed 
genes that were associated with NF-κB activity and downstream gene 
regulation. A selection of these genes were analysed using qRT-PCR to 
validate the results obtained through microarray analysis.  
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2.4.4.1. RNA extraction and quantification 
TRIzol® lysates were thawed at room temperature for 
approximately 5 minutes before the addition of 0.2 volume of chloroform. 
As samples were re-suspended in 1mL TRIzol® reagent, this equated to 
200µL chloroform. To ensure chloroform was thoroughly combined, 
samples were vortexed for approximately 15 seconds prior to 
centrifugation at 11,330 × g for 15 minutes at 4ºC. After centrifugation, 
500µL of the aqueous phase was transferred to a fresh tube, taking care not 
to touch the inter-phase layer so as to avoid RNA contamination. 500µL of 
70% ethanol was mixed well with the aqueous layer. 
The remainder of the protocol was carried out using an RNeasy mini 
kit (Qiagen), according the manufacturers instruction. Briefly, the samples 
were transferred to an RNeasy spin column suspended in a 2mL collection 
tube and centrifuged at 11,330 × g for 15 seconds at 4ºC to allow the RNA 
to bind to the RNeasy membrane. The flow-through was discarded and the 
RNA spin column membrane was washed with the two provided buffers, 
RW1 buffer and RPE buffer respectively, which efficiently removes any 
contaminants. After centrifugation at 11,330× g for 15 seconds at 4ºC, the 
flow-through was discarded between washes. Finally, 50µL of RNase-free 
water was added to the spin column and the RNA was eluted after 
centrifugation at 11,330 × g for 1 minute at 4ºC. To achieve the highest 
concentration of RNA eluted from the RNeasy spin column membrane, the 
final step was repeated using the same 50µL of eluted RNA. The eluted 
RNA was stored at -80ºC. 
Before the RNA extracts were further processed, their quantities and 
qualities was assessed to ensure that the RNA extracted was of the highest 
quality and showed no genomic DNA contamination at this stage. This 
procedure was performed by CBS at Cardiff University on RNA at 
concentrations between 50-500ng/µg using an Agilent 2100 Bioanalyzer 
System. Briefly, RNA samples are first separated electrophoretically and 
then detected via laser induced fluorescence detection which generates a 
ratio of 18S to 28S ribosomal subunits. The resultant figures generated by 
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the Bioanalyzer software are a gel-like image of the electrophoretic 
separation and an electropherogram for visualisation of the ribosomal 
subunit ratio. Both pieces of information are standardised and an 
algorithym within the software is used to calculate an RNA integrity 
number (RIN) for each RNA sample. RNA was only used for subsequent 
qRT-PCR if the RIN was above a threshold of 6 because this indicates that 
the RNA is of an adequate quality for qPCR.  
2.4.4.2. Reverse transcription reaction  
 1µg of eluted RNA was converted to single-stranded 
complementary DNA (cDNA) on ice using a high capacity cDNA reverse 
transcription kit (4368814, Applied BioSystems), according to the 
manufacturer’s protocol. The 1µg RNA was made up to a volume of 10µL 
using nuclease-free H2O. 10µL of 2× Reverse Transcription Master Mix 
(Table 2.7) was added to each sample and then placed in the thermal cycler 
under the conditions shown in Table 2.8, as specified by the manufacturer’s 
instructions for this kit. The reaction produced 20µL of single-stranded 
cDNA and this is stored at -20ºC. 
 
Table 2.7 The components of 10µL 2× Reverse Transcription Master Mix. 
Excluding, nuclease-free H2O, all components were included in the high capacity 
cDNA reverse transcription kit (Applied BioSystems). 
Component Volume 
10× RT Buffer 2.0µL 
25× dNTP Mix (100mM) 0.8µL 
10× RT Random Primers 2.0µL 
Multiscribe™ Reverse Transcriptase 1.0µL 
Nuclease-free H2O  4.2µL 
Total: 10µL 
Table 2.8 The optimal thermal cycler conditions for the high capacity cDNA 
reverse transcription kit (Applied BioSystems).  
The reaction volume was set at 20µL. 
 Step 1 Step 2 Step 3 Step 4 
Temperature (ºC) 25 37 85 4 
Time 10 min 120 min 5 sec ∞ 
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2.4.4.3. qRT-PCR primer design  
The primers specific for target genes were designed using 
NCBI/Primer-BLAST (Ye et al. 2012). This software provides a tool that is 
capable of finding primers specific to a gene of interest by creating the PCR 
primer in Primer3 and then using BLAST to screen the primer in a user-
selected databases to avoid issues such as primer dimers and non-specific 
binding.  
The target genes reference sequence was inserted into the Primer-
BLAST website and amplicon length was set to 70-200 base pairs to ensure 
that all qPCR products amplified at the highest efficiency. Additionally, the 
option of the designed primer to span an exon/exon boundary of the target 
gene mRNA was selected to ensure that the primer could distinguish 
between cDNA and potential contamination of genomic DNA. A list of 
primers is usually suggested and for each target gene the most suitable 
primer pair was selected based on properties such as compatible melting 
temperatures between the forward and reverse primers, GC content and 
complementarity between primer pairs. The primers selected and used for 
qRT-PCR are shown in Table 2.9  
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Table 2.9 The sequence of primer pairs for the endogenous control and target genes 
that were analysed using qRT-PCR.  
All primers for target genes were designed using Primer-BLAST and produced by 
Eurofins Genomics. These were supplied lyophilised and were resuspended in 
nuclease-free H2O to a concentration of 100µM. The primer for the endogenous control 
was provided by Eurogentec S.A, Belgium. 
Primer for endogenous control 
RSP14 
Forward 5’-GGC AGA CCG AGA TGA ACT CT-3’ 
Reverse 5’-CCA GGT CCA GGG GTC TTG GT-3’ 
 
Primers for target genes 
TRAF6 
Forward 5’-TGA AGG AGA GAA TCA GAG CAA GT-3’ 
Reverse 5’-GGC AGT TCC ACC CAC ACT AT-3’ 
 
RIPK1 
Forward 5’-GTG CTG AAA GCC GAG ATG AG-3’ 
Reverse 5’-TTG AGC TGT AGC CTG AAC CTT-3’ 
 
POLA2 
Forward 5’-TGA AGG CAC AAG AAG CTC CG-3’ 
Reverse 5’-GGG CTC GGA CAC AAA CTG TA-3’ 
 
SRSF7 
Forward 5’-CGA CCA AGA AGC AGT CGT-3’ 
Reverse 5’-CAC TTT ACA GAC ATC ACA AAT CCC-3’ 
 
POLR2A 
Forward 5’-ACC GAC ACT TGG CTC TCT TG-3’ 
Reverse 5’-CAC GTC CAC CGT TTC CTC AA-3’ 
 
SRSF6 
Forward 5’-TAG GAC GCC TGA GCT ACA AC-3’ 
Reverse 5’-CCA CGA AGC CGT ACC CAT TT-3’ 
 
OFD1 
Forward 5’-TGC CTT CAG TCC CTA GTG TC-3’ 
Reverse 5’-GGA ACA AAG GTG CTG AAC GT-3’ 
 
PRKCI 
Forward 5’-ACG GCA TGT GTA AGG AAG GAT-3’ 
Reverse 5’-CAA GAG CCC ACC AGT CAA CA-3’ 
 
UBA2 
Forward 5’-TTC TCC CAC ATC GAC CTG ATT G-3’ 
Reverse 5’-AAC CTG TGC CTT TGA TCT TCC A-3’ 
 
NSUN2 
Forward 5’-ACA AAA GCC ACG CAA AAG AGA T-3’ 
Reverse 5’-CAG GCA AGT TCT TCA GGA TAC C-3’ 
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2.4.4.4. Real-time quantitative polymerase chain reaction (qRT-PCR) 
Single-stranded cDNA was diluted 1:5 in nuclease-free H2O on ice 
and primer pairs were each diluted to a working stock of 10µM. A qRT-
PCR master mix was prepared for each individual primer pair (Table 2.10). 
The fluorescent qPCR chemistry used for these experiment was the SYBR® 
Green dye-based assay. SYBR® Green I dye is a fluorescent DNA-binding 
dye that binds to the minor groove of double-stranded DNA to emit a 
much higher fluorescent signal than that of unbound SYBR® Green I dye. 
Table 2.10 The components of 15µL of qRT-PCR master mix.  
This could be scaled depending on how many wells were required. 
Component Source Volume 
Power SYBR® Green PCR Master Mix 4368706, Applied BioSystems 10µL 
Forward primer (10µM working stock)  1µL 
Reverse primer (10µM working stock)  1µL 
DNase-free H2O  3µL 
Total: 15µL 
 
15µL of the correct qRT-PCR master mix was then loaded into the 
appropriate wells of a MicroAmp Fast Optical 96-well reaction plate 
(4346906, Applied BioSystems) whilst taking care to avoid air bubbles in 
the wells as this can disrupt the fluorescent signal. 5µL of cDNA was then 
added to the appropriate wells of the 96-well reaction plate and the plate 
was then sealed using a MicroAmp Optical Adhesive Film (4311971, 
Applied BioSystems). The plate was briefly centrifuged at 300 × g for 2 
minutes to remove any air bubbles that may be present and to concentrate 
all qRT-PCR reagents in each well. The sealed 96-well reaction plate was 
then placed in the ViiA™ 7 Real-Time PCR System (Applied BioSystems) 
and analysed under the conditions listed in Table 2.11.  
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2.4.4.5. Analysis of qRT-PCR results 
The qRT-PCR results were analysed using ExpressionSuite Software 
v1.1 (ThermoFisher Scientific) and the melt curves, amplification plots and 
threshold cycles (Ct) were calculated. The fold changes were then manually 
calculated by the comparative Ct method (2-ΔΔCt) using Equation 1 (Livak a 
Schmittgen 2001). The 2-ΔΔCt method compares the gene expression of the 
DE gene of interest between the UT and SU compound treated samples 
relative to an endogenous control gene, which in this scenario was RSP14.  
2!!!!! = [ (C!  𝐷𝐸  𝑔𝑒𝑛𝑒 − 𝐶!  𝑅𝑆𝑃14 𝑡𝑟𝑒𝑎𝑡𝑒𝑑  𝑠𝑎𝑚𝑝𝑙𝑒 −   C!  𝐷𝐸  𝑔𝑒𝑛𝑒 − 𝐶!  𝑅𝑆𝑃14 𝑈𝑇  𝑠𝑎𝑚𝑝𝑙𝑒)]                  Equation 1 
 
2.5. Statistical analysis 
Unless otherwise stated, the majority of statistical analyses were 
produced using GraphPad Prism 6 software (Graphpad Software Inc., CA, 
USA). The analysis of the microarray and qRT-PCR data are the exceptions. In 
these scenarios R software and ExpressionSuite Software v1.1. (ThermoFisher 
Scientific) were used. The ExpressionSuite Software v1.1. was used to analyse 
amplification and melt curve plots produced through qRT-PCR. 
Table 2.11 The thermal cycler conditions for qRT-PCR using the ViiA™ 7 Real-Time 
PCR System.  
 Hold 
Stage 
PCR 
Stage 
Melt Curve  
Stage 
 Step 1 Step 1  Step 2 Step 1 Step 2 Step 3 
Cycle number 1 40 1 
Temperature (ºC) 95 95 60 95 60 95 
Time 10 min 15 secs 1 min 15 secs 1 min 15 secs 
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Chapter 3 - Characterisation of the MM cell lines at 
baseline and in response to NF-κB stimulation or 
inhibition. 
3.1. Characterisation of four multiple myeloma cell lines 
This was the first project within our research group to use the multiple 
myeloma cell lines H929, U266B1, RPMI8226 and JJN3. Therefore, the first 
step of this project was to successfully grow and characterise the new MM 
cell lines. The main factors that were of interest to the project were the 
growth characteristics, cell surface phenotype and basal NF-κB activity of 
each MM cell line. 
3.1.1. Growth characteristics of myeloma cell lines 
3.1.1.1. Growth kinetics and cell cycle 
Optimal growth conditions were established by altering the seeding 
density, passage frequency and media formulation for each MM cell line to 
ensure that the cell viability of each cell line was maintained at a level 
exceeding 85%. Whilst culturing the individual cell lines, it became 
apparent that the growth rates among the MM cell lines were not the 
same. The JJN3 cell line had the fastest doubling time of approximately 
24h, the RPMI8226 cell line had an approximate doubling time of 48h and 
the H929 and U266B1 cell lines comparatively had the slowest doubling 
times of approximately 72h.  
For this reason, the cell cycle distribution of the four cell lines was 
investigated. Cells were harvested from each MM cell line under optimal 
growth conditions and then fixed with ice cold 70% ethanol. The passage 
number used for the harvested cells was similarly low between the MM 
cell lines and was between the range of 15-25 passages. The fixed cells 
were then incubated with propidium iodide (PI) and the cell cycle 
distribution was measured by flow cytometry. PI is a fluorescent dye that 
binds in a stoichiometric manner to double stranded DNA. Therefore, it 
can be used to identify cells in different stages of the cell cycle i.e. cells 
with different DNA content. FlowJo V.10.1 software was used to analyse 
PI cell cycle in each cell line. Briefly, cells were gated to exclude debris, 
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doublets and the sub G0/G1 cell cycle phase so that the software could fit a 
cell cycle model. This allowed the calculation of the percentage of cells in 
each phase of cell cycle to be quantified. 
Figure 3.1A shows representative cell cycle profiles for each of the 
four MM cell lines used throughout this thesis and Figure 3.1B presents a 
stacked bar chart showing the collated data from three independent 
experiments. Figure 3.1A shows that the cell cycle profiles differ between 
the cell lines based on the size and shape of peaks representing each cell 
cycle phase, and the scale on which the individual profiles are plotted.  
The data in Figure 3.1B shows that overall H929 has the most cells 
in the G0/G1 phase (53.8% ± 1.0%) and a two-way ANOVA showed that 
this was significantly higher than the U266B1, RPMI8226 and JJN3 cell 
lines (p = 0.004, p < 0.001 and p < 0.001, respectively). In addition, the H929 
cell line had the least cells in S phase (41.2% ± 3.5%) when compared to the 
other cell lines and this was also calculated to be significantly lower than 
the U266B1, RPMI8226 and JJN3 cell lines (p = 0.004, p < 0.001 and p < 
0.001, respectively).  
The JJN3 cell line has the least cells in the G0/G1 cell phase (40.8% ± 
0.6%) relative to the H929 (53.8% ± 1.0%), U266B1 (48.3 ± 1.4%) and 
RPMI8226 (43.9 ± 2.3%) cell lines demonstrating that more JJN3 cells were 
actively cycling. Moreover, the JJN3 cell line showed the highest 
percentage of cells in G2/M cell phase (11.0 ± 1.0%), although H929 also 
had a similarly high level of cells in the G2/M phase (10.6 ± 1.4%) and this 
was not found to be significantly different (p = 0.99).  
The cell lines RPMI8226 and JJN3 showed the highest percentage of 
cells in the S and G2/M cell cycle phases (total of 58.4% and 60.5%, 
respectively), suggesting that these cell lines were growing more rapidly. 
Moreover, the percentages of cells in the G0/G1, S and G2/M phases were 
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Figure 3.1 The PI cell cycle profiles for each of the MM cell lines H929, U266B1, 
RPMI8226 and JJN3.  
Flow cytometric analysis was used to investigate the cell cycle profiles of each MM 
cell line. (A) Representative examples of the cell cycle profiles for each of the MM cell 
lines produced in FlowJo V.10.1. (B) The percentage of cells in each phase of cell cycle 
was input into Graphpad Prism 6.0 software and used to plot a stacked bar chart. 
Values reported represent mean ± SD where n = 3. 
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not significantly different between RPMI8226 and JJN3 cell lines (p = 0.14, 
p = 0.71 and p = 0.08, respectively) suggesting that the growth rates of 
these two cell lines were similar. 
The U266B1 cell line showed a growth rate more similar to that of 
the H929 cell line. This was supported by the cell cycle profile in Figure 
3.1, which showed that both the U266B1 and H929 cell lines had a more 
similar percentage of cells in G0/G1 (48.3 ± 1.4% and 53.8% ± 1.0%, 
respectively), although this was still significantly different (p = 0.004, two-
way ANOVA).  
Altogether, this suggests that comparatively the H929 cell line 
possesses the slowest growth rate whereas the JJN3 cell line possesses the 
fastest growth rate. Moreover, the growth rate of RPMI8226 is more 
similar to that of the JJN3 cell line suggesting that this cell line also has a 
fast doubling time. Finally, Figure 3.1 suggests that the U266B1 cell line 
has a growth rate that is more similar to that of the H929 cell line 
compared to the RPMI8226 cell line. 
3.1.1.2. Baseline cell death 
Another characteristic that was observed whilst culturing the 
individual cell lines was the variation in baseline cell viability among the 
MM cell lines. To investigate this further, the cell death occurring at 
optimal growth conditions was analysed. Cells were harvested from each 
MM cell line and the forward scatter area (FSC-A) and side scatter area 
(SSC-A) was measured using an Accuri C6 flow cytometer after any cell 
debris was excluded. Based on the FSC-A and SSC-A profiles, cells were 
gated to allow the calculation of the percentage of viable and apoptotic 
cells in normal growth cultures for each MM cell line (Figure 3.2A).  
Figure 3.2B shows a stacked bar chart showing the collated data 
from three independent experiments. At optimal growth conditions, 
U266B1 and JJN3 cells demonstrated high levels of viability (93.7% ± 1.6% 
and 91.1% ± 1.9%, respectively). In contrast, RPMI8226 cell cultures 
showed the highest level of baseline cell death under optimal growth 
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Figure 3.2 Baseline viability for each of the MM cell lines H929, U266B1, RPMI8226 
and JJN3.  
Myeloma cells were analysed on an Accuri C6 flow cytometer. (A) Representative 
examples of the forward scatter (FSC-A) and side scatter (SSC-A) profiles after cell 
debris has been excluded. The gates applied represent the populations of apoptotic 
and viable cells. (B) The percentage of viable and apoptotic cells was input into 
Graphpad Prism 6.0 software and used to plot a stacked bar chart. Values reported 
represent mean ± SD where n = 3, triplicate. 
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conditions (15.2% ± 1.2%) while H929 manifested intermediate levels of 
apoptosis (11.5% ± 2.5%). This data corresponded with observations made 
while culturing the individual MM cell lines. For example, the RPMI8226 
cell line required more frequent replacement of the cell culture medium 
because it discoloured more quickly. 
 
3.1.2. Cell surface phenotype of myeloma cell lines 
The next stage of characterisation involved examining the baseline 
cell surface expression of CD38, CD138 and CD40. CD38 and CD138 
antigens are phenotypic hallmarks associated with MM plasma cells. On the 
other hand, CD40 was investigated due to the association of its ligand 
(CD40L) with the stimulation of NF-κB activity (Coope et al. 2002; Tai et al. 
2003; Hauer et al. 2005). In addition, although little is known of this antigen 
or its ligand, it was recently suggested that the amount of soluble CD40L 
present in MM patients is an indicator of MM disease stage (Kamińska et al. 
2016). 
Cells from each cell line were harvested, washed in PBS and then 
incubated with a combination of CD138-APC, CD38-PE and CD40-FITC 
conjugated monoclonal antibodies. A final wash in PBS was carried out to 
remove any unbound antibodies followed by analysis using flow cytometry.  
A gating strategy was then applied to the collected data to ensure 
that only viable myeloma cells were selected for analysis (see Figure 3.3). 
Briefly, a population of viable cells was identified based on FSC-A and SSC-
A and the doublets within this population excluded following gating based 
on FSC-A and FSC-height (FSC-H). Figure 3.3 demonstrates that the gating 
strategies were adjusted based on the individual cell lines because variation 
was observed among their respective flow cytometric profiles. This 
included variation in cell size (FSC-A), granularity due to baseline cell death 
(SSC-A) and the presence of doublets (FSC-A vs. FSC-H) within the 
different cell lines. 
The selected population of viable single cells was then forward-gated 
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into a histogram plot for the expression of each antigen and the mean 
fluorescent intensity (MFI) values for CD38, CD138 and CD40 were 
recorded. Representative overlay histograms of each cell surface marker are 
shown in Figure 3.4A, 3.5A and 3.6A to demonstrate whether the antigens 
measured showed expression above background (unlabelled controls). 
Figure 3.4B, 3.5B and 3.6B show collated data from three separate 
phenotyping experiments carried out for each cell line. 
Figure 3.4 shows that CD38 expression varied among the myeloma 
cell lines with RPMI8226 cells showing the highest expression of CD38 
(382,022 ± 20,524) when compared to the other three cell lines. H929 (57,598 
± 4,502) and JJN3 (62,122 ± 6,585) both had relatively lower expression of 
CD38 and U266B1 had the lowest expression of CD38 (5,841 ± 935). 
Moreover, the CD38 expression observed for each MM cell was significantly 
different to that of the respective unlabelled control (p < 0.001, multiple t 
test followed by Holm-Sidak correction). However, based on the overlaid 
histogram presented in Figure 3.4A, the U266B1 cell line appeared to have a 
bimodal CD38 expression profile. This suggests that while most of the cells 
present within this cell line had a low level of CD38 expression, a small sub-
population that expressed a higher level of CD38. 
Figure 3.5 shows the CD138 expression profiles for each myeloma 
cell line; consistent with their plasma cell origin, all four cell lines analysed 
demonstrated a relatively high level of CD138 expression. However, as was 
the case for CD38, the expression of CD138 was heterogeneous between the 
cell lines. U266B1 had the highest average expression of CD138 (701,296 ± 
60,920), H929 and RPMI8226 each have intermediate expression (564,907 ± 
90,150 and 417,464 ± 66,040, respectively) and JJN3 has the lowest CD138 
expression among the cell lines (288,862 ± 49,679). In addition, for all four 
MM cell lines shown in Figure 3.5B, the error bars span a large range for 
CD138 expression suggesting that there may exist day to day variation in 
the expression of this cell surface marker within each cell line. 
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Figure 3.4 Baseline CD38 expression in the MM cell lines H929, U266B1, RPMI8226 
and JJN3.  
CD38 expression was investigated in each cell line by staining cells with an anti-
CD38-PE conjugated antibody and then using flow cytometric analysis to measure 
MFI. (A) A representative overlay histogram is shown for each MM cell line 
(unstained control = n, stained CD38-PE antibody sample = n). (B) The average 
CD38-PE MFI for each cell line (unstained control = −, stained samples = +) where 
error bars represent SD (n = 3, duplicate), experimental duplicates shown. A multiple 
t test followed by Holm-Sidak correction was performed using Graphpad Prism 6.0 
software to investigate the statistical significance values between the unlabelled 
control and CD38 stained sample for each MM cell line (n = 3, duplicates averaged). 
The results are reported above the graph (** = p < 0.001, *** = p < 0.0001). 
101 107.2102 103 104 105 106
0
60
0
20
0
40
0
Co
un
t
CD38-A
A07 N H929 
Gate: (P3 in (P2 in all))
101 107.2102 103 104 105 106
0
60
0
20
0
40
0
Co
un
t
CD38-A
D08 N U266B1 -
Gate: (P3 in (P2 in all))
101 107.2102 103 104 105 106
0
60
0
20
0
40
0
Co
un
t
CD38-A
A11 N 8226 -
Gate: (P3 in (P2 in all))
101 107.2102 103 104 105 106
0
60
0
20
0
40
0
Co
un
t
CD38-A
E10 O JJN3
Gate: (P3 in (P2 in all))
Gate: [P2 in all] Gate: [P2 in all]
Gate: [P2 in all] Gate: [P2 in all]RPMI8226 JJN3 
H929 U266B1 
C
ou
nt
 
Gate: [P2 in all] Gate: [P2 in all]CD38-PE (area) 
Gate: [P2 in all] Gate: [P2 in all]
H929 U266B1 RPMI8226 JJN3
0
5000
10000
40000
60000
80000
350000
400000
450000
CD
38
-P
E-
A 
ex
pr
es
si
on
 (M
FI
)
- + + + - +
*** ** *** **
- -
78
	  	  
             A	  
	  	  
          B	  
	  	  
Figure 3.5 Baseline CD138 expression in the MM cell lines H929, U266B1, 
RPMI8226 and JJN3.  
CD138 expression was investigated in each cell line by staining cells with an anti-
CD138-APC conjugated antibody and then using flow cytometric analysis to measure 
MFI. (A) A representative overlay histogram is shown for each MM cell line 
(unstained control = n, stained CD138-APC Ab sample = n). (B) The average CD138-
APC MFI for each cell line (unstained control = −, stained samples = +) where error 
bars represent SD (n = 3, duplicate), experiemental duplicates shown. A multiple t test 
followed by Holm-Sidak correction was performed using Graphpad Prism 6.0 
software to investigate the statistical significance values between the unlabelled 
control and CD138 stained sample for each MM cell line (n = 3, duplicates averaged). 
The results are reported above the graph (** = p < 0.001, *** = p < 0.0001). 
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Figure 3.6 Baseline CD40 expression in the MM cell lines H929, U266B1, RPMI8226 
and JJN3.  
CD40 expression was investigated in each cell line by staining cells with an anti-
CD40-FITC conjugated antibody and then using flow cytometric analysis to measure 
MFI. (A) A representative overlay histogram is shown for each MM cell line 
(unstained control = n, stained CD40-FITC Ab sample = n). (B) The average CD40-
FITC MFI for each cell line (unstained control = −, stained samples = +) where error 
bars represent SD (n = 3, duplicate), experiemental duplicates shown. A multiple t test 
followed by Holm-Sidak correction was performed using Graphpad Prism 6.0 
software to investigate the statistical significance values between the unlabelled 
control and CD40 stained sample for each MM cell line (n = 3, duplicates averaged). 
The results are reported above the graph (NS = not significant, * = p < 0.05, ** = p < 
0.01, *** = p < 0.001). 
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Lastly, Figure 3.6 shows the CD40 expression of each myeloma cell 
line. RPMI8226 is the only one of the four cell lines analysed to express a 
relatively high level of CD40 (21,132 ± 3,857). Figure 3.6A and 3.6B show 
that U266B1 and JJN3 express CD40 at the lowest levels, although only JJN3 
expresses CD40 to a level that is significantly different (p = 0.16 and p = 0.02, 
respectively, multiples t test followed by Holm-Sidak correction) to that of 
the unstained control (1,854 ± 215 and 1822 ± 127 as opposed to 1,489 ± 300 
and 1,377 ± 166, respectively). In contrast, the overlay histogram for H929 in 
Figure 3.6A shows that the CD40-FITC antibody stained sample does not 
overlap with that of the unstained control suggesting that H929 may 
express a relatively low level of CD40. This is further confirmed by the 
collated data shown in Figure 3.6B for H929 when the CD40-FITC stained 
sample (2,840 ± 252) is compared to the unstained control (1,601 ± 138), this 
difference is significantly different (p = 0.0017, multiples t test followed by 
Holm-Sidak correction). 
3.1.3. Basal NF-κB activity of myeloma cell lines 
The final step in the characterisation of the myeloma cell lines 
involved investigating the basal NF-κB activity in each cell line. This was 
achieved using two techniques, electrophoretic mobility shift assay (EMSA) 
and enzyme linked immunosorbent assay (ELISA). For both assays, cells 
were harvested from each myeloma cell line and processed to generate 
nuclear extracts. 
EMSA is semi-quantitative method of visualising NF-κB DNA 
binding activity. Briefly, 2µg of nuclear extract protein from each cell line 
was electrophoretically separated on a DNA retardation gel in the presence 
of NF-κB consensus oligonucleotides labelled with 32P. The resultant DNA 
binding was then visualised using autoradiography. Figure 3.7A shows a 
representative EMSA that shows the NF-κB DNA binding activity within 
each cell line whereas Figure 3.7B shows the collated mean intensity of 
bands corresponding to the gel-retarded NF-κB DNA complexes derived 
from three separate EMSA experiments.  
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Figure 3.7 EMSA was performed on nuclear extract protein from the MM cell lines 
H929, U266B1, RPMI8226 and JJN3  
(A) Representative EMSA showing the amount of NF-κB DNA binding for each cell 
line. The arrows indicate the positions of the bands corresponding to the gel-
retarded NF-κB DNA complexes. (B) Image J software was used to quantify the 
mean intensity of bands corresponding to the gel-retarded NF-κB DNA complexes. 
A one-tailed, unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the significant difference between the indicated cell lines. Values 
reported are mean intensity ± SD where n = 3. 
 
Overall, Figure 3.7 illustrates that there was variation in the level of 
NF-κB DNA binding between the four myeloma cell lines. The bands 
indicating NF-κB DNA binding in H929 and U266B1 were of a relatively 
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low intensity (68,760 ± 12,224 and 84,666 ± 14,285, respectively), although 
the difference between the mean intensity bands was significant (p = 0.004). 
On the other hand, JJN3 had the strongest intensity band for NF-κB DNA 
binding (143,100 ± 9,425) when compared to the other three cell lines. 
RPMI8226 had an intermediate level intensity band (120,313 ± 19,019) that 
was more like the level of JJN3 than H929 and U266B1 cell lines but still 
significantly lower than the mean intensity band for the JJN3 cell line (p < 
0.001). 
An ELISA detecting active NF-κB subunits was also performed on 
the nuclear extract samples from each of the myeloma cell lines. This assay 
was a more quantitative technique than EMSA as it allowed quantification 
of active NF-κB subunit composition, therefore providing an insight as to 
which NF-κB pathway the cell lines were constitutively dependent on. The 
NF-κB family ELISA kit (Active Motif) was used and carried out according 
to the manufacturer’s instructions. H929, U266B1 and RPMI8226 were each 
assayed at 1µg nuclear extract per well while JJN3 was assayed at a lower 
quantity of 0.5µg nuclear extract per well to accommodate for the fact that 
the EMSA suggested that it could have a relatively higher amount of NF-κB. 
Standard curves were generated using known quantities of recombinant 
p65 protein (r2 >0.99) and recombinant p50 protein (r2 >0.96) to allow NF-κB 
subunit quantification in nanograms per microgram of nuclear extract 
protein. 
The results of three independent ELISA experiments are shown in 
Figure 3.8 for each MM cell line. Figure 3.8 demonstrates that p65, p50, p52, 
RelB and c-Rel NF-κB subunits were positively detected in all four myeloma 
cell lines suggesting that all cell lines possessed constitutive NF-κB activity. 
Moreover, the results reflected the pattern of heterogeneity in NF-κB 
activity that was observed by EMSA (Figure 3.7). Cumulatively, JJN3 
appeared to have the highest level of active NF-κB subunits. In comparison, 
H929 had the lowest cumulative level of NF-κB activity among the cell lines. 
Both U266B1 and RPMI8226 cell lines had a relatively intermediate 
cumulative level of NF-κB activity. 
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The ELISA also suggested that the MM cell lines did not express 
higher levels of those subunits involved in the canonical NF-κB pathway 
(p65, p50 and c-Rel) compared to subunits involved in the non-canonical 
NF-κB pathway (p52 and RelB). This indicated that the NF-κB signalling 
observed in each cell line was most likely the result of a combination of both 
canonical and non-canonical NF-κB pathways. In terms of canonical 
pathway signalling, the levels of active p50 and c-Rel protein were 
relatively higher in all four myeloma cell lines compared to the levels of the 
levels of p65 NF-κB subunit protein. Similarly, U266B1, RPMI8226 and JJN3 
expressed relatively increased levels of the non-canonical pathway subunit 
p52 in contrast to the level of RelB. H929 expressed the lowest levels of both 
non-canonical subunit proteins p52 and RelB when compared to the other 
cell lines. 
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Figure 3.8 ELISA experiments detecting active NF-κB subunits were performed on 
each of the four MM cell lines. 
ELISAs were carried out to allow p65, p50, p52 RelB and c-Rel subunit protein 
quantification. H929, U266B1 and RPMI8226 were assayed using 1µg nuclear 
extract/well and JJN3 at 0.5µg nuclear extract/well. Values reported are mean ± SD 
produced from duplicate values where n = 3. 
3.2. Manipulation of myeloma cell lines with CD40L stimulation 
Interactions of malignant plasma cells with the bone marrow 
microenvironment result in some of the hallmarks of MM pathophysiology 
e.g. the development of osteolytic bone lesions (Hideshima et al. 2007; Podar 
et al. 2007; Kuehl a Bergsagel 2012). Plasma cells expressing CD40 can 
interact with CD40L within this environment and CD40L has previously 
been shown to stimulate NF-κB activation, mainly via the non-canonical 
signalling pathway (Coope et al. 2002; Tai et al. 2003; Hauer et al. 2005). 
Therefore, the effect of CD40L stimulation on the cell surface phenotype and 
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NF-κB activity was investigated in the MM cell lines by co-culturing MM 
cells with fibroblasts expressing the CD40L. 
3.2.1. Effect of CD40L stimulation on myeloma cell surface 
phenotype 
Cells from each of the four cell lines were co-cultured with either 
CD40L or NTL transfected fibroblasts for 24h. An additional condition was 
added called ‘LIQ’ to act as a further control; this involved culturing MM 
cells in liquid monoculture as a comparator for the two co-culture 
conditions. At 24h, MM cells were removed from co-culture and LIQ 
conditions and washed in PBS. Subsequently, MM cells with incubated with 
CD38-PE and CD138-APC conjugated monoclonal antibodies before a final 
wash in PBS. CD38 and CD138 cell surface expression were analysed using 
flow cytometry to investigate whether CD40L stimulation altered the 
myeloma phenotype. 
The gating strategy shown in Figure 3.3 was applied to the collected 
flow cytometric data to select viable myeloma cells and the MFI values for 
CD38 and CD138 determined. Figure 3.9 shows dot plots presenting the 
collated data from three separate phenotyping experiments carried out for 
all cell lines after 24h CD40L stimulation. Figure 3.9A shows that CD38 
expression in the H929, U266B1, RPMI8226 and JJN3 cell lines was not 
significantly (p = 0.52, p = 0.99, p = 0.63 and p = 0.99, respectively) altered by 
co-culture with CD40L transfected fibroblasts.  
Figure 3.9B shows the CD138 expression after 24h co-culture with 
and without fibroblasts transfected with NTL or CD40L. Similarly, H929, 
U266B1, RPMI8226 and JJN3 cells were again not significantly effected by 
NTL or CD40L fibroblast co-culture compared to baseline LIQ expression 
levels (p = 0.25, p = 0.70, p = 0.18 and p = 0.30, respectively). However, 
although not significant, H929 and RPMI8226 cells appeared to show a 
minor decrease in CD138 expression after co-culture with CD40L 
transfected fibroblasts compared to LIQ cultures (397,911 ± 99,606 and 
289,459 ± 110,846 compared to 515,319 ± 49,662 and 421,179 ± 23,791, 
respectively). 
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Figure 3.9 Effect of 24h CD40L stimulation on CD38 and CD138 cell surface 
expression on the MM cell lines H929, U266B1, RPMI8226 and JJN3.  
At 24h, CD38 (A) and CD138 (B) expression was investigated using flow cytometric 
analysis after the MM cell lines H929, U266B1, RPMI8226 and JJN3 were co-cultured 
with and without CD40L or NTL transfected fibroblasts (n = 3, individual duplicates 
and overall mean shown). A two-way ANOVA followed by a Tukey’s multiple 
comparisons test was performed using Graphpad Prism 6.0 software to investigate 
the statistical significance values between specific conditions for each MM cell line (n 
= 3, duplicates averaged). The results are reported above the graph (NS = not 
significant). (CD40L= cells co-cultured with CD40L transfected fibroblasts, NTL= cells 
co-cultured with NTL transfected fibroblasts, LIQ= MM cells cultured alone). 
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Overall, Figure 3.9 indicates that CD40L stimulation for 24h did not 
significantly alter the myeloma cell surface phenotype in the myeloma cell 
lines H929, U266B1, RPMI8226 and JJN3. 
 
3.2.2. Effect of CD40L stimulation on NF-κB activity in MM cell lines 
MM cell lines were co-cultured with and without CD40L or NTL 
transfected fibroblasts. After 24h, MM cells were removed from each 
condition and used to generate nuclear extracts. NF-κB family subunit 
ELISAs were then carried out on the nuclear extracts to investigate whether 
CD40L, in comparison to NTL, had increased NF-κB activity in the MM cell 
lines.  
As with the previous experiments, H929, U266B1 and RPMI8226 
were each assayed at 1µg nuclear extract per well while JJN3 cells were 
assayed using 0.5µg nuclear extract per well to reflect the increased basal 
NF-κB observed in these cells. Standard curves were generated using 
known quantities of recombinant p65 protein (r2 >0.99) and recombinant 
p50 protein (r2 >0.96) to allow NF-κB subunit quantification in ng/µg of 
nuclear extract protein. The results of these experiments are shown in 
Figures 3.11 and 3.12. One experiment in duplicate was performed to 
investigate the cell lines U266B1 and JJN3 because it was assumed that these 
cell lines were unlikely to respond to CD40L stimulation due to low level of 
CD40 expression. On the other hand, three separate experiments were 
performed for the H929 and RPMI8226 cell lines as these cell lines expressed 
higher levels of CD40. For each cell line, nuclear extract samples were 
assayed in duplicate in the NF-κB ELISA assays. 
Figure 3.10 indicates that p65, p50, p52, RelB and c-Rel subunit 
activity were not significantly affected by 24h CD40L stimulation in H929 
cells (p > 0.05). However, although not significant, the levels of p52 were 
decreased following 24h co-culture with CD40L transfected fibroblasts 
when compared to LIQ culture (0.620 ± 0.15 and 0.750 ± 0.24, respectively). 
However, a similar decrease was also observed after 24h co-culture with 
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Figure 3.10 Effect of CD40L on NF-κB activity in the MM cell lines H929 and 
RPMI8226.  
ELISAs detecting NF-κB subunits were performed 1µg/well on H929 and RPMI8226 
nuclear extracts after 24h co-culture with and without CD40L or NTL transfected 
fibroblasts (n = 3, experimental duplicates shown and the mean of individual 
experiments are mapped with a line). A two-way ANOVA followed by a Tukey’s 
multiple comparisons test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between specific conditions for each MM 
cell line (n = 3, duplicates averaged). The results are reported above each graph (NS = 
not significant). (CD40L= cells co-cultured with CD40L transfected fibroblasts, NTL= 
cells co-cultured with NTL transfected fibroblasts, LIQ= cells cultured alone).  
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NTL transfected fibroblasts when compared to LIQ culture conditions (0.561 
± 0.15 and 0.750 ± 0.24, respectively), suggesting that the decrease in p52 
subunit activity was not caused by CD40L stimulation. 
Figure 3.10 shows that NF-κB subunit expression in the nucleus of 
RPMI8226 cells was increased by 24h co-culture with CD40L transfected 
fibroblasts. All five NF-κB subunits showed a substantial increase in their 
active protein levels in response to co-culture with CD40L transfected 
fibroblasts. The most pronounced and significant increases were seen in the 
nuclear expression of p65 (p = 0.02) and RelB (p = 0.03) NF-κB subunits. As 
all NF-κB subunits were increased by 24h CD40L stimulation in RPMI8226 
cells, this would suggest that both canonical and non-canonical NF-κB 
signalling were stimulated by CD40L. 
Figure 3.11 shows the effect CD40L on NF-κB in the cell lines U266B1 
and JJN3. The level of p65 in both JJN3 and U266B1 cells was not altered by 
co-culture with NTL or CD40L transfected fibroblasts when compared to 
the LIQ condition. However, in these cell lines p52, RelB and c-Rel NF-κB 
subunits all showed a slight increase in protein quantity after CD40L 
stimulation for 24h with p52 showing the most pronounced increase relative 
to RelB and c-Rel. On the other hand, p50 subunit protein was decreased 
after 24h co-culture with both NTL and CD40L transfected fibroblasts in 
both U266B1 and JJN3 cell lines. 
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Figure 3.11 Effect of CD40L on NF-κB activity in the MM cell lines U266B1 and 
JJN3.  
ELISAs detecting active NF-κB subunits were performed U266B1 and JJN3 nuclear 
extracts after 24h co-culture with and without CD40L or NTL transfected fibroblasts. 
U266B1 was assayed at 1µg/well and JJN3 at 0.5µg/well of nuclear extract protein 
where n = 1, duplicate. The graph shows n = 1, with individual experimental 
duplicates and overall mean. (CD40L= cells co-cultured with CD40L transfected 
fibroblasts, NTL= cells co-cultured with NTL transfected fibroblasts, LIQ= cells 
cultured alone).  
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3.3. The use of the non-specific NF-κB inhibitor BAY 11-7082 in 
myeloma cell lines 
3.3.1. Cytotoxicity of BAY 11-7082 in MM cell lines 
The first step in exploring the use of the non-specific NF-κB inhibitor 
BAY 11-7082 in MM cell lines involved assessing its cytotoxic potential. To 
investigate cytotoxicity, each MM cell line was treated within increasing 
concentrations of BAY 11-7082 ranging from 0.25µM to 15µM. After 48h, 
cells from each cell line were harvested and washed in PBS before staining 
with Annexin V-FITC and propidium iodide (PI). Cells were then analysed 
using flow cytometry to determine the percentage of apoptosis (Annexin 
V+/PI- + Annexin V+/PI+). 
The raw data plots measured by the flow cytometer for the cell line 
H929 after 48h treatment with increasing concentrations of BAY 11-7082 are 
shown in Figure 3.12. Cells were first gated based on FSC-A and side SSC-A 
to exclude debris and these events were forward gated into bivariate plots 
of Annexin V (Annexin V-FITC-H) against propidium iodide (PI-H) (Figure 
3.12). The scatter plots were split into quadrants so that the populations 
could be clearly identified and the percentage of apoptotic cells at each 
concentration of BAY 11-7082 were used to construct dose-response curves. 
Figure 3.13 presents the dose-response curves for each MM cell line and 
each graph was created from three separate experiments. The interpolated 
LD50 values and their respective 95% confidence intervals (CI) are reported 
for each cell line. 
Figure 3.12 and 3.14 illustrate that BAY 11-7082 is cytotoxic in all the 
myeloma cell lines tested. Comparison of the LD50 values for each cell line 
indicated that the JJN3 cell line was relatively more resistant to apoptosis in 
response to BAY 11-7082 (LD50 = 3.38µM, 95% CI [2.71µM, 4.21µM]). 
However, the sensitivity of RPMI8226 cells to BAY 11-7082 was more 
similar to that of JJN3 than H929 and U266B1 cell lines (LD50 = 3.19µM, 95% 
CI [2.19µM, 4.64µM]). Conversely, Figure 3.13 shows that H929 and U266B1 
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were the relatively most sensitive to apoptosis induced by BAY 11-7082. 
H929 and U266B1 had similar sensitivity as demonstrated by their LD50 
values of 1.37µM (95% CI [1.16µM, 1.62µM]) and 1.93µM (95% CI [1.48µM, 
2.52µM]), respectively. 
 
 
Figure 3.13 The cytotoxicity of BAY 11-7082 at 48h in the MM cell lines H929, 
U266B1, RPMI8226 and JJN3.  
The cell lines H929, U266B1, RPMI8226 and JJN3 were treated with increasing 
concentrations of BAY 11-7082 between 0.25µM and 15µM. At 48h, cell death was 
measured using Annexin V/PI positivity on an Accuri C6 flow cytometer. The 
percentage of apoptotic cells at each concentration of BAY 11-7082 was then 
calculated and dose-response curves were constructed using GraphPad Prism 6.0. 
LD50 values were interpolated and are reported for each cell line alongside 95% CI. 
Error bars represent mean ± SD, where n = 3, triplicate. 
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3.3.2. Inhibition of NF-κB activity by BAY 11-7082  
As BAY 11-7082 was cytotoxic at 48h in all four MM cell lines, the 
effect of this agent on NF-κB activity was assessed in the cell line RPMI8226 
to investigate whether there was a correlation between apoptosis and the 
effect on NF-κB activity.  
RPMI8226 cells were treated with increasing concentrations of BAY 
11-7082 ranging from 0µM to 10µM in 2µM increments. At 4h, RPMI8226 
cells from each concentration were harvested, washed in PBS to remove any 
BAY 11-7082 and nuclear extracts were derived from the washed cell 
pellets. This experiment was repeated three times and once all nuclear 
extracts were generated, they were assayed in duplicate at 1µg per well using 
NF-κB family subunit ELISA assays. This was carried out as per the 
manufacturer’s instructions and standard curves were generated using 
known quantities of recombinant p65 protein (r2 >0.99) and recombinant 
p50 protein (r2 >0.96) to allow NF-κB subunit quantification. The subunit 
quantities were then normalised compared to the values at 0µM and data of 
these experiments are presented in Figures 3.15.  
Figure 3.14 demonstrates that the quantities of all five NF-κB 
subunits were decreased in a dose-dependent manner after 4h exposure to 
increasing concentrations of BAY 11-7082. The p52 subunit showed the most 
significant decrease after 4h exposure to 10µM BAY 11-7082 (22.4% ± 4.9%, p 
< 0.001) when compared to 0µM. The p50 and RelB NF-κB subunits 
experienced the largest decrease in protein quantity (7.1% ± 10.4% at 10µM, 
p=0.003 and 8.6% ± 12.0% at 10µM, p = 0.003, respectively) compared to 
untreated levels. While p65 and c-Rel subunits experienced a significant 
decrease in protein level in response to 10µM BAY 11-7082, relatively the 
decrease in activity was the lowest observed among the NF-κB subunits 
(43.8% ± 9.2%, p = 0.005 and 46.2% ± 24.5%, p = 0.04, respectively).  
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Figure 3.14 Effect of BAY 11-7082 on NF-κB activity in the MM cell line RPMI8226. 
RPMI8226 cells were incubated with increasing concentrations of BAY 11-7082 for 4h. 
RPMI8226 was then assayed at 1µg/well of nuclear extract protein using ELISAs 
detecting active NF-κB subunits. Quantified protein values were normalised 
compared to 0µM BAY 11-7082 to give the relative percentage of each NF-κB subunit. 
The percentages reported correspond to n = 3, duplicate with mean shown. A one-
tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM and 10µM BAY 11-7082 for 
each NF-κB subunit (n = 3, duplicates averaged). 
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Alongside the three experiments shown in Figure 3.14, the 
cytotoxicity induced by BAY 11-7082 in RPMI8226 cells was investigated at 
24h. Briefly, cells were harvested, washed in PBS before staining with 
Annexin V-FITC and propidium iodide (PI). Annexin V/PI positivity was 
then analysed in triplicate by flow cytometer and the percentage of 
apoptotic cells at each concentration of BAY 11-7082 was calculated. The 
NF-κB ELISA data in Figure 3.14 was then plotted alongside the percentage 
of apoptosis at each concentration for each of the three experiments. The 
correlation between these two measurements was investigated by 
performing linear regression analysis. 
Figure 3.15 displays the correlation between individual subunit 
quantities (ng/µg) and the percentage of apoptosis at each increasing dose 
of BAY 11-7082. The linear regression analysis for all five NF-κB subunits 
produced negative correlations that were all highly significant (p < 0.001). A 
pattern similar to that observed in Figure 3.14 for fold change and 
significance is observed when the linearity of each subunits linear 
regression was considered. For example, the correlation between apoptosis 
and the quantity of p50, p52 and RelB subunits produced the highest 
linearity (r2 = 0.74, r2 = 0.72 and r2 = 0.61, respectively) whereas the negative 
correlation between the quantity of p65 and c-Rel subunits and apoptosis 
was relatively weaker (r2 = 0.57 and r2 = 0.30, respectively)  
Overall, Figure 3.14 and Figure 3.15 suggest that BAY 11-7082 is 
dose-dependently inhibiting NF-κB activity generated through both the 
canonical and non-canonical pathways because this agent is significantly 
decreasing all active NF-κB subunits in RPMI8226 cells at 4h. The strong 
correlations seen between increasing concentrations of BAY 11-7082, 
inhibition of overall NF-κB activity at 4h and subsequent apoptosis at 24h 
implies that apoptosis in response to BAY 11-7082 in RPMI8226 cells may be 
a consequence of inhibition of NF-κB activity.  
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Figure 3.15 Correlation of BAY 11-7082 induced cytotoxicity at 24h with NF-κB 
activity at 4h in RPMI8226 cells.  
RPMI8226 cells were incubated with increasing concentrations of BAY 11-7082. At 4h, 
nuclear extracts were generated and NF-κB subunit ELISAs were performed. 
Subsequently, at 24h the percentage of apoptotic cells was measured using Annexin 
V/ PI positivity for the corresponding conditions. The correlation between these 
measurements was investigated by linear regression using Graphpad Prism 6.0 
software. The linearity (r2) and p value are reported for each NF-κB subunit. The 
points plotted represent mean ± SEM for each experiment (n = 3).	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3.4. Discussion 
3.4.1. Characterisation of four multiple myeloma cell lines 
The MM cell lines used throughout this thesis were chosen because 
they each represent distinct clinical features (and different NF-κB 
mutational profiles) manifested in MM (Drexler a Matsuo 2000; Annunziata 
et al. 2007; Keats et al. 2007). For example, H929 was selected because it 
possesses no known genetic abnormalities in the NF-κB pathway. On the 
other hand, U266B1, RPMI8226 and JJN3 are characterised by activating 
mutations affecting the NF-κB pathway (Annunziata et al. 2007; Keats et al. 
2007). U266B1 and RPMI8226 possess inactivating TRAF3 mutations while 
JJN3 manifests an activating mutation in NF-κB inducing kinase (NIK).  
Additionally, the cell lines were each derived from plasma cells 
originating from different anatomical niches of the disease, secrete different 
classes of immunoglobulin and even differ in the clinical stage of MM that 
they are derived from. For example, H929, U266B1 and RPMI8226 were 
obtained from patients diagnosed with MM and were derived from pleural 
effusion or peripheral blood samples (Matsuoka et al. 1967; Nilsson et al. 
1970; Gazdar et al. 1986). Conversely, JJN3 is considered to be a more 
advanced stage of MM because it is derived from the bone marrow of a 
patient diagnosed with plasma cell leukaemia (Jackson et al. 1989). 
As a result, it was predicted that each cell line would possess its own 
individual characteristics in terms of growth, phenotype and NF-κB activity. 
Therefore, to gain a better understanding of the MM cell lines, the first aim 
of this project was to characterise them. 
It was noticed during the culture of each cell line that the apparent 
growth rates differed between the MM cell lines. The RPMI8226 and JJN3 
cell lines showed the fastest growth rates as evidenced by the requirement 
to split the cultures more frequently than H929 and U266B1 cell lines. 
Therefore, the first step of cell line characterisation was to investigate the 
growth kinetics of each cell line by measuring cell cycle distributions and 
basal levels of apoptosis.  
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The data shown in Figure 3.1 suggested that RPMI8226 and JJN3 
were the fastest growing myeloma cell lines because they had more cells in 
S phase and G2/M phase of the cell cycle and a significantly lower 
percentage of cells in G0/G1 phase than H929 and U266B1 cell lines (p < 0.05, 
two-way ANOVA). Moreover, the percentages of cells in the G0/G1, S and 
G2/M phases were not significantly different between RPMI8226 and JJN3 
cell lines (p = 0.14, p = 0.71 and p = 0.08, respectively) suggesting that the 
growth rates of these two cell lines were similar. 
H929 possesses the slowest growth rate and concordantly manifested 
significantly more cells within G0/G1 phase of cell cycle than U266B1, 
RPMI8226 and JJN3 cell lines (p = 0.004, p < 0.001 and p < 0.001, 
respectively). This suggests that at any one time more H929 cells were not 
actively cycling. In addition, U266B1 showed a similar growth rate to that of 
the H929 cell line and this was supported by the cell cycle profile, which 
showed that both the U266B1 and H929 cell lines had a similar percentage 
of cells in G0/G1, although this was still significantly different (p = 0.004, 
two-way ANOVA).  
H929 has been previously reported to possess a doubling time of 50h 
(Gazdar et al. 1986), U266B1 a doubling time of 40-45h (Hellman et al. 1988) 
and a doubling time of 33.5h and 20-35h for RPMI8226 and JJN3 cell lines, 
respectively (Collins 2015; DSMZ 2016). The average doubling time of a MM 
cell line is 54h ± 36h (Drexler a Matsuo 2000) so the four cell lines that were 
characterised here reflect the expected spectrum of growth kinetics. As 
such, the data in Figure 3.1 supports my personal observations made whilst 
culturing the respective cell lines and also previous observations reported in 
the literature and within cell line databases. 
Figure 3.2 suggests that all the MM cell lines experienced relatively 
low baseline apoptosis when cultured under standardised culture 
conditions. The U266B1 and JJN3 cell lines experienced the lowest levels of 
natural cell death whereas the H929 and RPMI8226 cell lines experienced 
more baseline apoptosis. RPMI8226 cells experienced the most baseline cell 
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death under optimal growth conditions and it was observed during cell 
culture that the medium that these cells were grown in was required to be 
replaced more regularly that the other cell lines due to discolouration. This 
did not appear to be associated with the growth kinetics of the cell line as 
RPMI8226 cells were not the most proliferative. It therefore remains 
possible that the growth conditions used for this cell line were sub-optimal. 
Furthermore, plasma cells are antibody-producing cells and the 
RPMI8226 cell line has been previously shown to actively synthesise and 
secrete higher levels of immunoglobulin than the other MM cell lines 
(Matsuoka et al. 1968). In the same study, it was found that baseline cell 
death was associated with the higher levels of immunoglobulin synthesis. 
In theory, the increased immunoglobulin synthesis of the RPMI8226 cells 
may have a higher demand for nutrients, which could be responsible for the 
elevated cell apoptosis observed. 
Overall, the growth characteristics of the four MM cell lines show 
heterogeneity both in terms of growth kinetics and baseline cell death under 
standardised growth conditions. Moreover, there did not seem to be an 
association between the level of baseline cell death and the rate of cell 
proliferation in each cell line. The cell proliferation of RPMI8226 and JJN3 
cell lines were both relatively high but JJN3 cells experienced a low level of 
baseline cell death while RPMI8226 experienced the highest levels of cell 
death.  
The phenotype of each myeloma cell line was also investigated by 
measuring the cell surface expression of three antigens; CD38, CD138 and 
CD40. CD38 and CD138 are common cell surface markers in MM and, as 
such, are used to identify malignant plasma cells in MM due to their 
consistent and relatively high expression (Lin et al. 2004). In vivo, CD38 is 
an activation marker that can function both enzymatically and through 
ligation to the adhesion molecule CD31, which is highly expressed on 
endothelial cells and B cells, to control MM cell migration, proliferation, 
differentiation and survival (Cesano et al. 1998; Deaglio et al. 1998; 
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Fernàndez et al. 1998; Horenstein et al. 2015). CD138, also known as 
syndecan-1, is expressed mainly on terminally differentiated B cells, making 
it a marker for plasma cells, although it is readily shed from the cell surface 
spontaneously or because of apoptosis induction (Jourdan et al. 1998; Yang 
et al. 2002; Ikeda et al. 2009). CD138 is an adhesion molecule that regulates 
cell, growth, proliferation and survival (Gharbaran 2015). CD40 is a cell 
surface marker that is not usually expressed on normal plasma cells but has 
been shown to be present in the early stages of MM, although its expression 
does not correlate to overall survival (Tong et al. 2000; Perez-Andres et al. 
2009). In B cells, CD40 is required for B cell activation and terminal 
differentiation to plasma cells (O'Connor et al. 2003). The ligand of CD40 is 
CD40L (also called CD154) and interactions have previously been shown to 
stimulate NF-κB activity, mainly via the non-canonical signalling pathway 
(Coope et al. 2002; Tai et al. 2003; Hauer et al. 2005).  
CD38, CD138 and CD40 cell surface antigens each contribute to the 
myeloma phenotype and it has been reported that 100% of existing MM cell 
lines express CD138, 89% positively express CD38 and 59% express CD40, 
(Drexler a Matsuo 2000). This study revealed variable expression of CD38 
within the four cells lines. CD38 was most highly expressed in RPMI8226 
cells, followed by H929 and JJN3, with the lowest level found in U266B1, 
which is in line with previous reports (Hata et al. 1994; Lagging et al. 1996; 
Deckert et al. 2014). However, the data were in slight contrast with a report 
published by (Gooding et al. 1999) where CD38 expression was lowest in 
JJN3, and U266B1 expressed an intermediate level of CD38. Furthermore, 
my results indicated that the U266B1 cell line contained a sub-population 
that expressed a higher level of CD38. It has previously been reported that 
the U266B1 cell line contained two sub-populations expressing different 
levels of the cell surface antigen CD38 (Lagging et al. 1996; Mahmoud et al. 
1998). However, it is possible that at different passage numbers and under 
specific growth conditions, the U266B1 cells can express a higher or lower 
proportion of CD38hi cells thereby altering the overall MFI for this antigen. 
This could explain why Gooding et al. observed a higher expression of 
CD38 (Gooding et al. 1999). 
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The data in Figure 3.4 implies that U266B1 expressed the highest 
levels of CD138, H929 and RPMI8226 expressed intermediate levels, and 
JJN3 expressed the lowest levels of CD138. Although it can be concluded 
that CD138 expression was heterogeneous in these MM cell lines, the 
expression of this cell surface marker was relatively high in all cell lines. 
This is in slight contrast to previous data in which RPMI8226 was the cell 
line that expressed the most CD138 (Gooding et al. 1999; Ikeda et al. 2009). 
Moreover, it was suggested that the expression in JJN3 was more similar to 
that of RPMI8226 and H929 (Gooding et al. 1999). This difference may be 
the result of the gating used for measuring CD138 expression in JJN3 
because it can be seen in Figure 3.4A that small sub-populations of cells are 
present with a lower level of CD138. When this is considered within the 
average MFI of CD138, it may lower the overall expression. The large error 
bars displayed alongside the data in Figure 3.4 also suggests that the level 
of CD138 expression in the cell lines was variable. CD138 is easily shed 
from the surface of MM cells and this may explain the variability in 
expression within an individual cell line (Jourdan et al. 1998; Yang et al. 
2002; Ikeda et al. 2009).  
In this thesis, the RPMI8226 cell line was the only MM cell line 
analysed that expressed a relatively high level of CD40. H929, U266B1 and 
JJN3 also expressed a lower level of CD40, but only H929 and JJN3 were 
significantly different to unstained control (p < 0.01, multiples t test). In 
keeping with these findings, RPMI8226 was previously shown to express 
relatively high levels of CD40 while U266B1 was shown to express a much 
lower level of this antigen (Tong et al. 1994; Fernandes et al. 2009).  
In conclusion, the expression of CD38, CD138 and CD40 were found 
to be heterogeneous among the myeloma cell lines H929, U266B1, 
RPMI8226 and JJN3. Therefore, as CD38 (Kang et al. 2006; Tirumurugaan et 
al. 2008) and CD40 (Hinz et al. 2001) are both NF-κB regulated target genes, 
heterogeneous expression off these cell surface markers may suggest that 
NF-κB activity may also be differentially regulated in each MM cell line.  
103
	  	  
Consequently, baseline NF-κB activity was measured in each MM 
cell line and the NF-κB activity within the myeloma cell lines was also 
found to be heterogeneous. Based on EMSA and ELISA data, H929 
possessed the lowest level of NF-κB activity, JJN3 was found to have the 
highest level of NF-κB activity, and both U266B1 and RPMI8226 possessed 
an intermediate level. These observations correlate with the genetic 
abnormalities associated with the respective cell lines and support previous 
findings (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 2010) 
but contrast with previous EMSA data that showed U266B1 to have higher 
NF-κB DNA binding activity than RPMI8226 (Hideshima et al. 2006; 
Hideshima et al. 2009). 
The results from the ELISAs confirm that the MM cell lines all 
possess constitutive NF-κB activity that arises as a combination of both the 
canonical and non-canonical NF-κB signalling pathways. This is in 
accordance with previously published data where it was reported that 
U266B1, RPMI8226 and JJN3 all rely on both NF-κB signalling pathways 
(Annunziata et al. 2007; Keats et al. 2007; Hideshima et al. 2009; Demchenko 
et al. 2010).  
However, the ELISAs may not have been an appropriate tool to 
quantify the baseline levels of the NF-κB subunits p52, RelB and c-Rel in the 
MM cell lines. This is because their quantification in these experiments 
relied on using a p65 recombinant protein as a protein standard since a 
specific recombinant protein was not available for p52, RelB or c-Rel. For 
this reason, the levels of these subunits measured can only be assumed to be 
approximate quantities rather than specific quantities of each subunit. The 
ELISA’s also showed variability between individual experiments and this 
was mainly a consequence of the quality of the standard curves generated 
from the p65 or p50 recombinant proteins for each experiment. As a result, 
this may add further error to the exact NF-κB subunit levels quantified in 
the ELISA’s.  
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Furthermore, there may potentially be issues with the specificity of 
the antibodies provided in the NF-κB ELISA kits, as well as issues with the 
binding of specific NF-κB subunit dimers to the immobilised 
oligonucleotide. For these reasons, it has been discussed that the ELISA kits 
may be missing p52 homodimer binding (personal communication with 
Professor Neil Perkins). Consequently, there is a possibility that the ELISA’s 
used may inaccurately under quantify the levels of some NF-κB subunits, 
especially those derived from the non-canonical pathway. 
For the reasons discussed above, western blots could have been used 
in the place of the EMSA and ELISA techniques to more accurately 
determine the level of canonical and non-canonical pathway signalling in 
the MM cell line H929, U266B1, RPMI8226 and JJN3. Overall, with the use 
of the right combination of antibodies, this technique could have provided 
in depth information regarding the specific NF-κB pathway processing in 
each of the four MM cell lines. Antibodies targeting phosphorylated p100, 
p100 and p52 proteins could have provided information regarding non-
canonical processing, whereas antibodies specific to IκBα, p65 and 
phosphorylated IκBα proteins could have given information on canonical 
pathway processing. 
Finally, the main conclusion that can be drawn from the cell cycle, 
phenotype and NF-κB activity characterisation is that the MM cell lines 
H929, U266B1, RPMI8226 and JJN3 reflect the heterogeneity that is 
commonly observed in multiple myeloma. 
3.4.2. Manipulation of myeloma cell lines with CD40L stimulation 
The interaction of CD40 on malignant plasma cells with CD40L 
within the bone marrow microenvironment is an important interaction that 
can promote MM cell survival mainly through activation of non-canonical 
NF-κB signalling (Coope et al. 2002; Tai et al. 2003; Hauer et al. 2005). In 
addition, CD38 is a NF-κB regulated target gene so an increase in NF-κB 
activity through CD40L stimulation may alter the myeloma phenotype 
(Kang et al. 2006; Tirumurugaan et al. 2008). Therefore, the cell surface 
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phenotype and NF-κB activity was investigated in each MM cell line 
following co-culture of the MM cells with CD40L expressing fibroblasts.  
The RPMI8226 cell line was found to possess the highest level of 
CD40 cell surface expression whereas the H929 cell line had minimal CD40 
expression. For this reason, it was predicted that the RPMI8226 and H929 
MM cell lines were more likely to respond to CD40L stimulation in terms of 
cell surface CD38 and CD138 expression and NF-κB activity compared to 
the U266B1 and JJN3 cell lines. Moreover, previous work has shown that 
CD40L stimulation increased CD38 expression in CLL B cells (Willimott et 
al. 2007; Patten et al. 2008). In contrast, at 24h, CD40L stimulation did not 
significantly alter cell surface CD38 or CD138 expression in H929, U266B1, 
RPMI8226 and JJN3 cells relative to unstimulated cells. Although not 
significant, the H929 and RPMI8226 cell lines did experience a minor 
decrease in CD138 expression following 24h CD40L stimulation. However, 
as CD138 is easily shed from the surface of MM cells (Jourdan et al. 1998; 
Yang et al. 2002; Ikeda et al. 2009), it is possible that the force used to extract 
the MM cell lines from the CD40L transfected fibroblasts may have 
contributed to the minor decrease observed.  
Figure 3.10 showed that NF-κB activity was increased through CD40 
activation in the RPMI8226 cell line because the levels of all active NF-κB 
subunits were increased following 24h CD40L stimulation, with the most 
prominent increases seen in the p65 and RelB subunits (p = 0.02 and p = 
0.03, respectively). This indicates that CD40L stimulation is positively 
regulating NF-κB activity generated through both canonical and non-
canonical signalling. This effect was not mirrored in the H929 cell line 
following CD40L stimulation and the active NF-κB subunit levels remained 
unchanged. The phenotype characterisation showed that RPMI8226 cells 
possess significantly higher levels of CD40 cell surface expression compared 
to H929 cells. Therefore, this may explain why the RPMI8226 cell line was 
more susceptible to an increase in NF-κB subunit levels in response to CD40 
activation. 
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The results replicate previous findings that CD40 activation induced 
NF-κB activity generated through both the canonical and non-canonical 
signalling pathways (Coope et al. 2002; Tai et al. 2003; Hauer et al. 2005).  
In conclusion, only NF-κB activity was significantly altered as a 
consequence of CD40L stimulation in the CD40 expressing MM cell line 
RPMI8226.  
3.4.3. The use of the non-specific NF-κB inhibitor BAY 11-7082 in 
myeloma cell lines 
One of the main aims of this thesis was to explore the use of NF-κB 
inhibitors in MM. As a first step, the effect of a commercially available non-
specific NF-κB inhibitor, BAY 11-7082, was investigated in the myeloma cell 
lines. BAY 11-7082 has been shown to non-sepcifically inhibit NF-κB 
signalling by irreversibly inhibiting IκBα phosphorylation through the 
inhibition of IKK activation and this subsequently induced apoptosis in 
leukaemia cells (Pierce et al. 1997; Mori et al. 2002; Strickson et al. 2013). 
Therefore, as all the myeloma cell lines were shown to display constitutive 
NF-κB activity, it was predicted that inhibition of NF-κB would induce 
apoptosis but that the sensitivity of the MM cell lines may be 
heterogeneous. 
The cytotoxicity of BAY 11-7082 was first investigated and it was 
found to induce dose-dependent cytotoxicity in all four MM cell lines 
tested, which replicates the previous studies showing that BAY 11-7082 was 
cytotoxic to MM cell lines (Dai et al. 2004b; Rauert-Wunderlich et al. 2013). 
As predicted, sensitivity to the NF-κB inhibitor varied among the cell lines. 
H929 was the most sensitive cell line to apoptosis induced by BAY 11-7082 
and JJN3 was the most resistant cell line. U266B1 and RPMI8226 both 
displayed intermediate sensitivity to the agent but U266B1 showed 
sensitivity more similar to that of H929 whereas RPMI8226 was almost as 
resistant as JJN3.  
The pattern observed in cytotoxicity inversely correlated with the 
level of constitutive NF-κB activity in each MM cell line. For example, JJN3 
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possessed the most NF-κB activity but was the most resistant myeloma cell 
line to BAY 11-7082 induced apoptosis. An explanation for this could relate 
to the function of NF-κB because the transcription factor regulates genes 
involved in anti-apoptosis and drug resistance (Gilmore 2007; Demchenko a 
Kuehl 2010). Therefore, cells with more NF-κB activity may be able to resist 
the inhibition caused by BAY 11-7082. However, this is contrast with other 
published data that suggests the inverse in which MM cell lines with a 
higher level of baseline activity of p65 and p52 subunits were more sensitive 
to apoptosis induced by IKK inhibition, although this was specific to IKKβ 
inhibition (Annunziata et al. 2007). As a result, Annunziata et al. reported 
that the JJN3 cell line was more sensitive to apoptosis induced through 
IKKβ inhibition when compared to the H929 cell line. 
The correlation between apoptosis and the level of NF-κB inhibition 
by BAY 11-7082 was then investigated in the MM cell line RPMI8226, a MM 
cell line that possessed a comparatively intermediate NF-κB activity and a 
demonstrated a relatively intermediate sensitivity to BAY 11-7082. NF-κB 
subunit ELISA assays showed that p65, p50, p52, RelB and c-Rel active NF-
κB subunits experienced a significant dose-dependent decrease in response 
to 10µM BAY 11-7082 (p = 0.005, p = 0.003, p < 0.001, p = 0.003 and p = 0.04, 
respectively). The largest fold changes were observed for p50 and RelB 
subunits, which are canonical and non-canonical associated NF-κB subunits, 
respectively. This suggests that BAY 11-7082 regulates NF-κB subunits 
involved in both NF-κB pathways and implies that BAY 11-7082 is an 
inhibitor of both canonical and non-canonical signalling pathways, which 
replicates previous findings (Jayandharan et al. 2011; Rauert-Wunderlich et 
al. 2013). As BAY 11-7082 is predicted to be an inhibitor of IKK activation, 
this would suggest that it is capable of inhibiting both IKKα and IKKβ 
activation, which would explain the dual inhibition observed for canonical 
and non-canonical NF-κB activity.  
Moreover, Figure 3.15 shows that a highly significant negative 
correlation existed between NF-κB inhibition and the induction of apoptosis 
in response to BAY 11-7082. This suggests that inhibition of NF-κB activity 
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generated as a consequence of both canonical and non-canonical pathway 
signalling may contribute to the apoptotic effect induced by BAY 11-7082 in 
the MM cell lines. However, several studies have shown that BAY 11-7082 
possesses other molecular targets and it is a possibility that this is 
contributing to the cytotoxicity of BAY 11-7082 in the MM cell lines (Lee et 
al. 2012; Rauert-Wunderlich et al. 2013; Strickson et al. 2013). For example, 
Stickson et al. 2013 showed that BAY 11-7082 is not a direct inhibitor of 
IKKα and IKKβ, but instead inhibits their activation by targeting 
components of the ubiquitin system, such as TRAF6, to prevent the 
formation of K63-pUb and linear-pUb chains. Moreover, as ubiquitination is 
involved in a wide range of signalling pathways, including proteasomal 
degradation and DNA damage, BAY 11-7082 inhibition of multiple 
ubiquitination events is more likely the cause of the concentration-
dependent apoptosis measured in the MM cell lines (Strickson et al. 2013).  
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Chapter 4 – Evaluation of a series of novel IKKα 
inhibitors for the treatment of multiple myeloma 
NF-κB signalling is generally described as occurring through two 
distinct pathways; the canonical and non-canonical NF-κB signalling 
pathways. The canonical pathway is mainly activated through IKKβ-mediated 
phosphorylation of the IκB proteins, which allows activated dimers of p65, 
p50 and c-Rel to translocate to the nucleus and then bind DNA κB elements 
(Adli et al. 2010). On the other hand, the non-canonical NF-κB pathway is 
mainly activated through NF-κB inducing kinase (NIK)-mediated 
phosphorylation of IKKα (Malinin et al. 1997; Ling et al. 1998). Activated IKKα 
then phosphorylates the precursor subunit p100, which leads to proteolytic 
processing of the p52 NF-κB subunit, which can form homo- or hetero-dimers 
with the RelB NF-κB subunit (Senftleben et al. 2001; Solan et al. 2002). The 
activated NF-κB p52/RelB dimers then translocate to the nucleus where they 
bind DNA κB elements to induce a transcriptional response.  
Several studies have documented that MM tumours and cell lines 
possess a large number of genetic aberrations that lead to constitutive NF-κB 
activity, preferentially through activation of the non-canonical NF-κB 
pathway (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 2010). 
Furthermore, constitutive RelB activation is observed in approximately 40% of 
MM cases and the phenotypic advantage of this has been found to be to 
promote MM cell survival by increasing the expression of anti-apoptotic NF-
κB target genes such as cIAP2 (Cormier et al. 2013). Therefore, the dependence 
of MM cells on the non-canonical NF-κB pathway indicates its importance in 
MM disease progression and that inhibition of this NF-κB pathway may 
provide a promising therapeutic option in MM.  
The NF-κB pathways can be specifically inhibited at several points; 
prevention of IκB protein degradation, inhibition of IKK activation and 
blockade of NF-κB DNA-binding (Godwin et al. 2013). Due to the crucial roles 
that IKK plays in the regulation of NF-κB activity, both through canonical and 
non-canonical pathway activation, inhibition of IKK activation may provide a 
promising therapeutic strategy.  
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Multiple IKKβ inhibitors have been evaluated in MM and these have 
been found to induce a number of anti-tumour effects, mainly through 
canonical NF-κB pathway inhibition. These include inhibiting cell 
proliferation and cell growth, inducing apoptosis and cell cycle arrest, 
overcoming IL-6 medicated cell growth and drug resistance, and down-
regulating a number of NF-κB canonical pathway regulated genes, including 
IκBα, Bcl-2 and cyclin D1 (Hideshima et al. 2002; Bharti et al. 2003; Hideshima 
et al. 2006; Annunziata et al. 2007; Jourdan et al. 2007; Hideshima et al. 2009).  
However, concerns over the safety profile of IKKβ inhibitors have 
prevented further development of these specific agents in MM. For example, 
complete ablation of the canonical pathway activity through IKKβ inhibition 
is likely to impair the function of the adaptive and innate immune system, 
due to the complexity through which NF-κB signalling can regulate 
immunity, and may also lead to IL-1β induced neutrophilia and inflammation 
(Greten et al. 2007; Vallabhapurapu a Karin 2009; Hsu et al. 2011). In addition, 
hepatic toxicity is a possible adverse event of IKKβ inhibitors because IKKβ 
knockout mouse models indicate that the embryonic lethality of this 
phenotype is a result of hepatocyte apoptosis (Li et al. 1999b; Tanaka et al. 
1999).  
Specific inhibitors of IKKα may be beneficial in overcoming some of the 
adverse events that are associated with canonical pathway inhibition 
(DiDonato et al. 2012). IKKα mainly governs the activation of the non-
canonical NF-κB pathway so specific pharmacological inhibitors of IKKα 
would be expected to inhibit non-canonical NF-κB pathway activation in MM 
as opposed to canonical pathway activation (Senftleben et al. 2001; Solan et al. 
2002). 
In mice, deletion of IKKα induces perinatal lethality due to defects in 
skeletal and epidermal development, although this has been shown to be 
independent of NF-κB activation (Li et al. 1999a; Gerondakis et al. 2006). 
Replacing the kinase activation serine residues in IKKα with alanine residues 
to prevent the activation of IKKα, can overcome lethality by still allowing 
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expression of the protein itself (Cao et al. 2001). This produces a phenotype 
that is similar to that which arises in the absence of NIK or nfkb2, which 
encodes the p100 protein, in that defects are present in lymphoid 
organogenesis, germinal centre formation and generation of mature follicular 
dendritic cells (Senftleben et al. 2001; Bonizzi et al. 2004; Gerondakis et al. 
2006). Moreover, these effects have been shown to arise because these 
processes are regulated by p52/RelB dimers through non-canonical NF-κB 
pathway activation (Bonizzi et al. 2004). In B-cells, IKKα has been shown to be 
essential for normal B-cell development and immature B-cells experience 
increased turnover due to apoptosis (Kaisho et al. 2001). The apoptosis has 
been demonstrated to be a consequence of decreased transcription of the anti-
apoptotic protein Bcl-2 through ablation of BAFF-induced NF-κB non-
canonical activation (Claudio et al. 2002a). Overall, this indicates a role for the 
non-canonical pathway in B-cell proliferation, maturation and apoptosis. In 
addition, dual IKK inhibition has been shown induce a more potent cytotoxic 
effect in MM cells when compared to IKKβ inhibition alone, which indicates 
that non-canonical pathway inhibition may be contributing to their overall 
apoptotic effect (Rauert-Wunderlich et al. 2013).  
Therefore, my hypothesis was that the use of a novel IKKα inhibitor 
may represent a promising strategy for the treatment of MM. The specific 
aims of this chapter were to evaluate a series of pharmacological agents 
designed to inhibit IKKα in terms of their cytotoxicity, regulation of Mcl-1 
expression and effect on NF-κB activity in the MM cell line, RPMI8226.  
 
4.1. The kinase inhibitory profiles of the IKKα inhibitory agents 
Prof. Simon MacKay at the University of Strathclyde kindly provided 
nine novel IKKα inhibitory pharmacological agents and these agents will be 
referred to from here on as the SU series of compounds. Table 4.1 shows the 
predicted inhibitory concentrations that induce 50% reduced function (IC50) 
in the kinases IKKα, IKKβ and CDK9 for each of the nine SU compounds. 
Table 4.1 shows that each SU compound possesses a different kinase 
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inhibitory profile. SU1257 has a relatively unique inhibitory profile because it 
has been designed to be a structural analogue of the SU series but the 
compound does not possess IKKα, IKKβ or CDK9 inhibitory properties. For 
this reason, SU1257 represents an ideal control compound throughout the 
evaluation of the other SU series compounds. 
Table 4.1 The predicted mechanistic data for the IKKα inhibitory SU series. 
The IC50 value for the kinases IKKα, IKKβ and CDK9 for each of the nine SU 
compounds. A summary for each compound is also provided. 
 IKKα IKKβ CDK9 Summary 
SU1257 - - - 
A structural analogue of the other 
SU compounds but without IKKα 
or IKKβ properties. 
SU1053 28nM 4190nM ~1000nM 
>140 times preferential inhibition 
of IKKα over IKKβ. A weak 
inhibitor of CDK9. 
SU1261 10nM 680nM 16nM 
>65 times preferential inhibition of 
IKKα over IKKβ. A potent inhibitor 
of CDK9.  
SU1349 16nM 3352nM 13nM 
An IKKα inhibitor with some weak 
inhibition of IKKβ. A potent 
inhibitor of CDK9. 
SU1361 8nM 964nM 20nM 
A dual IKKα and CDK9 inhibitor 
with weak IKKβ inhibitory 
properties 
SU1365 26nM 1500nM ~20nM 
A dual IKKα and CDK9 inhibitor 
with weak IKKβ inhibitory 
properties 
SU1372 7nM 587nM 18nM 
>80 times preferential inhibition of 
IKKα over IKKβ. A potent inhibitor 
of CDK9. 
SU1411 ~10nM ~500nM ~700nM 
50 times preferential inhibition of 
IKKα over IKKβ. A weak inhibitor 
of CDK9. 
SU1438 10nM 511nM ~700nM 
>50 times preferential inhibition of 
IKKα over IKKβ. A weak inhibitor 
of CDK9. 
 
Table 4.1 shows that SU1349 was the most potent inhibitor of CDK9 
(IC50 = 13nM) and a potent inhibitor of IKKα (IC50 = 16nM). Similarly, SU1372 
was the most potent IKKα inhibitor (IC50 = 7nM) but was also a relatively 
potent inhibitor of CDK9 (IC50 = 18nM). The compounds SU1261, SU1361 and 
SU1365 possessed comparable kinase inhibitory profiles. For example, all 
three compounds were potent inhibitors of IKKα (10nM, 8nM and 26nM, 
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respectively) and CDK9 (16nM, 20nM and ~20nM, respectively), but 
demonstrated weak inhibitory action against IKKβ (680nM, 964nM and 
1500nM, respectively). SU1411 and SU1438 were both shown to be 
preferential IKKα inhibitors (IC50 = ~10nM) with weak inhibition of IKKβ 
(IC50 = ~500nM and IC50 = 511nM, respectively) and CDK9 (IC50 = ~700nM). 
Moreover, Table 4.1 shows that SU1053 was a weak inhibitor of both the 
IKKβ (IC50 = 4190nM) and CDK9 (IC50 = ~1000nM) kinases but was a 
relatively potent inhibitor of IKKα (IC50 =28nM). 
 
4.2. Cytotoxicity of the SU series of IKKα inhibitory agents in the 
MM cell line RPMI8226 
The high frequency of genetic abnormalities in MM that induce 
constitutive NF-κB activation, mainly through abnormalities affecting the 
non-canonical pathway, indicates a role for the non-canonical NF-κB 
signalling pathway in MM cell survival and disease progression (Annunziata 
et al. 2007; Keats et al. 2007; Demchenko et al. 2010).  Moreover, it is predicted 
that the apoptotic effect induced by dual IKK inhibitors is a consequence of 
both canonical and non-canonical pathway inhibition (Rauert-Wunderlich et 
al. 2013).Therefore, the cytotoxicity of the nine novel IKKα inhibitors was 
compared in the RPMI8226 MM cell line. The RPMI8226 cell line was chosen 
as the MM cell line to investigate the SU series in because this MM cell line 
was found to possess an intermediate level of baseline NF-κB activity as a 
consequence of an inactivating TRAF3 mutation (Annunziata et al. 2007; 
Keats et al. 2007; Demchenko et al. 2010). Similarly, the RPMI8226 cell line 
was found to be intermediately sensitive to cytotoxicity induced by the non-
specific NF-κB inhibitor BAY 11-7082 when compared to the H929, U266B1 
and JJN3 MM cell lines.  
RPMI8226 cells were incubated with increasing concentrations of each 
SU compound ranging from 0.5µM to 20µM. At 48h, the cells were harvested 
and washed in PBS before being labelled with Annexin V-FITC and 
propidium iodide (PI). The labelled cells were then analysed using flow 
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cytometry to determine the percentage of apoptosis (Annexin V+/PI- + 
Annexin V+/PI+ + Annexin V-/PI+) occurring at each concentration. Figure 
4.1 shows the cytotoxicity of each IKKα inhibitory agent at 48h in the 
RPMI8226 cell line and the results shown are collated from two independent 
experiments. 
Figure 4.1 shows that SU1257, SU1053 and SU1372 were the least 
cytotoxic compounds at 48h in the RPMI8226 cells and it was not possible to 
interpolate an accurate LD50 value from the data. For this reason, the LD50 
value were described as >20µM. In addition, Figure 4.1 shows that the 
remaining six IKKα inhibitory agents induced cytotoxicity in a concentration-
dependent manner in RPMI8226 cells at 48h. Comparison of the LD50 values 
for each SU compound indicates that SU1349 was the most cytotoxic agent 
(LD50 = 1.15µM) whereas SU1261 was the least cytotoxic of these agents (LD50 
= 3.92µM). SU1361 and SU1365 both induce a relatively similar level of 
apoptosis in RPMI8226 cells at 48h, as evidenced by their comparable LD50 
values (LD50 = 2.25µM and LD50 = 1.96µM, respectively). Although Table 4.1 
indicates that SU1438 and SU1411 both possess similar kinase profiles in 
relation to IKKα, IKKβ and CDK9, Figure 4.1 shows that SU1411 was 
comparatively more cytotoxic than SU1438 in the RPMI8226 MM cell line at 
48h (LD50 = 3.60µM and LD50 = 2.26µM, respectively). 
Based on the kinase inhibitory data in Table 4.1 and the initial 
cytotoxicity screening profiles in Figure 4.1, six of the nine SU compounds 
were chosen for further characterisation concerning cytotoxicity, Mcl-1 
expression and NF-κB activity. The chosen SU compounds were SU1257, 
SU1053, SU1349, SU1372, SU1411 and SU1438. SU1261, SU1361 and SU1365 
were omitted from further investigation due to Table 4.1 suggesting that they 
each had a kinase inhibitory profile that was comparable to SU1349 and 
SU1372. For example, these compounds were potent inhibitors of CDK9 and 
IKKα, but weak inhibitors of IKKβ. Moreover, SU1349 was the most potent 
inhibitor of CDK9 whereas SU1372 was conversely the most potent inhibitor 
of IKKα. 
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Therefore, the cytotoxicity of SU1257, SU1053, SU1349, SU1372, 
SU1411 and SU1438 in the RPMI8226 cell line was further investigated to 
allow the collated results to include a total of four independent experiments. 
This would allow a more robust calculation of the LD50 values as well as the 
95% CI. Figure 4.2 shows the cytotoxicity profiles of each of the six chosen 
IKKα inhibitory agents at 48h in the RPMI8226 cell line and the results now 
represent four independent experiments. 
Figure 4.2 indicates that it was still not possible to calculate accurate 
LD50 values for the least cytotoxic SU compounds SU1257, SU1053 and 
SU1372 and their predicted LD50 values were designed to be >20µM. 
Comparison of the remaining three SU compounds’ LD50 values showed that 
SU1349 was the most cytotoxic compound in the RPMI8226 cells at 48h (LD50 
= 1.92µM, 95% CI [1.32µM – 2.89µM]). Furthermore, SU1411 was 
comparatively more cytotoxic than SU1438, despite the similarity in their 
kinase inhibitory profiles (LD50 = 3.15µM, 95% CI [2.87µM – 3.46µM] and 
LD50 = 5.56µM, 95% CI [4.85µM – 6.38µM], respectively). The cytotoxicity of 
the three most cytotoxic SU series compounds in RPMI8226 cells at 48h is 
summarised in Figure 4.3. Figure 4.3 shows the mean LD50 values alongside 
95% CI generated through Annexin-V/PI positivity (n = 4). In addition, an 
unpaired one-tailed t-test was performed on the data to investigate the 
statistical difference between the LD50 values calculated for each SU series 
compound in the RPMI8226 cell line. 
Figure 4.3 shows that the SU1349 and SU1411 compounds did not 
induce significantly different cytotoxic effects in the RPMI8226 cell line (p = 
0.821). On the other hand, the LD50 value interpolated for SU1438 was 
significantly higher than the LD50 value interpolated for SU1349 (p = 0.026) in 
the RPMI8226 cell line. Conversely, the LD50 value interpolated for SU1438 
was not significantly different from the LD50 value interpolated for SU1411 in 
RPMI8226 cells (p = 0.066). In summary, the cytotoxicity of SU1349 was 
significantly greater than SU1438 but the cytotoxicity of SU1411 was 
relatively similar to both SU1349 and SU1418 in RPMI8226 cells. 
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Figure 4.2 The cytotoxicity profiles of SU1257, SU1053, SU1349, SU1372, SU1411 
and SU1438 at 48h in RPMI8226 cells. 
To fully investigate the cytotoxicity profiles of each SU compound in RPMI8226 cells 
RPMI8226 cells were incubated with a more specific range of concentrations of SU 
compounds. At 48h, the percentage of apoptosis was measured using Annexin V/PI 
positivity on an Accuri C6 flow cytometer. The percentage of apoptotic cells at each 
concentration of SU compound was calculated and dose-response curves were 
constructed using Graphpad Prim 6.0. LD50 values were interpolated and are reported 
for each SU compound alongside 95% CI. Error bars represent mean ± SD, where n = 
4. 
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Figure 4.3 A summary of the relative cytotoxicity of SU1349, SU1411 and SU1438 in 
RPMI8226 cells at 48h. 
The mean LD50 values generated through Annexin V/PI positivity are shown for 
increasing concentrations of SU1349, SU1411 and SU1438 in RPMI8226 cells at 48h. 
The results shown were interpolated using the dose-response curves in Figure 4.2 
using Graphpad Prism 6.0. The values reported represent mean LD50 values ± 95% CI 
(µM) where n = 4. A one-way ANOVA followed by a Tukey’s multiple comparison 
test was performed using Graphpad Prism 6.0 software to investigate the significant 
difference between the LD50 values calculated for the indicated SU series compounds 
in the RPMI8226 cell line. 	  	  	  
4.3. Regulation of Mcl-1 expression in the MM cell line 
RPMI8226 by the SU series of IKKα inhibitory agents 
In myeloma cells, Mcl-1 expression plays a critical role in maintaining 
cell viability (Derenne et al. 2002; Zhang et al. 2002). Furthermore, high 
expression of Mcl-1 in cancer cell lines has been linked to constitutively high 
NF-κB activity (Liu et al. 2014). In addition, previous studies have 
demonstrated that inhibition of NF-κB activity is accompanied by the down 
regulation of Mcl-1 expression in MM cell lines and may precede the 
activation of apoptotic pathways (Meinel et al. 2010). Therefore, Mcl-1 
expression was quantified in the RPMI8226 cell line following 4h incubation 
(prior to any evidence of apoptosis induction) with increasing concentrations 
of each SU compound to investigate whether IKKα inhibition modulated the 
expression of Mcl-1. 
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RPMI8226 cells were treated separately with each of the IKKα 
inhibitory agents SU1257, SU1053, SU1349, SU1372, SU1411 and SU1438 at 
concentrations of 0.5µM, 1µM, 2.5µM and 5µM. At 4h, cells were harvested 
and then fixed and permeabilised before staining with an anti-Mcl-1-IgG1 
antibody (Santa Cruz Biotechnology) followed by secondary labelling with a 
goat anti-mouse IgG1-FITC antibody (Santa Cruz Biotechnology). The stained 
RPMI8226 cells were then analysed using flow cytometry to quantify the 
intracellular Mcl-1 expression in cells treated with each concentration of SU 
compound. 
A gating strategy was applied to the collected flow cytometry data to 
ensure that only viable, single cells were analysed. The serially gated cell 
populations were then assessed for Mcl-1 expression (MFI values) at each 
concentration of each SU compound. Figure 4.4 shows the representative 
overlaid histograms for Mcl-1 expression in untreated RPMI8226 cells and 
RPMI8226 cells treated with a 5µM of each SU compound for 4h.  
Figure 4.4 shows that following 4h incubation with 5µM SU1257, Mcl-1 
expression was not significantly altered in RPMI8226 cells relative to 
untreated cells. In contrast, the other SU compounds induced a decrease in 
Mcl-1 expression at 4h in RPMI8226 cells. Figure 4.4 shows that when used at 
a concentration of 5µM for 4h, SU1372 induced the greatest overall decrease in 
Mcl-1 expression in RPMI8226 cells.  
To further investigate the regulation of Mcl-1 expression by the 
selected SU compounds, the Mcl-1-FITC MFI at each concentration of each 
IKKα inhibitor was determined and then expressed as a percentage of the 
untreated controls. Figure 4.5 shows the collated data from three separate 
experiments for RPMI8226 cells, outlining the dose-dependent regulation of 
Mcl-1 expression by the agents SU1257, SU1053, SU1349, SU1372, SU1411 and 
SU1438 at 4h.  
Figure 4.5 shows that all six IKKα inhibitory agents analysed did not 
induce a significant decrease in Mcl-1 expression at 5µM relative to untreated 
cells following 4h treatment in RPMI8226 cells.  
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Figure 4.4 Representative overlay histograms of Mcl-1 expression in RPMI8226 cells 
at 4h after exposure to SU1257, SU1053, SU1349, SU1372, SU1411 and SU1438. 
Mcl-1 expression was investigated in RPMI8226 cells after treatment with increasing 
concentrations of each of SU compound. At 4h, intracellular Mcl-1 expression was 
investigated by staining cells with an anti-Mcl-1-FITC conjugated antibody and the 
average MFI was measured by flow cytometry. To gain an accurate MFI for each cell 
surface marker, gating was applied to gate viable myeloma cells (P1) and exclude any 
doublets (P2). The resultant gating was used to create overlay histograms from which 
the MFI of Mcl-1 expression at each concentration could be determined. A 
representative overlay histogram is shown for each SU compound in RPMI8226 cells 
after 4h (untreated = n, 5µM SU compound = n). 
103.9 106.1105
0
75
0
20
0
40
0
60
0
Co
un
t
Mcl-1-FITC-A
B07 SU1438 4h 5uM 1
Gate: (P2 in (P1 in all))
103.5 106.1104 105
0
90
0
50
0
Co
un
t
Mcl-1-FITC-A
G05 SU1257 4h 5uM Mcl-1 1
Gate: (P2 in (P1 in all))
103.5 106.1104 105
0
90
0
50
0
Co
un
t
Mcl-1-FITC-A
A05 SU1053 4h 5uM Mcl-1 1
Gate: (P2 in (P1 in all))
103.5 106.1104 105
0
65
0
20
0
40
0
Co
un
t
Mcl-1-A
F05 SU1372 4h 5uM 2
Gate: (P1 in all)
103.5 106.1104 105
0
65
0
20
0
40
0
Co
un
t
Mcl-1-A
D05 SU1349 4h 5uM 2
Gate: (P1 in all)
103.5 106.1104 105
0
65
0
20
0
40
0
Co
un
t
Mcl-1-A
G05 SU1411 48h 5uM 1
Gate: (P1 in all)
Mcl-1-FITC-AMcl-1-FITC-A
Mcl-1-FITMcl-1- C-A
Gate: [P2 in [P1 in all]] Gate: [P2 in [P1 in all]]
Gate: [P2 in [P1 in all]] Gate: [P2 in [P1 in all]]
SU1257 
SU1349 
Co
un
t
Co
un
t
Co
un
t
Co
un
t
SU1053 
SU1372 
Mcl-1-F -AMcl-1-FITC-A
te: [P2 in [P1 in all]] Gate: [P2 in [P1 in all]]
SU1411 
Co
un
t
Co
un
t
SU1438 
121
	  	  
Figure 4.5 indicates that 5µM SU1053 and SU1372 induced the largest 
average decrease in Mcl-1 expression compared to untreated RPMI8226 cells 
(76.4% ± 16.3% and 75.6% ± 7.4%, respectively) relative to the other SU agents, 
although the decrease in Mcl-1 expression was not significant for either agent 
(p = 0.24 and p = 0.12, respectively). For both SU1053 and SU1372, Figure 4.5 
shows that this was accompanied by a dose-dependent decrease in Mcl-1 
expression in RPMI8226 cells at 4h from concentrations of 1µM onwards, with 
respect to untreated RPMI8226 cells.  
In addition, increasing concentrations of SU1349 induced a dose-
dependent decrease in Mcl-1 expression in RPMI8226 cells at 4h from 
concentrations of 1µM onwards, that plateaued following exposure to 2.5µM 
and 5µM SU1349 (78.5% ± 7.8% and 80.4% ± 10.1%, respectively) when 
compared to untreated cells. However, the decrease in Mcl-1 expression 
induced by 5 µM SU1349 compared to untreated RPMI8226 cells was not 
significant (p = 0.18).  
Figure 4.5 also shows that 5µM SU1257, SU1411 and SU1438 did not 
significantly (p = 0.40, p = 0.40 and p = 0.33, respectively) alter Mcl-1 
expression at 4h compared to untreated RPMI8226 cells (93.3% ± 10.8%, 94.1% 
± 11.8% and 88.2% ± 6.6%, respectively) and the three agents did not induce a 
dose-dependent reduction in Mcl-1 expression.  
Overall, Figure 4.5 highlighted the potential inconsistency between the 
dose-dependent decrease and maximum decrease in normalised Mcl-1 
expression at 5µM, and the calculated p values, especially for the SU 
compounds SU1349, SU1372 and SU1053.  
In conclusion, Mcl-1 expression was decreased in a dose-dependent 
manner by SU1349 and SU1372 at 4h in RPMI8226 cells. In addition, SU1053, 
SU1411 and SU1438 induced a relatively weaker dose-dependent decrease in 
Mcl-1 expression in RPMI8226 cells whereas SU1257 did not affect Mcl-1 
expression. 
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Figure 4.5 The dose-dependent regulation of Mcl-1 expression in RPMI8226 cells at 
4h following treatment with SU1257, SU1053, SU1349, SU1372, SU1411 and SU1438. 
Mcl-1 expression was investigated in RPMI8226 cells after treatment with increasing 
concentrations of each of SU compound ranging from 0µM to 5µM. At 4h, intracellular 
Mcl-1 expression was investigated by staining RPMI8226 cells with an anti-Mcl-1-FITC 
conjugated antibody following fixation and permeabilisation. The average Mcl-1-FITC 
MFI at each concentration of SU compound was measured using an Accuri flow 
cytometer and normalised to the untreated control. A one-tailed unpaired t-test was 
performed using Graphpad Prism 6.0 software to investigate the statistical significance 
values between 0µM to 5µM for each SU compound in RPMI8226 cells at 4h (n = 3, 
duplicates averaged). The results are reported for each graph (NS = not significant, p > 
0.05). Error bars represent mean ± SD where n = 3, experimental duplicates plotted.  
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4.4. Inhibition of NF-κB activity in the MM cell line RPMI8226 by 
the SU series of IKKα inhibitory agents 
5. The association between cytotoxicity and the inhibition of 
constitutive NF-κB activity induced by the six SU compounds was 
investigated in more detail using an ELISA-based assay to detect the active 
NF-κB subunits p65, p50, p52 and RelB in nuclear extracts. These four 
subunits were selected to provide information on whether IKKα inhibition 
was effecting the canonical and/or the non-canonical NF-κB signalling 
pathway(s) in RPMI8226 cells. 
6. RPMI8226 cells were incubated separately with each SU compound: 
SU1257 SU1053, SU1349, SU1372, SU1411 and SU1438, at concentrations of 
0µM, 1µM, 2.5µM and 5µM. At 4h, cells were harvested and nuclear extracts 
generated. 1µg of RPMI8226 nuclear extract protein was assayed using the 
NF-κB family ELISA kit (Active Motif), as per the manufacturer’s instructions. 
Standard curves were generated alongside the assay using known quantities 
of recombinant p65 protein (r2 > 0.99) and recombinant p50 protein (r2 > 0.96) 
to allow NF-κB subunit quantification in nanograms per microgram of 
nuclear extract protein.  
7. Figures 4.7, 4.8, 4.9, 4.10, 4.11 and 4.12 show the quantities of active 
p65, p50, p52 and RelB NF-κB subunit proteins in the nucleus of RPMI8226 
cells following 4h treatment with increasing concentrations of SU1257, 
SU1053, SU1349, SU1372, SU1411 and SU1438, respectively. For each Figure, 
the data shown consists of the collated data from three separate experiments 
where the individual nuclear extract samples were assayed in duplicate.  
4.4.1. Inhibition of NF-κB activity in RPMI8226 cells by SU1257 
Figure 4.6 shows that 5µM SU1257 significantly decreased the levels 
of p65 (p = 0.034) in the nuclear extracts of RPMI8226 cells relative to the 
untreated control samples. Figure 4.6 also shows that this was accompanied 
by a dose-dependent decrease in active p65 protein. 
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Conversely, Figure 4.6 demonstrates that the p50, p52 and RelB NF-
κB subunits showed no significant decrease in nuclear protein levels 
following 4h with 5µM SU1257 relative to the untreated group (p = 0.053, p = 
0.128 and p = 0.144, respectively). However, all three NF-κB subunits 
appeared to show a dose-dependent decrease in active protein level. 
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Figure 4.6 Effect of SU1257 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compound 
SU1257 for 4h. RPMI8226 cells were then harvested and used to generate nuclear 
extract samples. The MM cell line was then assayed at 1µg/well of nuclear extract 
protein using ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A 
one-tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM to 5µM for SU1257 in 
RPMI8226 cells for each NF-κB subunit (n = 3, duplicates averaged). The results are 
reported above the graph (NS = not significant, p > 0.05). Values reported are mean ± 
SD produced from duplicate measurements where n = 3, experimental duplicates 
shown.	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4.4.2. Inhibition of NF-κB activity in RPMI8226 cells by SU1053 
Figure 4.7 demonstrates that 5µM SU1053 significantly decreased the 
levels of p50, p52 and RelB in RPMI8226 cells relative to the untreated 
samples (p = 0.035, p = 0.007 and p = 0.016, respectively). As can be seen in 
Figure 4.7, SU1053 induced a dose-dependent inhibition of p50, p52 and 
RelB nuclear protein levels in RPMI8226 cells, although the dose-dependent 
decrease was relatively stronger for p52 activity following SU1053 
treatment. In contrast, Figure 4.7 shows that the level of nuclear p65 was not 
significantly different in RPMI8226 cells treated with SU1053 when 
compared to untreated controls (p = 0.305). 
4.4.3. Inhibition of NF-κB activity in RPMI8226 cells by SU1349 
Figure 4.8 shows that 5µM SU1349 significantly decreased the levels 
of active p65 (p = 0.024) and p52 (p = 0.021) in RPMI8226 cells relative to the 
untreated samples in a dose-dependent manner. Figure 4.8 also shows that 
the level of active p50 protein was significantly decreased following 
treatment with SU1349 (p = 0.038), although not in a dose-dependent 
manner, but instead the p50 level plateaued at concentrations of 1µM, 2.5µM 
and 5µM (0.54 ± 0.04ng/µg, 0.68 ± 0.01ng/µg and 0.61 ± 0.09ng/µg) 
compared to untreated RPMI8226 cells (1.04 ± 0.22ng/µg). Conversely, 
Figure 4.8 indicates that the average level of active RelB protein was 
increased by 5µM SU1349 in RPMI8226 cells relative to the untreated 
samples, although this was not significant (p = 0.111). However, this increase 
could be a result of one set of duplicate measurements skewing the overall 
average of RelB protein measured at 5µM SU1349. 
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Figure 4.7 Effect of SU1053 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compound 
SU1053 for 4h. RPMI8226 cells were then harvested and used to generate nuclear 
extract samples. The MM cell line was then assayed at 1µg/well of nuclear extract 
protein using ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A 
one-tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM to 5µM for SU1053 in 
RPMI8226 cells for each NF-κB subunit (n = 3, duplicates averaged). The results are 
reported above the graph (NS = not significant, p > 0.05). Values reported are mean ± 
SD produced from duplicate measurements where n = 3, experimental duplicates 
shown.	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Figure 4.8 Effect of SU1349 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compound 
SU1349 for 4h. RPMI8226 cells were then harvested and used to generate nuclear 
extract samples. The MM cell line was then assayed at 1µg/well of nuclear extract 
protein using ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A 
one-tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM to 5µM for SU1349 in 
RPMI8226 cells for each NF-κB subunit (n = 3, duplicates averaged). The results are 
reported above the graph (NS = not significant, p > 0.05). Values reported are mean ± 
SD produced from duplicate measurements where n = 3, experimental duplicates 
shown. 	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4.4.4. Inhibition of NF-κB activity in RPMI8226 cells by SU1372 
Figure 4.9 demonstrates that 5µM SU1372 significantly decreased the 
levels of p65, p50 and p52 in RPMI8226 cells relative to the untreated 
samples (p = 0.018, p = 0.023 and p = 0.049, respectively). For the active levels 
of p65 and p50 proteins in RPMI8226 cells, Figure 4.9 shows that there was a 
comparatively strong dose-dependent decrease. On the other hand, Figure 
4.9 demonstrates that 5µM SU1372 increased the amount of nuclear RelB 
protein in RPMI8226 cells relative to the untreated samples, although this 
was not significant (p = 0.059). The pattern shown suggests that although 
1µM SU1372 initially decreased RelB activity relative to the untreated 
sample (0.07 ± 0.04ng/µg compared to 0.11 ± 0.04ng/µg, respectively), a 
dose-dependent increase in nuclear RelB protein was observed with 
concentrations of 2.5µM and 5µM SU1372 (0.15 ± 0.07ng/µg and 0.19 ± 
0.05ng/µg, respectively). However, Figure 4.9 again shows that this may be 
due to one set of duplicate measurements at each concentration skewing the 
overall average of RelB protein measured at 5µM SU1372. 
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Figure 4.9 Effect of SU1372 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compound 
SU1372 for 4h. RPMI8226 cells were then harvested and used to generate nuclear 
extract samples. The MM cell line was then assayed at 1µg/well of nuclear extract 
protein using ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A 
one-tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM to 5µM for SU1372 in 
RPMI8226 cells for each NF-κB subunit (n = 3, duplicates averaged). The results are 
reported above the graph (NS = not significant, p > 0.05). Values reported are mean ± 
SD produced from duplicate measurements where n = 3, experimental duplicates 
shown.	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4.4.5. Inhibition of NF-κB activity in RPMI8226 cells by SU1411 
Figure 4.10 shows that 5µM SU1411 significantly decreased the levels 
of p65, p50 and p52 activity (p = 0.014, p = 0.014 and p = 0.015, respectively) 
in RPMI8226 cells relative to the untreated samples. For all three NF-κB 
subunits, Figure 4.10 shows that SU1411 induced a relatively strong dose-
dependent decrease in RPMI8226 cells.  
4. In Figure 4.10, the level of nuclear RelB protein was also decreased 
in a dose-dependent manner in RPMI8226 cells following 4h treatment with 
SU1411, although to a weaker extent than that observed for p65, p50 and p52 
activity. However, the decrease that SU1411 induced in RelB activity at 5µM 
was significantly different to the untreated level of nuclear RelB protein (p = 
0.039). 
4.4.6. Inhibition of NF-κB activity in RPMI8226 cells by SU1438 
Figure 4.11 demonstrates that 5µM SU1438 significantly decreased the 
levels of p65 and RelB activity in RPMI8226 cells when compared to 
untreated nuclear protein levels (p = 0.027 and p = 0.002, respectively). 
Moreover, both significant changes in p65 and RelB activity that were 
induced by 5µM SU1438 were accompanied by dose-dependent decreases.  
In contrast, the levels of active p50 and p52 subunit were not 
significantly altered by treatment for 4h with 5µM SU1438 when compared 
to untreated RPMI8226 cells (p =0.126 and p = 0.472, respectively). Figure 
4.11 shows that nuclear p50 protein was not dose-dependently decreased by 
SU1438, but instead the decrease plateaued following treatment with 1µM, 
2.5µM and 5µM (0.32 ± 0.12ng/µg, 0.34 ± 0.11ng/µg and 0.35 ± 0.17ng/µg, 
respectively) relative to untreated controls (0.54 ± 0.11ng/µg). Figure 4.11 
also shows that, although the level of active p52 subunit decreased following 
treatment with 1µM SU1438 when compared to the untreated control, the 
level of p52 activity then increased with 2.5µM and 5µM SU1438 (0.79 ± 
0.16ng/µg, 0.85 ± 0.15ng/µg, respectively).  
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Figure 4.10 Effect of SU1411 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compound 
SU1411 for 4h. RPMI8226 cells were then harvested and used to generate nuclear 
extract samples. The MM cell line was then assayed at 1µg/well of nuclear extract 
protein using ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A 
one-tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM to 5µM for SU1411 in 
RPMI8226 cells for each NF-κB subunit (n = 3, duplicates averaged). The results are 
reported above the graph (NS = not significant, p > 0.05). Values reported are mean ± 
SD produced from duplicate measurements where n = 3, experimental duplicates 
shown. 
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Figure 4.11 Effect of SU1438 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compound 
SU1438 for 4h. RPMI8226 cells were then harvested and used to generate nuclear 
extract samples. The MM cell line was then assayed at 1µg/well of nuclear extract 
protein using ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A 
one-tailed unpaired t-test was performed using Graphpad Prism 6.0 software to 
investigate the statistical significance values between 0µM to 5µM for SU1438 in 
RPMI8226 cells for each NF-κB subunit (n = 3, duplicates averaged). The results are 
reported above the graph (NS = not significant, p > 0.05). Values reported are mean ± 
SD produced from duplicate measurements where n = 3, experimental duplicates 
shown.	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4.4.7. Summary of inhibition of NF-κB activity in RPMI8226 cells by 
the SU series of IKKα inhibitory agents as measured by ELISA 
Table 4.2 summarises the data presented in Figures 4.7-4.12, which 
showed the inhibition of NF-κB subunit activity induced by the IKKα 
inhibitory agents SU1257, SU1053, SU1349, SU1372, SU1411 and SU1438 at 
4h in RPMI8226 cells. As a result, Table 4.2 outlines the statistical 
significance between 5µM of each IKKα inhibitory agent and untreated 
sample for the active NF-κB subunits p65, p50, p52 and RelB and, if relevant, 
the general direction of the alteration in subunit activity. 
Table 4.2 shows that when used at a concentration of 5µM in 
RPMI8226 cells for 4h, five of the six selected IKKα inhibitory agents 
significantly decreased the levels of at least one NF-κB subunit classically 
associated with both the canonical and non-canonical NF-κB pathways. This 
indicates that the IKKα inhibitory agents SU1053, SU1349, SU1372, SU1411 
and SU1438 induced an inhibitory effect on both the canonical and non-
canonical NF-κB pathways.  
The only SU agent that did not induce significant regulation of 
canonical and non-canonical NF-κB pathway associated subunits was 
SU1257. This agent significantly decreased the activity of only the p65 NF-κB 
subunit, although this was only just within the boundary for significance (p 
= 0.04). This indicates that SU1257 did not significantly inhibit the non-
canonical NF-κB pathway, but may be inhibiting p65 mediated canonical 
pathway activity. 
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4.4.8. Inhibition of NF-κB activity in RPMI8226 cells by SU1257, 
SU1349 and SU1411 as measured by western blot analysis 
The association between cytotoxicity and the inhibition of 
constitutive NF-κB activity induced by the SU compounds SU1257, SU1349, 
and SU1411 was also briefly investigated using western blot analysis 
detecting the NF-κB proteins phosphorylated p100 (p-p100), total p100, 
IκBα, phosphorylated p65 (p-p65) and total p52. Theses proteins were 
detected to provide information on whether SU1257, SU1349 and SU1411 
were effecting the processing of canonical and/or the non-canonical NF-κB 
subunits in RPMI8226 cells. As IKKα is responsible for phosphorylating 
p100 to the active subunit p52, the level of p-p100, total p100 and total p52 
protein was analysed as an output of non-canonical NF-κB activity. 
Conversely, p-p65 and IκBα were measured to assess canonical pathway 
activity. IκBα is also known to be downstream gene product of NF-κB 
activity. 
RPMI8226 cells were incubated separately with each SU compound: 
SU1257, SU1349 and SU1411, at concentrations of 0µM, 1µM, 2.5µM and 
5µM. At 4h, cells were harvested and whole cell lysates were generated. 4µg 
of RPMI8226 whole cell lysate protein from each condition was assayed 
using western blot analysis. The levels of p-p100, total p100, p-p65, total p52 
and IκBα were evaluated in each sample. In all experiments, β-actin protein 
was assessed as a control. 
Figure 4.12 shows a representative western blot showing the 
quantities of active p-p100, total p100, p-p65, total p52 and IκBα NF-κB 
proteins in RPMI8226 cells following 4h treatment with increasing 
concentrations of SU1257, SU1349 and SU1411.  
Figure 4.12 demonstrates that SU1411 and SU1349 both substantially 
decreased levels of p-p100, p-p65 and IκBα in a dose-dependent manner in 
RPMI8226 cells. Figure 4.12 also indicates that the SU compound SU1411 
also decreased the level of β-actin across increasing concentrations in 
RPMI8226, indicating the possibility of unequal protein loading. However, 
the decrease in β-actin across increasing concentrations of SU1411 was not 
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as prominent as the decrease p-p100, p-p65 and IκBα proteins, suggesting 
that unequal protein loading was not fully responsible for the decrease in 
the proteins visualised.  
	  	   	  
Figure 4.12 Representative western blot showing the effect of SU1257, SU1349, and 
SU1411 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of the SU compounds 
SU1257, SU1349 and SU1411 for 4h at the concentrations of 0µM, 1µM, 2.5µM and 
5µM. RPMI8226 cells were then harvested and used to generate whole cell lysates. 
SDS-PAGE and western blot analysis was used to investigate the level of NF-κB 
pathway proteins in 4µg whole cell lysates from RPMI8226 cells generated from each 
condition. The levels of phospho (p)-p100, total (T) p100, p-p65, T p52 and IκBα were 
evaluated in each sample. In all experiments, β-actin was used as a control. Protein 
bands are labelled for corresponding NF-κB protein and molecular weight. UT = 
untreated (0µM).	  
 
Figure 4.12 also shows that total p100 protein decreased while total 
p52 increased following treatment with increasing concentrations of SU1349 
and SU1411 for 4h in RPMI8226 cells. This indicates that the two SU agents 
are not specifically inhibiting the non-canonical NF-κB pathway because the 
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changes in the levels of these proteins suggest that p100 processing is 
continuing.  
Figure 4.12 shows that SU1257 also induced a decrease in p-p65 in a 
dose-dependent manner in RPMI8226 cells. In contrast to SU1349 and 
SU1411, Figure 4.12 also shows that SU1257 induced a dose-dependent 
decrease in total p52 protein but did not appear to effect the levels of total 
p-p100, total p100, IκBα or β-actin in RPMI8226 cells. 
In summary, western blot analysis showed a dose-dependent 
decrease in both canonical and non-canonical NF-κB activity after treatment 
with increasing concentrations of the SU compounds SU1349 and SU1411 in 
RPMI8226 cells, although the results indicate that the agents may be more 
specifically effecting the canonical NF-κB pathway. In addition, Figure 4.12 
suggests that SU1257 seemingly decreased only canonical NF-κB activity. 
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4.5. The effect of increasing concentrations of SU1257 and 
SU1053 on cytotoxicity and Mcl-1 expression in RPMI8226 cells 
The data so far suggested that the IKKα inhibitory agents SU1257 and 
SU1053 were the least cytotoxic inhibitors when compared to SU1349, 
SU1372, SU1411 and SU1438. Moreover, when SU1257 and SU1053 were 
investigated for cytotoxicity at 48h at the maximum concentration of 20µM 
(Figure 4.2), the percentage of apoptosis induced was well below 50% (24.1% 
± 1.8% and 40.9% ± 7.2%, respectively). Therefore, it was not initially possible 
to interpolate an LD50 value for cytotoxicity for these two SU inhibitory 
agents so these two compounds were re-assessed for cytotoxicity at two 
higher concentrations of 50µM and 100µM to allow an accurate assessment of 
their respective LD50 values.  
Alongside these experiments, Mcl-1 expression was also investigated 
at 4h using 10µM and 20µM of SU1257 and SU1053. This was performed to 
confirm the results of Figure 4.5, in which both SU1257 and SU1053 did not 
significantly alter Mcl-1 expression at the maximum concentration of 5µM, 
and investigate whether Mcl-1 remained unchanged at higher concentrations 
of each agent. 
RPMI8226 cells were treated separately with SU1257 and SU1053 at 
concentrations of 0.1µM, 0.5µM, 1µM, 2.5µM, 5µM, 10µM, 20µM, 50µM and 
100µM. At 4h, RPMI8226 cells were harvested from the concentrations of 
0.5µM, 1µM, 2.5µM, 5µM, 10µM and 20µM and then fixated and 
permeabilised before staining with an anti-Mcl-1-IgG1 antibody (Santa Cruz 
Biotechnology) followed by secondary labelling with a goat anti-mouse IgG1-
FITC antibody (Santa Cruz Biotechnology). The stained RPMI8226 cells were 
then analysed using flow cytometry to quantify the intracellular Mcl-1 
expression at each concentration of each compound. 
A gating strategy was applied to the collected flow cytometric data to 
ensure that only viable, single RPMI8226 cells were analysed. The serially 
gated cell populations were then assessed for Mcl-1 expression (MFI values) 
at each concentration. The Mcl-1-FITC MFI values at each concentration for 
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each SU agent was determined and normalised to the untreated MFI for 
RPMI8226 cells. Figure 4.13A shows the collated data from three separate 
experiments for RPMI8226 cells (n = 1, duplicate for 10µM and 20µM SU1257 
only), outlining the dose-dependent regulation of Mcl-1 expression by the 
agents SU1257 and SU1053 at 4h when used at increased concentrations. 
The same experiments were continued to 48h, at which point 
RPMI8226 cells were harvested from all concentrations used and washed in 
PBS before being labelled with Annexin V-FITC and PI. The labelled cells 
were then analysed using flow cytometry to determine the percentage of 
apoptosis (Annexin V+/PI- + Annexin V+/PI+ + Annexin V-/PI+) occurring at 
each concentration. Figure 4.13B shows the cytotoxicity of SU1257 and 
SU1053 at 48h in the RPMI8226 cell line with the two increased 
concentrations of 50µM and 100µM analysed and the results shown were 
collated from four independent experiments. 
Figure 4.13A shows that when used at two increased concentrations of 
10µM and 20µM, SU1257 induced a modest decrease in Mcl-1 expression in 
RPMI8226 cells (81.4% ± 2.5% and 85.7% ± 0.9%, respectively) relative to the 
normalised untreated sample, although no statistical evaluation was 
performed as the experiment was n =1 in duplicate. In contrast, SU1053 
induced a moderate dose-dependent decrease with increasing concentrations 
that continued past 5µM. At the highest concentration of 20µM, SU1053 
decreased Mcl-1 expression at 4h in RPMI8226 cells to 63.6% ± 18.0%, 
although this was still not significantly different from the untreated control 
sample (p = 0.085).  
Figure 4.13B shows the dose-response curve for SU1257 when the 
higher concentrations of 50µM and 100µM were added. It was still not 
possible to accurately interpolate an LD50 value as the maximum percentage 
apoptosis induced at 100µM SU1257 was 57.1% ± 1.5% in RPMI8226 cells. 
This suggests that SU1257 was relatively non-cytotoxic in RPMI8226 cells. 
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Figure 4.13 The cytotoxicity profiles and regulation of Mcl-1 expression in 
RPMI8226 cells after exposure to SU1257 and SU1053 at increased concentrations. 
To fully investigate SU1257 and SU1053 in RPMI8226 cells, these two SU compounds 
were incubated with RPMI8226 cells at higher increasing concentrations. (A) At 4h, 
intracellular Mcl-1 expression was measured on an Accuri C6 flow cytometer and 
normalised to the untreated control. A one-tailed unpaired t-test was performed 
using Graphpad Prism 6.0 software to investigate the statistical significance values 
between 0µM to 20µM for SU1053 in RPMI8226 cells (n = 3, duplicates averaged). The 
results are reported above the graph (NS = non-significant, p < 0.05). Error bars 
represent SD where n = 3, duplicate (n = 1, duplicate for 10µM and 20µM SU1257), 
experimental duplicates plotted. (B) At 48h, cytotoxicity was investigated using 
Annexin V/PI positivity on an Accuri C6 flow cytometer. The percentage of apoptotic 
cells at each concentration of SU compound was calculated and dose-response curves 
were constructed using Graphpad Prim 6.0. Where possible, LD50 values were 
interpolated and are reported alongside 95% CI. Error bars represent mean ± SD, 
where n = 4, experimental duplicates shown. 
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On the other hand, Figure 4.13B shows that at increased 
concentrations of 50µM and 100µM, SU1053 continued to induce a dose-
dependent increase in cytotoxicity following a concentration of 5µM and an 
LD50 value was positively interpolated (LD50 = 32.4µM, 95% CI [26.5µM, 
39.6µM]). Overall Figure 4.13B suggests that while SU1053 is relatively less 
cytotoxic than some of the other SU compounds, it does become cytotoxic at 
higher concentrations. 
 
4.6. Discussion 
In this chapter, a series of novel IKKα inhibitory compounds were 
evaluated in the MM cell line RPMI8226. The RPMI8226 cell line was chosen 
because this MM cell line was found to possess an intermediate level of 
baseline NF-κB activity in Chapter 3 and possesses an inactivating TRAF3 
mutation, so it was hypothesised that this MM cell line would be susceptible 
to IKKα inhibition by virtue of constitutive activation of the non-canonical 
NF-κB pathway (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 
2010). Overall, nine novel IKKα inhibitory compounds were evaluated 
(kindly provided by Prof. Simon MacKay, University of Strathclyde). Each of 
the SU compounds used were specifically designed to target IKKα, although 
each had a unique kinase inhibitory profile.  
4.6.1. Cytotoxicity of the SU agents in RPMI8226 cells 
The cytotoxicity of all nine SU agents was first screened in RPMI8226 
cells following 48h incubation with increasing concentrations of each agent 
(n =2) and it was hypothesised that the cytotoxicity of each SU compound 
would correlate with their respective IKKα, IKKβ and CDK9 kinase 
inhibitory profiles. Therefore, the aim was that the pairing of the available 
kinase inhibitory data with initial cytotoxicity in RPMI8226 cells, would 
allow a decision on a smaller selection of IKKα inhibitory agents to take 
forward for further investigation. 
Three of the SU compounds, SU1257, SU1053 and SU1372, induced a 
low level of cytotoxicity in RPMI8226 cells such that accurate LD50 values 
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could not be calculated. Conversely, the remaining six SU agents, SU1261, 
SU1349, SU1361, SU1365, SU1411 and SU1438, were more potent and 
induced cytotoxicity in a concentration-dependent manner in RPMI8226 
cells. However, the conclusion was that the kinase inhibitory profiles did 
not completely correlate with the cytotoxicity induced in the initial 
screening. For example, both SU1349 and SU1372 had similar kinase 
inhibitory profiles with respect to CDK9 and IKKα and IKKβ, but their 
respective cytotoxicity profiles in RPMI8226 cells were markedly different. 
Based on initial LD50 values, SU1349 was the most cytotoxic agent whereas 
SU1372 was relatively one of least cytotoxic agents. This suggests that the 
cytotoxicity induced by these agents may not be a consequence of their 
inhibition of CDK9, IKKα and IKKβ, and the SU compounds may be 
inducing their effects through off-target kinase inhibition, particularly in the 
case of SU1349. 
Similarly, the kinase profile data suggested that SU1411 and SU1438 
had similar inhibitory profiles because they both preferentially inhibited 
IKKα over IKKβ and CDK9. However, the initial cytotoxicity data for LD50 
values suggested that SU1411 was more cytotoxic than SU1438. For this 
reason, these four SU compounds were included in the selection of agents 
for further analysis. SU1257 and SU1053 were also chosen; SU1257 due to its 
unique inhibitory profile and SU1053 because it showed the weakest 
inhibition of both the IKKβ and CDK9 kinases but was a relatively potent 
inhibitor of IKKα.  
In conclusion, the chosen SU compounds included SU1257, SU1053, 
SU1349, SU1372, SU1411 and SU1438 and the cytotoxicity of these six agents 
was further investigated to allow a more robust comparison of the variation 
in cytotoxicity (n = 4). SU1257, SU1053 and SU1372 remained the least 
cytotoxic compounds in RPMI8226 cells and it was not possible to 
interpolate an accurate LD50 value for these agents. However, when SU1053 
was reassessed at two increased concentrations of 50µM and 100µM, an 
LD50 value was successfully interpolated. This indicated that although 
SU1053 was relatively non-cytotoxic, it become more cytotoxic at higher 
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concentrations. The same was not true for increased concentrations of 50µM 
and 100µM SU1257 so this agent was classified as essentially non-cytotoxic 
in RPMI8226 MM cells. 
Further investigation revealed that the pattern of cytotoxicity for 
SU1349, SU1411 and SU1438 was consistent with the initial screening. 
SU1438 was significantly less cytotoxic than SU1349, whereas SU1349 and 
SU1411 induced a comparatively similar level of cytotoxicity in RPMI8226 
cells, although SU1411 was also comparatively similar in cytotoxicity to 
SU1438. Overall, except for SU1257, this suggested that the kinase inhibitory 
profiles did not completely explain the cytotoxicity induced by the SU 
compounds. 
Although the use of specific IKKα inhibitors in MM has not yet been 
described elsewhere, it has been demonstrated that knockdown or depletion 
of IKKα in MM cells does not effect their overall survival or viability 
(Annunziata et al. 2007; Rauert-Wunderlich et al. 2013), but may instead 
impact on MM cell growth and proliferation (Hideshima et al. 2009). In 
addition, knockdown of IKKα in B-cells has been shown to be non-toxic 
(Senftleben et al. 2001). This correlates with the pattern observed in terms of 
SU compound cytotoxicity and the relationship with their IKKα kinase 
inhibitory profile. For example, the lack of cytotoxicity induced by SU1053 
and SU1372, both of which are selective potent inhibitors of IKKα, suggests 
that IKKα inhibition is not the dominant cause of apoptosis in the RPMI8226 
MM cell line. 
CDK9, unlike other Cdc2-like kinases, does not participate in cell 
cycle regulation but is instead involved in cell differentiation through 
regulation of RNA transcription (de Falco a Giordano 1998; Napolitano et 
al. 2000). Inhibition of CDK9 has been shown to induce cytotoxicity in MM 
cells through inhibition of transcription and Mcl-1 protein levels, although 
the CDK9 inhibitors used in these studies were more potent towards CDK9 
than the SU agents (Manohar et al. 2011; Dolloff et al. 2012; Jorda et al. 
2014). In contrast, the data for the SU compounds suggests that CDK9 
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inhibition does not seem to be one of the main contributing causes of 
apoptosis in RPMI8226 cells. This is evident in the disparity in cytotoxicity 
between SU1349 and SU1372, both of which have kinase inhibitory profiles 
indicating that they are similarly potent inhibitors of CDK9. 
4.6.2. Mcl-1 regulation by the SU agents in RPMI8226 cells 
To begin exploring the effect of IKKα inhibition on NF-κB activity, 
the dose-dependent regulation of Mcl-1 expression at 4h was quantified in 
RPMI8226 cells for each of the six selected SU IKKα inhibitory agents. Mcl-1 
is an important anti-apoptotic protein that is relevant in the survival and 
progression of MM (Derenne et al. 2002; Zhang et al. 2002; Meinel et al. 
2010). Moreover, a constitutive level of NF-κB activity correlates with the 
expression of Mcl-1 in MM cell lines (Liu et al. 2014). Therefore, it was 
hypothesised that the regulation of Mcl-1 expression in RPMI8226 cells by 
the SU agents would correlate with their cytotoxicity. 
At all of the concentrations of SU1257 tested, the level of Mcl-1 
expression remained comparable to the untreated controls, which was 
consistent with the lack of cytotoxicity observed with this agent in 
RPMI8226 MM cells. On the other hand, SU1053, SU1349, SU1372 and 
SU1438 all decreased Mcl-1 expression in a dose-dependent manner, 
although the level of down-regulation was variable among the SU 
compounds and did not directly correlate with cytotoxicity. The largest 
overall decrease in Mcl-1 expression (at 5µM) was seen with SU1053, 
although this was not significant. The dose-dependent decrease in Mcl-1 
expression by SU1053 continued when higher concentrations of 10µM and 
20µM were analysed, although this was still not significant (p = 0.24). 
SU1349 and SU1372 showed a similar down-regulation pattern in 
terms of Mcl-1 expression with increasing concentrations. Several studies 
have shown that CDK9 inhibition significantly decreases Mcl-1 expression, 
which contributes to cell apoptosis (Manohar et al. 2011; Dolloff et al. 2012; 
Jorda et al. 2014). SU1349 and SU1372 are both potent inhibitors of CDK9 
and both induced a strong dose-dependent down-regulation in Mcl-
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expression at 4h, which may suggest that CDK9 inhibition is contributing to 
this effect.  
Both SU1411 and SU1438 did not decrease Mcl-1 expression in a 
dose-dependent manner but did induce a relatively weak decrease in Mcl-1 
expression at 5µM when compared to the untreated controls. Similar to 
their cytotoxic effects, SU1411 and SU1438 induced different decreases in 
Mcl-1 expression, despite the similarity in their kinase inhibitory profiles. 
Overall, this shows that the apoptosis induced by most of the SU IKKα 
inhibitors does not correlate with the level of down-regulation of Mcl-1 
expression so Mcl-1 down-regulation is unlikely to be the main cause of 
apoptosis. In addition, neither do the kinase inhibitory profiles of most of 
the SU compounds correlate with the level of down-regulation in Mcl-1 
expression that was induced in RPMI8226 MM cells. 
4.6.3. NF-κB activity regulation by the SU agents in RPMI8226 cells 
In order to further characterise the IKKα inhibitory pharmacological 
agents, the dose-dependent effect of each agent on NF-κB activity was 
investigated in more detail using an ELISA-based method for detecting the 
active NF-κB subunits p65, p50, p52 and RelB in the MM cell line RPMI8226.  
The results demonstrated that five of the six selected IKKα inhibitory 
agents significantly decreased the levels of at least one NF-κB subunit 
classically associated with both the canonical and non-canonical NF-κB 
pathways. This suggests that SU1053, SU1349, SU1372, SU1411 and SU1438 
inhibited both the canonical and non-canonical NF-κB pathways. The 
remaining SU agent, SU1257, only significantly decreased p65 activity, 
indicating that SU1257 was not significantly inhibiting the non-canonical 
pathway activation. 
As mentioned previously, the ELISA possessed caveats that meant 
that it may not have been an appropriate tool to quantify the effect that the 
SU compounds induced on NF-κB activity. For example, there were 
potential issues with method of subunit quantification used for the ELISA’s, 
the specificity of the antibodies provided in the NF-κB ELISA kit and issues 
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with the binding of specific NF-κB subunit dimers to the immobilised 
oligonucleotide (personal communication with Professor Neil Perkins). 
Therefore, western blot analysis was also used to visualise the dose-
dependent effect of SU1257, SU1411 and SU1349 on NF-κB proteins. This 
technique also showed that SU1349 and SU1411 induced a does-dependent 
decrease in canonical and non-canonical NF-κB associated proteins, 
although inhibition of the canonical pathway seemed the most prominent. 
In addition, similar to ELISA, western blot analysis also revealed that 
SU1257 dose-dependently decreased p-p65 protein, indicating that SU1257 
inhibits the canonical NF-κB pathway. 
However, western blotting was only used to visualise the effect that 
the SU compounds SU1257, SU1349 and SU1411 had on NF-κB activity in 
the MM cell line RPMI8226. Therefore, to fully explore the SU compounds 
effect on NF-κB activity more western blotting could have been utilised to 
investigate the effect that the SU compounds SU1053, SU1438 and SU1372 
had on NF-κB pathway processing in RPMI8226 cells. Furthermore, with the 
use of the right combination of antibodies (such as those used in Figure 
4.12), western blotting could have provided more in depth information 
regarding the specific NF-κB pathway processing following treatment with 
these IKKα inhibitory compounds. For example, antibodies targeting 
phosphorylated p100, and total p100 and p52 proteins could have provided 
definitive proof of non-canonical pathway inhibition by SU1053, SU1438 
and SU1372 as p100 functions as both the precursor of p52 and a RelB-
specific inhibitor.  
The five SU agents that regulated both canonical and non-canonical 
associated NF-κB subunits were all potent inhibitors of IKKα, with at least a 
50-fold preference towards IKKα inhibition when compared to IKKβ. IKKα 
is mainly responsible for the phosphorylation of the precursor subunit p100 
to the activated p52 NF-κB subunit, which can form homo- or hetero-dimers 
with the RelB NF-κB subunit (Senftleben et al. 2001; Solan et al. 2002). In 
addition, knockdown of IKKα in B-cells substantially decreased the level of 
p52 subunit while conversely increasing p100 protein (Senftleben et al. 
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2001). For this reason, it was hypothesised that IKKα inhibition by these five 
SU agents would preferentially inhibit the non-canonical associated NF-κB 
subunits, resulting in a dose-dependent decrease in nuclear p52 and RelB 
protein.  
However, the variable inhibition of non-canonical NF-κB subunits 
induced by the SU agents did not readily relate to the IKKα inhibition 
profiles for each agent. For example, although SU1438 was as potent an 
IKKα inhibitor as SU1411, ELISA indicated that it did not significantly 
inhibit p52 activity whereas SU1411 did. Furthermore, SU1053, the least 
potent IKKα inhibitor, induced the most significant overall decrease in p52 
activity (p = 0.007). Moreover, ELISA showed that all five agents induced a 
significant dose-dependent down-regulation of at least one of the canonical 
NF-κB pathway proteins, p65 or p50. This was regulatory pattern was 
confirmed using western blot analysis, which showed that both SU1349 and 
SU1411 induced a substantial dose-dependent decrease in p-p65, IκBα and 
p-p100 proteins. Conversely, total p52 protein was dose-dependently 
increased by SU1349 and SU1411 in RPMI8226 cells, which may indicate 
lack of specificity towards non-canonical NF-κB inhibition by these SU 
agents. 
Therefore, the presence of canonical pathway inhibition by the SU 
agents may indicate that inhibition of IKKα in the MM cell line RPMI8226 
may also be inhibiting canonical pathway activity generated through p65 
and p50 activation. Several studies have demonstrated that both IKKα and 
IKKβ can carry out phosphorylation of IκBα, although IKKα is the least 
efficient kinase and cannot replace IKKβ (DiDonato et al. 1997; Mercurio et 
al. 1997; Régnier et al. 1997; Lam et al. 2008). Additionally, it has been 
reported that both IKKα and IKKβ can phosphorylate the p65 subunit to 
promote transactivation potential (Perkins 2006). However, the lack of 
correlation in effect on NF-κB activity and IKKα inhibitory potential may 
indicate the possibility of additional kinase targets for the SU agents that 
may regulate NF-κB activity.  
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Another irregularity that emerged when considering the effects of 
the SU compounds on the non-canonical pathway was the increase in RelB 
activity induced by SU1349 and SU1372. These two agents have similar 
kinase inhibitory profiles and differ from the other SU agents in the respect 
that they each possess potent inhibitory action against CDK9. This may 
indicate that CDK9 inhibition is involved in the inhibition of the non-
canonical NF-κB pathway, especially through inhibition of RelB activity. 
However, it is more likely that variation between ELISA experiments for 
these two SU compounds is the reason because for both the RelB ELISA 
results for these compounds, outliers can be identified that may have 
skewed the statistical result. 
4.6.4. Conclusion 
The aim of this chapter was to evaluate a series of pharmacological 
agents designed to inhibit IKKα in terms of their cytotoxicity, regulation of 
Mcl-1 expression and effect on NF-κB activity in the MM cell line, 
RPMI8226. This chapter has shown that the majority of IKKα inhibitory SU 
agents were dose-dependently cytotoxic in RPMI8226 cells, although the 
level of cytotoxicity did not correlate with dose-dependent down-regulation 
of the anti-apoptotic protein Mcl-1 or NF-κB activity. This suggests that 
another mechanism exists by which the IKKα inhibitors induce their 
cytotoxicity. Moreover, the effects induced by these agents could not be 
explained completely by their kinase inhibitory profiles. 
The exception to this was SU1257, an agent that been designed to be 
a structural analogue of the other compounds but has no IKKα or IKKβ 
inhibitory properties. SU1257 was shown to be relatively non-toxic even 
when used at increased concentrations, did not alter Mcl-1 expression, and 
did not significantly inhibit the non-canonical NF-κB pathway. Therefore, 
the kinase inhibitory profile for this agent matches the effects that this agent 
induces in MM and warrants its use as a control compound in experiments 
investigating these agents. 
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In conclusion, these agents may provide a promising strategy for 
MM treatment but the specific cause of apoptosis will need to be further 
investigated. 
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Chapter 5 – The effect of the SU series of IKKα 
inhibitory agents on global gene expression in MM cells. 
Microarray-based techniques are capable of simultaneously assessing 
the gene expression of thousands of different genes through the measurement 
of mRNA expression in a single reaction (Slonim a Yanai 2009). This removes 
the difficulty of pre-selecting and measuring putative genes of interest, 
including specific tumour suppressor genes and/or oncogenes, for analysis as 
microarray-based techniques allow for global gene expression to be quantified 
in a single experiment. In addition, the completion of multiple gene 
sequencing projects has provided the information required for the specific 
annotation of arrays and improvements to the actual design of the individual 
gene probes on the microarray chips (Hubank 2004). Microarrays can 
therefore provide in-depth information on the underlying biological pathways 
that are altered both in disease and by pharmacological agents. Moreover, the 
data generated through microarray-based techniques is usually highly 
reproducible and quantitative.  
Microarray-based techniques have been used to investigate global gene 
expression in several haematological malignancies to clarify the specific 
expression abnormalities that give rise to cancer biology and to sub-stratify 
specific tumour types. Examples include chronic lymphocytic leukaemia and 
various B-cell lymphomas (Dürig et al. 2003; Jelinek et al. 2003; Staudt a Dave 
2005). In MM, microarray-based techniques have been used to reveal the 
specific gene expression profiles that are responsible for differentiating MM 
cells from normal plasma cells and identify the transcriptional characteristics 
associated with poor prognosis (Zhan et al. 2002; Shaughnessy et al. 2005). In 
addition, global gene expression profiling has also been shown to provide 
predictive prognostic markers and identify new therapeutic targets within 
relevant signalling pathways in MM (Decaux et al. 2008; Hose et al. 2011). 
Moreover, several studies have specifically used microarray-based techniques 
to understand the role of the NF-κB pathways in MM through analysis of 
aberrant gene expression (Annunziata et al. 2007; Keats et al. 2007; 
Demchenko et al. 2010). 
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The previous chapter characterised the SU series of pharmacological 
agents in terms of their cytotoxicity and altered nuclear NF-κB expression. The 
next step was to develop a deeper understanding of the mode of action of the 
SU series. The SU series was designed to target the NF-κB pathway through 
inhibition of IKKα. For this reason, the effect of these compounds on global 
gene expression was investigated using Affymetrix GeneChip® HTA 2.0 gene 
expression analysis.  
The overall aim of this experiment was to investigate whether the 
individual agents targeted distinct sets of genes or whether a common set of 
genes was altered by the SU compounds, but perhaps in a quantitatively 
different fashion. Therefore, this chapter will cover the following key steps: 
1. Experimental design and sample generation.  
2. Quality control of the Affymetrix Gene Chips 
3. Comparison of altered gene expression 
4. Selection of genes for qRT-PCR validation 
5. qRT-PCR results 
6. Comparison of qRT-PCR and Affymetrix Gene Chips 
 
5.1. Affymetrix GeneChip® HTA 2.0 gene expression analysis 
5.1.1. Experimental design and sample generation 
Five compounds from the SU series were chosen for global gene 
expression analysis. These were SU1257, SU1053, SU1438, SU1411 and 
SU1349. SU1257 does not possess IKKα, IKKβ or CDK9 inhibitory properties 
(Table 4.1) and was found to be non-cytotoxic in the RPMI8226 cell line. 
SU1349 was shown to be a potent inhibitor of both CDK9 and IKKα (Table 
4.1), and was the most cytotoxic SU series compound in RPMI8226 cells. 
SU1411 and SU1438 preferentially inhibited IKKα with weak inhibition of 
IKKβ and CDK9 (Table 4.1). Nevertheless, SU1411 was found to be more 
cytotoxic than SU1438 in RPMI8226 cells following exposure for 48h. 
Of the cytotoxic compounds, SU1053 was the weakest inhibitor of 
both the IKKβ and CDK9 kinases but was a relatively potent inhibitor of 
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IKKα (Table 4.1); SU1053 was significantly less cytotoxic than SU1411 and 
SU1438.  
The RPMI8226 MM cell line was selected for the global gene 
expression analysis because this MM cell line was found to possess an 
intermediate level of NF-κB activity so was used to characterise the SU 
series compounds in the previous chapter. Three treatments of each 
pharmacological agent were performed and samples were generated with 
doses-response experiments performed in parallel. 
RPMI8226 cells were incubated alone and in the presence of 
increasing concentrations of the SU compounds SU1257, SU1053, SU1438, 
SU1411 and SU1349. At 4h, cells were harvested from untreated and from 
cells treated with 2.5µM of each SU compound to generate TRIzol® lysates. 
Samples were subsequently processed for RNA extraction once three 
replicate sets for each treatment were collected. Each SU compound was 
used at a concentration of 2.5µM because this was found to be a 
concentration where most of the SU series compounds effected viability, 
Mcl-1 expression and NF-κB activity in the RPMI8226 cell line. 
Prior to RNA extraction, dose-dependent cytotoxicity in the parallel 
samples was measured at 48h by flow cytometry using Annexin V/PI 
positivity for all experiments in which a 4h TRIzol® lysate was generated. 
The aim of this was to ensure that the SU compounds were inducing the 
expected cytotoxic effect prior to commitment to undertaking the 
microarray analysis. The cytotoxicity dose-response curves for all samples 
used in the microarray analysis are shown in Appendix Figure I. It shows 
that all samples treated with SU compound samples induced the expected 
cytotoxicity at 48h.  
Following RNA extraction, RNA quality was assessed using an 
Agilent 2100 Bioanalyzer System. All the RNA extracts generated for the 
microarray analysis achieved an RNA integrity value of 10, which is the 
highest quality value possible. Thus, high quality samples were available 
for global gene expression analysis. 
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Once all the samples were validated, the resulting RNA extracts were 
analysed by Affymetrix GeneChip® Human Transcriptome Array (HTA) 2.0 
as per the manufacturer’s instructions by Dr Amanda Redfern, Central 
Biotechnology Services (CBS), Cardiff University. This particular type of 
microarray was chosen due to the high level of information it delivers; not 
just gene expression levels, but also alternate splicing events. For the 
purposes of this study, the focus of analysis revolved around the alteration 
of gene expression that each individual SU compound induced at 4h in the 
RPMI8226 cell line. 
In summary, 18 individual samples were analysed using Affymetrix 
GeneChip® HTA 2.0 corresponding to n = 3 for each treatment condition. 
Overall, six treatment conditions were analysed. These were untreated (UT) 
RPMI8226 cells and RPMI8226 cells treated with 2.5µM of SU1257, SU1053, 
SU1438, SU1411 or SU1349 for 4h.  
5.1.2. Quality control and normalisation of the Affymetrix GeneChip® 
HTA 2.0 microarray data 
The data from the Affymetrix GeneChip® HTA 2.0 analysis was 
returned by CBS in the form of a series of CEL files. These were opened and 
analysed using the statistical software environment, R. An assessment of the 
quality of the raw data from each of the individual Affymetrix GeneChips 
was performed.  
A histogram of distribution of the Log2 transformed perfect match 
(PM) probe intensities for each sample array analysed was plotted to 
compare the variation in PM probe intensity between the 18 individual 
sample arrays (Figure 5.1A). This shows the overall signal from the 
individual sample arrays and can indicate one or a subset of arrays has 
given a different signal across the chip. Figure 5.1A demonstrates that the 
general shape of all 18 sample arrays was similar, which would be expected 
for replicate arrays derived from a cell line. However, the centre of the 
distribution histogram for each sample array differed slightly suggesting 
that the dataset would benefit from normalisation. 
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Therefore, the PM probe intensities for all 18 sample arrays were 
normalised using RMA normalisation. To check that the RMA 
normalisation was effective, a histogram of the distribution of Log2 PM 
probe intensities for each individual sample array was plotted using the 
RMA normalised data (Figure 5.1B). Figure 5.1B shows that following 
normalisation the distribution of signals follows a Gaussian bell-shaped 
curve. 
A boxplot of the RMA normalised sample arrays (Figure 5.1C) 
demonstrates that the median, lower quartile and upper quartile of RMA 
normalised Log2 PM probe intensities were comparable across all 18 
individual sample arrays. This indicates that the RMA normalisation for the 
18 individual sample arrays had been effective. 
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Figure 5.1 Quality control of the Affymetrix HTA 2.0 individual sample arrays. 
(A) A histogram was plotted of the microarray data to compare the distribution of 
Log2 transformed PM probe intensities between individual sample arrays. A 
histogram (B) and a boxplot (C) demonstrating the effect RMA normalisation had on 
the distribution on Log2 intensities between different sample arrays. The data shown 
represent n = 3 for each condition. (UT = untreated). 
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5.1.3. Investigating the global gene expression effects of the SU series 
Following RMA normalisation of data from the 18 Affymetrix 
GeneChips, an analysis on the global effects of the SU compounds was 
performed. The objective of this analysis was to determine how the 
pharmacological agents grouped by their effects on overall gene expression 
across the whole GeneChip. This allowed an investigation of whether the 
individual sample arrays reflected their treatment condition and whether 
group replicates were homogenous. Two methods were used: (1) the 
generation of a distance matrix followed by clustering and (2) a principal 
component analysis. 
5.1.3.1. Distance matrix and hierarchical cluster analysis of microarrays 
The Log2 PM probe intensities were used to calculate the Euclidean 
distance between each sample and plotted using the ‘corrplot’ package 
(Wei a Simko 2016). The distances were assembled into a matrix to 
produce Figure 5.2A. The most distant set of arrays from untreated cells 
was found in cells treated with SU1349, with most of the SU1349 replicates 
having a distance greater than 100 when compared to the other 
GeneChips. 
Figure 5.2A shows that changes between 60 and 100 were caused by 
both SU1438 and SU1411-treated arrays. In comparison, UT, SU1257 and 
SU1053-treated arrays all showed lower distance matrix values (typically 
ranging from 50 to 80). One exception to this pattern was the SU1257 
(array 2), which indicates that this sample was an outlier. 
The distance matrix was then used to generate a hierarchical cluster 
diagram using the complete linkage cluster method (Figure 5.2B). 
Hierarchical clustering is a technique that can identify and represent 
different patterns within the data. The clustering used in Figure 5.2B was 
unsupervised clustering because no previous information was assumed 
about the data and the samples were arranged based on sample variation 
in the PM probe intensities. The cluster analysis initially produced two 
main branches that were subsequently split into two sub-branches each. 
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Figure 5.2 Distance matrix and hierarchical cluster analysis of the microarray data.  
The RMA normalised microarray data was used to produce a distance matrix using 
the Euclidean method (A). The distance matrix was then subjected to a hierarchical 
cluster analysis using the complete linkage clustering method (B). The four main 
branches within the hierarchical cluster analysis are highlighted. The data shown 
represents n=3 for each condition. 
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The four branches are highlighted in Figure 5.2B by the coloured boxes. 
Similar to Figure 5.2A, SU1349 treated samples were identified as most 
different and distinct from the other treatments because they clustered 
together in one of the four branches. In addition, Figure 5.2B shows that 
eight of the nine arrays for UT, SU1257 and SU1053 clustered on the same 
branch demonstrating that these groups showed a similar global gene 
expression signatures that were distinct from the SU1349-treated branch. 
An exception was one of the SU1257 treated arrays, SU1257 (array 2), 
which clustered on the other of the two main cluster branches, indicating 
that it showed a distinct global gene expression signature. This again 
suggests that SU1257 (array 2) was an outlier.  
Figure 5.2B also shows that four of SU1438 and SU1411-treated 
arrays clustered on the same branch as the SU1349-treated samples 
suggesting a degree of similarity in global gene expression. The SU1438 
(array 1) and SU1411 (array 1)-treated sample arrays clustered closer to the 
UT, SU1053 and SU1257-treated arrays. This indicates that these two 
arrays possessed some additional variation in global gene expression.  
5.1.3.2. Principal component analysis of arrays 
A principal component analysis (PCA) was performed on the RMA 
normalised sample data to extend the assessment of the global changes in 
gene expression. This method identifies patterns within the PM probe 
intensities and uses these to transform the data into its principal 
components. The principal components are then used to express the data 
in such a way that highlights the similarities and differences among the 18 
individual sample arrays.  
Table 5.1 and Figure 5.3A show the top 10 principal components 
produced from analysis of the 18 sample arrays using PCA. Figure 5.3A 
and Table 5.1 demonstrate that cumulatively, principal components 1 to 10 
contributed to a total of 82.5% of the variance between the individual 
microarrays. Overall, principal component 1 and 2 were cumulatively 
responsible for 45.4% of the variability within the data. 
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Table 5.1 Results of the principal component analysis on the microarray data 
The variances of the 10 largest principal components produced by PCA of the 
microarray data are shown in the table below.  
Principal 
Component 
Standard 
deviation 
Proportion of 
Variance 
Cumulative 
Proportion 
1 154.0 33.6% 33.6% 
2 91.3 11.8% 45.4% 
3 84.5 10.1% 55.5% 
4 65.7 6.1% 61.6% 
5 54.0 4.1% 65.7% 
6 52.94 4.0% 69.7% 
7 49.9 3.5% 73.2% 
8 48.1 3.3% 76.5% 
9 46.7 3.1% 79.6% 
10 45.3 2.9% 82.5% 
 
Therefore, the PCA was visualised by principal components 1 and 2 
(Figure 5.3B). Generally, the arrays can be grouped based on their 
respective treatment group as indicated in Figure 5.3B using the ovals. 
Based on the visualisation by principal components 1 and 2, the three 
SU1349-treated arrays were distinct from the other sets of SU compound 
treated arrays. Similarly, SU1438 and SU1411-treated arrays are presented 
in a manner that suggests that both compounds induced comparable 
alterations in global gene expression. Visualisation of both UT and SU1053 
treated samples by principal components 1 and 2 showed that these six 
arrays are closely related and can be grouped together. In contrast, the 
three SU1257 arrays were difficult to cluster as a comparable group of 
similarly treated arrays. This is a consequence of one array appearing quite 
distant when visualised by the principal components 1 and 2, which 
supports the observation from hierarchical cluster analysis with regards to 
SU1257 (array2). 
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Figure 5.3 Principal component analysis of Affymetrix HTA 2.0 data.  
A PCA was performed on the RMA normalised data to investigate the overall 
variability between the individual sample arrays. (A) A plot of the variances 
associated with each principal component was produced from the results of the PCA. 
(B) A scatter graph showing the grouping of individual sample arrays based on 
principal component 1 and 2, which contributed to the most variability within the 
data. Individual sample arrays within the same treatment group were circled where 
possible. The data shown represents n = 3 for each condition. 
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In conclusion, the distance matrix and PCA revealed three groups 
of distinct gene expression changes caused by the SU series of compounds: 
1. SU1349 had the most distinct set of changes indicating a 
qualitative difference from UT and the other compounds in the changes 
caused.  
2. SU1438 and SU1411 caused changes in gene expression when 
compared to UT but these were distinct to those induced by SU1349 
treatment.  
3. Both SU1053 and SU1257 caused more subtle changes in global 
gene expression with some extra variation in one of the SU1257 
samples. 
 
5.1.4. Visualisation of differentially expressed probesets 
The next step of the analysis involved the visualisation of 
differentially expressed (DE) probesets. The treatment group replicates 
were averaged, the array probes were condensed to their respective 
probesets and DE probesets were identified within each UT vs. treated 
comparison. Two different methods were used for the visualisation of the 
DE probesets; (1) Volcano plots and (2) Venn diagrams.  
5.1.4.1. Visualising changes with Volcano plots 
The DE probesets were first visualised using volcano plots showing 
fold change (Log2 (FC)) and statistical significance (-Log10 (p value)) for each 
treated contrast compared to UT (Figure 5.4). Lines at x = 1 and x = -1 were 
added to highlight those probesets that had a two-fold change (Log2 (FC) ≥ 
1) in either direction. 
The volcano plots in Figure 5.4 have been arranged based on the 
cytotoxicity of that SU compound in RPMI8226 cells with SU1257 being the 
least cytotoxic and SU1349 being the most cytotoxic. Overall, Figure 5.4 
demonstrates that as the cytotoxicity of the SU compound increased so did 
the number of probesets breaching the threshold of a Log2 (FC) ≥ 1 with a 
significance of p ≤ 0.05.  
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Figure 5.4 shows that the UT vs. SU1257 contrast has the fewest 
probesets experiencing a Log2 (FC) ≥ 1 paired with p ≥ 0.05, which produced 
a relatively flat shape. In contrast, SU1349 induced the most significant 
changes in probeset expression relative to UT. Compared with the other 
four SU compounds, the volcano plot for UT vs. SU1349 showed the most 
probesets with a Log2 (FC) ≥ 1 in both directions and the most probesets 
with a significant (p ≤ 0.05) alteration in expression. The UT vs. SU1053 
contrast generated a volcano plot that has more probesets showing 
significant changes than that of UT vs. SU1257. Moreover, UT vs. SU1438 
and UT vs. SU1411 produce volcano plots that were relatively similar in 
shape and size. This suggests that the quantitative nature of the changes 
induced by SU1438 and SU1411 were comparable.  
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Figure 5.4 Volcano plots of the contrasts for UT sample arrays vs. treated arrays to 
identify differentially expressed (DE) probesets. 
The individual arrays corresponding to UT and treated were grouped (where n = 3) 
and then multiple linear models were fitted to each group to condense Affymetrix 
HTA 2.0 probesets. Once in this state, empirical Bayes moderated t-statistics test was 
performed for each contrast (UT vs. SU1257, UT vs. SU1053, UT vs. SU1438, UT vs. 
SU1411 and UT vs. SU1349) to investigate the difference between treated arrays and 
UT arrays. Volcano plots of the results of the test were plotted to help in identification 
of DE probesets. Lines at x = 1 and x = -1 were plotted to show those probesets with a 
Log2 (FC) of one or greater in either direction.	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5.1.4.2. Visualising gene expression changes using Venn diagrams 
The overlaps in altered probesets were visualised by plotting a 
Venn diagram of the significantly (p ≤ 0.05) upregulated and down-
regulated probesets (Figure 5.5). UT vs. SU1349 possesses the highest 
number of altered probesets in total (426 upregulated; 756 down-
regulated). UT vs. SU1438 and UT vs. SU1411 specifically shared 42 
upregulated and 22 down-regulated DE probesets. However, in total, they 
had 88 upregulated and 25 down-regulated DE probesets in common 
because 49 (46 upregulated and 3 down-regulated DE probesets) were 
shared with SU1349. Figure 5.5 also shows that UT vs. SU1257 possessed 
the fewest altered probesets (4 upregulated) and UT vs. SU1053 also has 
relatively few DE probesets (5 upregulated, 17 down-regulated). 
In conclusion, DE probesets, defined as Log2 (FC) ≥ 1 in either 
direction and p ≤ 0.05, were present for all treated samples when 
compared with UT controls although the number of DE probesets varied 
depending on the SU compound. The variation in the number of DE 
probesets appeared to parallel the level of cytotoxicity; SU1257 induced 
the least altered probesets and SU1349 induced the most. 
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Figure 5.5 Venn diagram showing the number of differentially expressed (DE) 
probesets for each compound when using Log2 (FC) > 1 and p < 0.05 thresholds. 
The results of the empirical Bayes moderated t-statistics test was sorted to include 
only those probesets that experienced a two-fold change in either direction (down-
regulated = Log2 (FC) ≤ -1, upregulated = Log2 (FC) ≥ 1) and a p ≤ 0.05. A multiple 
comparison test was performed followed by Benjamini and Hochberg correction to 
investigate the similarities in the DE probesets between the UT and treated contrasts 
and used to plot a Venn diagram. The number of probesets that were upregulated 
(Log2 (FC) ≥ 1) are shown in green and down-regulated probesets (Log2 (FC) ≤ 1) are 
shown in red. Zero values have been omitted for clarity. 
 
 
5.1.5. Annotation of differentially expressed (DE) genes relating to 
DE probesets 
With the identification of the DE probesets, the next step involved 
converting the probesets to their respective gene names and annotating the 
genes. The Affymetrix GeneChip® HTA 2.0 includes probesets that 
correspond to gene expression changes and alternate splicing events. For 
this analysis, only the probesets matching human genes were used.  
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The identification pipeline generated a gene list that contained 556 
annotated genes and the ‘gplots’ package (Warnes et al. 2016) in R was used 
to generate the heat map of the global gene alterations shown in Figure 5.6. 
Figure 5.6 shows that the annotated genes followed the same pattern that 
was observed for the probesets in Figure 5.4 and Figure 5.5. For example, 
SU1257 showed the lowest number of altered genes with a Log2 (FC) ≥ 1 in 
either direction whereas SU1349 differentially regulated the most annotated 
genes. 
For this reason, only SU1438, SU1411 and SU1349 were analysed 
further as these caused more gene alteration and more cytotoxicity in the 
RPMI8226 MM cell line. The gene lists for these SU compounds are 
visualised in the Venn diagram (Figure 5.7). The data indicates that the SU 
compounds down-regulated more genes than they upregulated in 
RPMI8226 myeloma cells.  
The list of DE genes specific for the UT vs. SU1349 contrast was too 
long (83 upregulated and 419 down DE genes) to be placed in the Venn 
diagram in Figure 5.7; a list of these DE genes is available in Appendix 
Tables I and II. Eight genes (6 upregulated and 2 down-regulated DE genes) 
were shared by all three of compounds. SU1438 and SU1411 shared 24 DE 
genes (10 upregulated and 14 down-regulated DE genes). In addition, the 
SU1349 shared more DE genes with SU1438 (2 upregulated and 8 down-
regulated DE genes) than with SU1411 (1 upregulated and 1 down-
regulated DE genes).  
Overall, each SU compound showed some unique characteristics in 
terms of gene regulation but they also shared common regulatory 
pathways. 
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Figure 5.6 Global gene alterations in 556 differentially expressed (DE) genes 
induced by the SU compounds when compared to UT controls 
The probesets of the empirical Bayes moderated t-statistics were labelled with gene 
symbols and the DE genes located (p ≤ 0.05 and Log2 (FC) ≥ 1, in either direction). This 
generated a list of 556 genes that were DE in at least one of the SU-treated samples 
when compared to UT controls. The heat map was generated using the ‘gplots’ 
package in R Studio and shows the global gene alterations in 556 DE genes.	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5.1.6. Selection of DE genes to be used for validation in qRT-PCR 
The microarray analysis to date revealed qualitative and quantitative 
changes in gene expression as a result of exposure to the SU compounds. 
Therefore, DE genes were selected for validation by quantitative RT-PCR 
using a four-step process: 
1. Enrichment analysis of Gene Ontology (GO) terms 
2. Pathway enrichment analysis of DE genes 
3. Expression levels of the DE genes 
4. Specific association of DE genes with the SU compounds, 
SU1438, SU1411 and SU1349. 
5.1.6.1. Enrichment analysis of biological Gene Ontology terms 
First, an enrichment analysis of the DE regulated gene lists for 
SU1438, SU1411 and SU1349 was carried out using the online enrichment 
tool Enrichr (Chen et al. 2013; Kuleshov et al. 2016). To retrieve the gene 
lists used in this analysis, the DE genes were separated based on Log2 (FC). 
For SU1438 and SU1411, this was a Log2 (FC) ≥ 1 in either direction but this 
threshold produced 522 genes for SU1349. This list of DE genes was too 
long to be used for the enrichment analysis in Enrichr so for SU1349 a cut-
off of Log2 (FC) ≥ 1.5 in either direction was applied. This produced 
manageable gene lists of 52, 52 and 92 genes for SU1438, SU1411 and 
SU1349, respectively. The new SU1349 gene list consisting of 92 DE genes 
can be found in Appendix Table III. 
The Gene Ontology (GO) terms for the above lists of genes was 
analysed using the online tool Enrichr (Chen et al. 2013; Kuleshov et al. 
2016). Appendix Figure II shows the number of DE genes associated with 
the eight GO categories for each treatment condition following sorting of 
the GO terms using R. Appendix Tables IV, V and VI show the identity of 
the DE genes for each treatment condition and the number of GO 
categories each DE gene is involved in. Based on this information, smaller 
lists of DE genes were selected based on involvement in >7 GO terms or if 
they were associated with the GO terms: cell cycle, transcription, 
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signalling or apoptosis. These GO terms were specifically chosen due to 
their association with NF-κB signalling. This reduced the genes lists to 21, 
25 and 41 genes for SU1438, SU1411 and SU1349 respectively. The new DE 
gene lists are shown in Appendix Table VII for each of the more cytotoxic 
SU compounds. 
5.1.6.2. Pathway profiles for the SU1438, SU1411 and SU1349 GO gene 
lists 
These revised DE gene lists for SU1438, SU1411 and SU1349 were 
re-inserted into the Enrichr analysis tool and a pathway enrichment 
analysis was performed. The Appendix Tables VIII, IX and X display the 
full list of the results for the pathway enrichment analysis for the SU1438, 
SU1411 and SU1349 DE gene lists, respectively. DE genes were selected for 
further analysis based on whether they regulated pathways connected to 
transcription, apoptosis, cell cycle or directly modulated NF-κB signalling. 
This reduced the gene lists to 8, 6 and 9 genes for SU1438, SU1411 and 
SU1349, respectively (Appendix Tables XI, XII and XIII).  
5.1.6.3. Expression levels of the SU1438, SU1411 and SU1349 DE gene lists 
Finally, 10 DE genes that would be used for microarray validation 
using qRT-PCR were chosen from the final gene lists for these SU 
compounds. For this, genes were identified based on high expression and 
fold change (Appendix Tables XI, XII and XIII), and specific association 
with the SU compounds, SU1438, SU1411 and SU1349. Only those genes 
that were expressed to a relatively high level in both UT and treated 
samples were considered for qRT-PCR because this would ensure that 
these genes would be positively detected. 
Figure 5.8 presents a summary of the Log2 expression of each of the 
10 final DE genes that were used for validation of the microarray in the 
qRT-PCR experiments for all the array groups, including the UT, SU1257 
and SU1053 array groups. As can be seen in Figure 5.8, all 10 selected DE 
genes were highly expressed in UT RPMI8226 cells. 
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TRAF6, RIPK1, POLA2 and SRSF7 are DE genes specifically 
associated with the action of SU1349 (Figure 5.7). Figure 5.8 also 
demonstrates that down regulation of TRAF6 and RIPK1 was specifically 
related to the action of SU1349, whereas both SU1438 and SU1411 down-
regulate POLA2 and SRSF7 genes but to a lesser extent. Although POLR2A 
was previously shown to be a unique DE gene for SU1438 (Figure 5.7), 
Figure 5.8 shows that SU1053, SU1411 and SU1349 also down-regulate 
POLR2A. SRSF6 expression was altered by both SU1438 and SU1349 
(when Log2 (FC) ≥ 1 and p ≤ 0.05) (Figure 5.7), this is also reiterated in 
Figure 5.8 where SRSF6 transcription was markedly repressed by SU1438 
and SU1349. Treatment with SU1053 and SU1411 also caused a reduction 
in SRSF6 transcription but to a lesser extent. 
PRKCI, OFD1 and UBA2 were differentially down-regulated in 
response to both SU1438 and SU1411 (Figure 5.7). Figure 5.8 confirms that 
OFD1, PRKCI and UBA2 were all substantially down-regulated by both 
SU1438 and SU1411 but remained relatively unaffected following 
treatment with SU1053 and SU1349. The final selected DE gene was 
NSUN2, which was found to be a DE gene unique to SU1411 (Figure 5.7). 
Figure 5.8 shows that SU1411 induced the highest level of down-
regulation in NSUN2 transcription but also suggests that SU1438 
substantially down-regulated NSUN2 relative to UT controls. 
Table 5.2 lists the transcriptional product of each of the 10 chosen 
DE genes, along with the function of the subsequent protein. Table 5.2 
demonstrates that all DE genes chosen have a role in regulating NF-κB 
activation, apoptotic pathways, DNA replication, transcription or protein 
modification. 
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5.2. Validation of the microarray data using qRT-PCR 
Primer pairs specific for the 10 target DE genes and an additional 
endogenous control gene (RSP14) were designed using NCBI/Primer-BLAST 
(Ye et al. 2012). A representative example of the melting curve and 
amplification plot for the endogenous control gene and each of the target DE 
genes are shown in Appendix Figures III – XIII. 
The samples used in the qRT-PCR experiments were created from the 
identical experiments used to generate the TRIzol® lysates for the Affymetrix 
GeneChip® HTA 2.0. Therefore, they should provide a robust means of 
validating the microarray data because they were collected from the same 
RPMI8226 cells under the same treatment conditions at the same time. The 
TRIzol® lysates were processed to RNA extracts and the RNA integrity of the 
eluted RNA was checked by CBS at Cardiff University using an Agilent 2100 
Bioanalyzer System. Appendix Figure XIV shows that all the processed 
samples had a RIN ≥ 9.7, which suggests the eluted RNA was of a high 
quality. The eluted RNA was subsequently reverse transcribed into cDNA 
and then analysed using specific primers by qRT-PCR. 
Figure 5.9 and Figure 5.10 show the fold changes for each of the 10 DE 
genes following exposure to the five compounds in the SU series: SU1257, 
SU1053, SU1438, SU1411 and SU1349. Figure 5.9 and Figure 5.10 both show 
that SU1257 did not significantly alter any of the 10 genes analysed using 
qRT-PCR. In addition, SU1053 treatment was responsible for significantly 
down-regulating only SRSF7 expression (p = 0.021). 
Figures 5.9 and 5.10 shows that qRT-PCR measured a relatively large 
decrease in TRAF6, RIPK1, POLA2, SRSF7 and SRSF6 expression following 
treatment with SU1349, although only the down-regulation of TRAF6 
expression was significant (p = 0.034). An explanation for this may be the 
large variation between the replicates for SU1349 treatment, which is 
indicated by the relatively large error bars shown for these genes in Figure 
5.10. In addition, Figure 5.10 shows that SU1438 similarly significantly down-
regulated TRAF6 expression (p = 0.041). 
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Figures 5.9 and 5.10 suggest that SU1438 treatment was also 
responsible for significantly decreasing the expression of OFD1 (p = 0.040) 
and NSUN2 (p = 0.041), the latter of which was also significantly down-
regulated by SU1411 treatment (p = 0.003). In addition, Figure 5.9 and 5.10 
show that SU1411 was also responsible for significantly down-regulating 
POLA2 (p = 0.005), POLR2A (p = 0.043), SRSF7 (p = 0.018), PRKCI (p = 0.022) 
and UBA2 (p = 0.008). 
The relationship between the microarray gene expression levels and 
qRT-PCR gene expression levels among the UT and SU compound treated 
samples was explored to allow validation of the microarray data. Figure 5.11 
plots the microarray gene expression (Log2 expression) and qRT-PCR fold 
change (Log2 (2-ΔΔCt)) for each sample group and DE gene.  
Figure 5.11 shows that there was a correlation in nine of the 10 genes. 
The exception was TRAF6 where qRT-PCR did not replicate the expression 
changes observed in the microarray for the SU series compounds SU1411 
and SU1438, and SU1053. This may be due to the difference in the relative 
sensitivities of the two assays or the differences in the normalisation 
methods that each assay employs (Morey et al. 2006). 
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5.3. Discussion 
The aim of this chapter was to investigate whether individual agents 
targeted distinct sets of genes or whether a common set of genes was altered 
by the SU compounds, but perhaps in a quantitatively different fashion. To 
achieve this, the Affymetrix GeneChip® HTA 2.0 was used to assess global 
gene expression in untreated RPMI8226 cells and RPMI8226 cells following 
treatment with SU1257, SU1053, SU1349, SU1411 and SU1438.  
5.3.1. Quality control of the microarray experiment 
A potential pitfall in microarray-based techniques is the small 
number of replicates because these experiments are often time-consuming 
and expensive. Therefore, throughout the process of carrying out the 
microarray analysis in this thesis, multiple quality control assessments were 
performed to ensure that variability in the gene expression analysis was 
minimised. The aim was that this would allow a robust global gene 
expression analysis to be performed, where any alterations in gene 
expression identified would be unlikely to have arisen through accidental 
associations or due to inherent variation caused by poorly controlled 
experimental conditions. 
Variability can arise through three main sources in a microarray-
based gene expression analysis: experimental, technical or analytical 
(Hubank 2004). The Affymetrix GeneChip® HTA 2.0 was carried out on 
RNA samples from the untreated and treated RPMI8226 cells. The 
experimental design of a microarray experiment is an important step that is 
often overlooked in microarray-based studies (Slonim a Yanai 2009). For 
this reason, careful consideration was given to the selection of the MM cell 
line to be used and the concentration and exposure time chosen for each SU 
compound. In addition, all microarray samples were taken on the same day 
from one MM cell line, ensuring equal passage number, and all samples 
were prepared at the same time. 
To reduce experimental variability, prior to RNA extraction, dose-
dependent cytotoxicity in parallel samples was measured at 48h. This was 
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performed to ensure that the SU compounds were inducing the expected 
cytotoxic effects so that samples not responding as previously observed 
were not included in the microarray analysis. This ensured validation of the 
samples used in the microarray analysis to guarantee that any alterations in 
gene expression were representative of the inhibitory action of the SU 
compounds. Appendix Figure I demonstrated that all samples used in the 
microarray analysis induced the expected cytotoxicity in RPMI8226 cells, 
based on the characterisation described in Chapter 4.  
In addition, the quality of the RNA was measured to ensure that 
poor RNA quality was not a factor that contributed to technical variation 
within the microarray analysis. RNA is inherently less stable than DNA and 
can be affected by many factors, including poor sample preparation and 
pre-analysis storage. All RNA extracts used in the Affymetrix GeneChip® 
HTA 2.0 analysis were of the highest quality (RNA integrity = 10), which 
minimised technical variability.  
Once the Affymetrix GeneChip® HTA 2.0 had been performed and 
the resulting data retrieved as CEL files, all subsequent analysis was 
performed using the statistical software environment, R (R-Core-Team 
2014). R is a highly versatile piece of software that provides a variety of 
statistical and graphical techniques, and is constantly being developed and 
refined by leading statisticians. Many packages that are useful in 
microarray data analysis are available for use in R through Bioconductor, 
another open-source platform that offers a collection of software packages 
scripted in the R language for computational biology and bioinformatics 
(Gentleman et al. 2004). For this reason, R remains one of the most 
advanced tools for the analysis of microarray-based techniques such as 
Affymetrix GeneChip® HTA 2.0. However, one disadvantage of R is that it 
does not have a graphical user interface and instead relies on an 
understanding of the R programming language to write R scripts to 
perform statistical and graphical analysis, which can prove to be time 
consuming. 
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R was used to first assess the quality of the raw data produced by 
each of the individual Affymetrix GeneChips to ensure that the measures 
took to reduce experimental and technical variability had been a success. 
This confirmed that the 18 separate GeneChip arrays were similar and 
comparable, which would be expected for arrays derived from an identical 
cell line. Therefore, this indicated that technical variability had been 
successfully minimised and the individual sample arrays were comparable, 
which further validated the microarray-based experiment.  
In conclusion, all quality control techniques applied confirmed that 
experimental and technical variability was minimised appropriately, and 
verified the use of further graphical and statistical manipulation of the 
microarray data. 
5.3.2. Assessing qualitative and quantitative alterations in gene 
expression measured by the microarray analysis 
6. The initial step of the microarray analysis in R investigated the 
global effects of the SU compounds in RPMI8226 cells and determined how 
the transcriptional effects of the pharmacological agents grouped based on 
overall gene expression across the whole GeneChip. This indicated that 
three groups of distinct gene expression changes caused by the SU series of 
compounds could be clearly identified; (1) SU1349 had the most distinct set 
of changes indicating a qualitative difference from UT and the other 
compounds in the gene changes caused, (2) SU1438 and SU1411 caused a 
change in gene expression when compared to UT but in a distinct way to 
SU1349 treatment, and (3) SU1053 and SU1257 caused more subtle changes 
in gene expression with some extra variation in one of the SU1257 samples.  
Initial visualisation of the qualitative changes in probesets showed 
that each SU IKKα inhibitory agent was responsible for indicating DE 
probesets in RPMI8226 cells, when compared to the untreated group. 
Moreover, the number of DE probesets correlated with the cytotoxicity of 
the SU agent in RPMI8226 cells. For example, SU1257 induced the least DE 
probesets and was relatively non-cytotoxic in RPMI8226 cells. On the other 
hand, the most cytotoxic SU agent, SU1349, induced the greatest number of 
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DE probesets in RMPI8226 cells. Overall, this may suggest that some of the 
DE probesets may be related to genes that contribute to the apoptosis 
induced by these agents in MM cells despite the samples being taken after 
just 4h of exposure to SU compound. However, Figure 5.4 showed that 
SU1438 and SU1411 produce DE volcano plots that were relatively similar 
in shape and size, which suggests that the quantitative nature of the 
changes induced by SU1438 and SU1411 may be comparable. Conversely, 
this may indicate that the DE probesets do not relate to DE genes that are 
involved in the induction of apoptosis by the SU agents because the 
cytotoxicity of SU1438 and SU1411 was shown to be significantly different 
in Chapter 4.  
The quantitative nature of the DE probesets induced by each SU 
agent compared to the untreated group were visualised by plotting a Venn 
diagram of the number of upregulated and down-regulated probesets 
(Figure 5.5). As was suggested by the volcano plots, the Venn diagram 
indicated that the number of DE expressed probesets correlates with the 
cytotoxicity of the SU compound in RPMI8226 cells. Interestingly, the three 
most cytotoxic agents, SU1438, SU1411 and SU1349, shared a significant 
number of the same DE probesets. Moreover, each SU compound possessed 
unique DE probesets. Therefore, identification of the possible DE genes 
relating to the DE probesets could indicate specific genes that are involved 
in the mechanism of action of these agents.  
For this reason, the probesets were annotated to their respective 
human genes. Once annotated, 556 annotated genes were identified as DE 
by at least one SU compound and Figure 5.6 was plotted to qualitatively 
assess the global gene alterations induced by the five SU compounds in 
RPMI8226 cells. Qualitatively, the pattern shown mirrored the pattern 
observed for the DE probesets in Figure 5.4, in that the number of DE genes 
increased with the increasing cytotoxicity of the SU compounds.  
The number of DE genes induced by the three more cytotoxic SU 
compounds was assessed in more detail to quantitatively determine the 
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exact number of DE genes and their identities (Figure 5.7). Quantitatively, 
these SU compounds down-regulated more genes and DE genes were both 
shared and unique for each SU compound. Moreover, the most DE genes 
were shared by both the SU1438 and SU1411. Chapter 4 showed that both 
agents possessed a relatively similar inhibitory profile so the fact that they 
shared a relatively high number of DE genes could be indicative of their 
shared mechanism of action. Interestingly, SU1438 relative to SU1411 
shared more DE genes with SU1349, although these compounds have 
significantly different cytotoxic potential and inhibitory profiles.  
The number of genes that were differentially regulated by SU1349 
was significantly much higher than the number regulated individually by 
both SU1438 and SU1411. Quantitatively, this may indicate that the 
increased kinase inhibitory potency for CDK9, shown in Chapter 4, could be 
responsible for inducing a higher number of DE genes. However, it is more 
likely that the increased number of DE genes may also be explained by 
SU1349 having more off-target effects than predicted in the inhibitory 
profile, which contributes to its increased cytotoxic potential in MM cells. 
SU1053 was shown in Chapter 4 to possess a similar inhibitory profile to 
SU1349, although it induced substantially less cytotoxicity in RPMI8226 
cells. This chapter has shown that number of genes that were differentially 
regulated by SU1349 was significantly much higher than the number 
regulated individually by SU1053. Therefore, it seems likely that the 
relatively increased cytotoxicity of some of the SU compounds is likely to 
arise because of off-target inhibitory effects. 
In conclusion, the gene expression analysis revealed qualitative and 
quantitative changes in gene expression that were both shared among the 
SU agents and that were unique to each SU agent. Overall, the pattern that 
emerged was that an increase in the number of DE probesets or the number 
of DE genes, correlated with the cytotoxicity of that SU agent in RPMI8226 
cells. However, it is likely that the cytotoxicity induced by these agents is 
caused, at least in part, because of off-target kinase inhibitory effects. 
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5.3.3. Assessing qualitative and quantitative alterations in gene 
expression measured by the microarray analysis 
The quantitative and qualitative changes in global gene expression 
that were revealed by the analysis required validation using a smaller and 
more reproducible technique. The technique that was chosen to validate the 
microarray analysis was quantitative RT-PCR. Data verification using a 
method such as qRT-PCR is recommended for use with microarray analysis 
(Hubank 2004). Therefore, to validate the microarray analysis using qRT-
PCR, a small selection of 10 representative DE genes belonging to the 
SU1438, SU1411 and SU1349 contrasts were selected. 
The DE genes to be used in the qRT-PCR validation were chosen 
based on four main factors; gene ontology, pathway profiles, expression 
levels and association with specific SU compounds. The online enrichment 
tool, Enrichr, was chosen to be used in the microarray analysis because this 
tool is relatively newer than other available enrichment tools and has a 
database that is frequently updated (Kuleshov et al. 2016). In addition, 
Enrichr provides a variety of in depth enrichment information on the gene 
lists inserted and has a relatively friendly user interface. One of the 
drawbacks of using this tool was that the SU1349 vs. untreated contrast (522 
genes) was too large to be used to select qRT-PCR genes due to the list 
being too comprehensive to insert into the Enrichr tool. Therefore, further 
filtering (Log2 (FC) ≥ 1.5, in either direction) was required to reduce the 
SU1349-regulated gene list. Although this allowed creation of a more 
manageable list (92 genes), it resulted in the exclusion of many DE genes. 
Shortening the SU1349 DE gene list also reduced the comparability with the 
SU1438 and SU1411 compounds’ DE gene lists, which were created using 
the initial filtering (Log2 (FC) ≥ 1, in either direction) and were of a more 
manageable size (52 and 52 genes, respectively). 
The 10 selected DE genes were used in qRT-PCR experiments that 
analysed the level of these genes in RPMI8226 cells, following treatment 
with SU1257, SU1053, SU1411, SU1438 and SU1349. To reduce experimental 
and technical variation the samples used in the qRT-PCR experiments were 
created from the identical experiments used to generate the TRIzol® lysates 
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for the Affymetrix GeneChip® HTA 2.0. Therefore, ensuring a robust 
validation of the microarray analysis using matched samples. As a further 
quality assurance, the quality of the RNA was checked and this was found 
to be of a high quality, where RIN ≥ 9.7. This was slightly less than the 
quality of the RNA used within the microarray analysis (RIN = 10). This 
may be a consequence of the longer storage time of the RNA whilst the 
microarray computational analysis was taking place, which may have 
resulted in a slight loss in RNA stability and quality. 
Overall, the results of the qRT-PCR indicated that this technique 
successfully validated the microarray analysis because similar gene 
expression changes were observed for the same set of 10 DE microarray 
genes in both experiments. Moreover, when the relationship between the 
microarray gene expression levels and qRT-PCR gene expression levels 
among the UT and SU compound treated samples was explored, this 
indicated that there was a correlation in nine of the 10 genes. The exception 
was TRAF6 where qRT-PCR did not replicate the expression changes 
observed in the microarray for the SU series compounds SU1411 and 
SU1438, and SU1053.  
In conclusion, the qRT-PCR successfully validated the microarray 
analysis and demonstrated that variability in gene expression following 
treatment with the SU agents in RPMI8226 cells was most likely due real 
biological regulation by these agents. Therefore, this study has produced 
the first high quality microarray dataset analysing the use of novel IKKα 
inhibitors in MM. 
5.3.4. Final conclusions 
This chapter has successfully highlighted that the SU compounds 
differentially regulate the expression of multiple genes; some which were 
shared and some were unique to specific agents. In addition, it was shown 
that an increased amount of DE genes was associated with the increase in 
cytotoxicity of an SU agent in RPMI8226 MM cells. However, the data 
presented in this chapter has also indicated that the effects of the SU 
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compounds is more likely to be due to off-target kinase inhibition rather than 
direct NF-κB inhibition. 
The quality control carried out throughout the course of the 
microarray analysis has also been successful in reducing variability and was 
shown to have contributed to producing a high-quality microarray dataset. 
The selection of 10 DE genes from the microarray data were validated using 
qRT-PCR and this further verified the quality of the dataset. As a result, this 
study has produced the first high quality microarray dataset analysing the 
use of novel IKKα inhibitors in MM. Therefore, the work undertaken in this 
thesis chapter lays the groundwork for further research into the global gene 
expression regulation of the SU IKKα inhibitory agents SU1257, SU1053, 
SU1438, SU1411 and SU1349 in the MM cell line RPMI8226. 
188
	  	  
Chapter 6 – Evaluation of a novel NIK inhibitor for the 
treatment of multiple myeloma 
NF-κB inducing kinase (NIK) is a MAP3K-related protein kinase that 
activates NF-κB mainly through the phosphorylation of IKKα, which 
predominantly results in non-canonical NF-κB pathway signalling (Malinin et 
al. 1997; Ling et al. 1998). NIK is also capable of phosphorylating IKKβ to 
activate the canonical pathway but NIK has less affinity for this IKK so IKKα 
is the preferred substrate (Ling et al. 1998; Senftleben et al. 2001). In normal 
cells, NIK is present at undetectable levels due to TRAF3, which is a negative 
regulator of NIK (Liao et al. 2004). TRAF3 interacts with NIK to induce the 
proteasomal degradation of NIK, which mainly inhibits non-canonical NF-κB 
pathway signalling but may additionally negatively regulate canonical 
pathway signalling (Liao et al. 2004; Zarnegar et al. 2008). 
Several studies have documented that MM tumours and cell lines 
possess a high number of genetic aberrations leading to NIK overexpression 
and stabilisation (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 
2010). This is a result of inactivating mutations in negative regulators of NIK, 
such as TRAF3, and activating mutations in NIK and positive regulators of 
NIK, such as CD40. The overexpression of NIK in MM contributes to the 
increased NF-κB signalling observed because higher constitutive levels of NIK 
allows the phosphorylation of both IKKα and IKKβ resulting in both non-
canonical and canonical NF-κB pathway signalling (Annunziata et al. 2007; 
Keats et al. 2007; Demchenko et al. 2010). 
TRAF3 deficiency has been shown to substantially enhance the survival 
of B cells (Xie et al. 2007; Gardam et al. 2008). Furthermore, the enhancement 
in survival was associated with the stabilisation and subsequent 
overexpression of NIK that allows constitutive activation of non-canonical 
pathway signalling independent of external stimuli (He et al. 2006).  
Moreover, the knockdown of NIK expression in MM cell lines that 
expressed a high level of NIK protein induced cell apoptosis; the same effect 
was not observed in those cell lines that contained a low level of NIK 
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expression (Annunziata et al. 2007). This supports the concept that NIK 
overexpression contributes to increased survival and tumourigenesis in MM 
cells and MM cells with high NIK levels are dependent on NIK. The survival 
signals induced by NIK are likely to be through activation of both the 
canonical and non-canonical NF-κB pathway signalling (Annunziata et al. 
2007; Demchenko et al. 2010). 
Deletion or inactivating mutations of the TRAF3 gene are common 
events in MM and are a characteristic of the RPMI8226 and U266B1 MM cell 
lines (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 2010). U266B1 
cells possess a frame-shift mutation in TRAF3 that results in the transcribed 
TRAF3 protein lacking the functioning NIK-binding domain. On the other 
hand, the TRAF3 protein is undetectable in RPMI8226 cells due to a bi-allelic 
deletion of TRAF3. The TRAF3 deficiency present in both of these MM cell 
lines has been shown to contribute to their relatively high level of NF-κB 
activity (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 2010). 
Furthermore, the JJN3 cell line possesses an activating unbalanced 
rearrangement of NIK that results in a NIK protein that lacks the TRAF3-
binding domain (Annunziata et al. 2007; Keats et al. 2007; Demchenko et al. 
2010). This means that, although TRAF3 is still expressed to a high level in 
JJN3 cells, the mutant NIK protein is unable to interact with TRAF3 and this 
gives rise to both NIK overexpression and increased NF-κB activity 
(Annunziata et al. 2007; Keats et al. 2007; Sasaki et al. 2008; Demchenko et al. 
2010). 
The over expression of NIK in U266B1, RPMI8226 and JJN3 MM cell 
lines likely contributes to their relatively increased NF-κB activity when 
compared to H929 as this is a MM cell line that does not possess NIK 
activating mutations (Annunziata et al. 2007; Keats et al. 2007; Demchenko et 
al. 2010). 
Therefore, my hypothesis was that the use of a novel NIK inhibitor, 
CW15337, may represent a promising strategy for the treatment of MM, 
particularly in the context of NIK activation. The specific aims of this chapter 
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were to evaluate the use of this pharmacological agent in terms of cytotoxicity, 
regulation of Mcl-1 expression and effect on NF-κB activity in the four MM 
cell lines, each representing different clinical features of MM. In addition, the 
relative effects of CW15337 on the transcription of genes that were 
significantly altered following exposure to the IKKα inhibiting SU compounds 
were also investigated. 
6.1. Cytotoxicity of CW15337 in MM cell lines 
NIK overexpression as a result of TRAF3 deficiency has been shown to 
enhance B cell survival through constitutive activation of the non-canonical 
NF-κB pathway that is independent of ligand activation (He et al. 2006; Xie et 
al. 2007; Gardam et al. 2008). Moreover, Annunziata et al. demonstrated that 
MM cell lines that overexpress NIK were sensitive to apoptosis induced by 
knockout of NIK (Annunziata et al. 2007). This suggests that NIK 
overexpression contributes to MM cell survival and MM cells with NIK 
overexpression become dependent on NIK for their survival. Additionally, 
several studies have demonstrated that NIK inhibition induces apoptosis in 
MM cell lines (Demchenko et al. 2014; Takeda et al. 2016). Therefore, the 
cytotoxicity of the novel NIK inhibitor, CW15337, was investigated in the 
four MM cell lines, H929, U266B1, RPMI8226 and JJN3, to investigate 
whether sensitivity to apoptosis would vary according to the TRAF3 and 
NIK status of each MM cell line.  
Each MM cell line was incubated with increasing concentrations of 
CW15337 ranging from 0.5µM to 10µM. At 48h, MM cells were harvested and 
washed in PBS before being labelled with Annexin V-FITC and PI. The 
labelled cells were then analysed using flow cytometry to determine the 
percentage of apoptosis (Annexin V+/PI- + Annexin V+/PI+ + Annexin V-
/PI+) occurring at each CW15337 concentration. Figure 6.1 shows the 
cytotoxicity of CW15337 at 48h in each MM cell line and the results shown 
are collated from three independent experiments. 
Figure 6.1 shows that the novel NIK inhibitor induced cytotoxicity in a 
concentration-dependent manner in all of the MM cell lines analysed. 
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Figure 6.1 The cytotoxicity of the NIK inhibitor CW15337 at 48h in MM cell lines.  
The MM cell lines H929, U266B1, RPMI8226 and JJN3 were treated with increasing 
concentrations of CW15337 between 0.5µM and 10µM. At 48h, cell death was 
measured using Annexin V/PI positivity on an Accuri C6 flow cytometer. The 
percentage of apoptotic cells at each concentration of CW15337 was then calculated 
and dose-response curves were constructed using GraphPad Prism 6.0. LD50 values 
were interpolated and are reported for each cell line alongside 95% CI. Error bars 
represent mean ± SD, where n = 3, triplicate.	  
 
Comparison of the LD50 values for each MM cell line shows that JJN3 was the 
most resistant cell line to apoptosis induced by CW15337 (LD50 = 2.38µM, 
95% CI [2.25µM, 2.52µM]). The LD50 values for H929 (LD50 = 1.44µM, 95% CI 
[1.34µM, 1.55µM]) and RPMI8226 (LD50 = 1.88µM, 95% CI [1.82µM, 1.94µM]) 
0.5 1 2.51.5 5 102
0
20
40
60
80
100
[CW15337] µM
A
po
pt
os
is
 (%
)
H929
LD50 = 1.44µM
95% CI [1.34µM, 1.55µM]
0.5 1 2.51.5 5 102
0
20
40
60
80
100
[CW15337] µM
A
po
pt
os
is
 (%
)
U266B1
LD50 = 1.04µM
95% CI [877nM, 1.24µM]
0.5 1 2.51.5 5 102
0
20
40
60
80
100
[CW15337] µM
A
po
pt
os
is
 (%
)
RPMI8226
LD50 = 1.88µM
95% CI [1.83µM, 1.95µM]
0.5 1 2.51.5 5 102
0
20
40
60
80
100
[CW15337] µM
A
po
pt
os
is
 (%
)
JJN3
LD50 = 2.38µM
95% CI [2.25µM, 2.52µM]
192
	  	  
are relatively similar and represent a relatively intermediate level of 
sensitivity to apoptosis in response to CW15337. 
Based on LD50 value alone, U266B1 (LD50 = 1.04µM, 95% CI [887nM, 
1.24µM]) was the most sensitive MM cell line to cytotoxicity induced by 
CW15337. However, Figure 6.1 shows that the dose-response curve for 
U266B1 plateaued at a level of apoptosis of 57.6% ± 7.52% at 10µM compared 
to the peak apoptosis for H929, RPMI8226 and JJN3 at 10µM (99.8% ± 0.1%, 
95.8% ± 2.0% and 99.4% ± 0.4%, respectively). This could either suggest a 
subset of cells within the U266B1 cell line that are inherently resistant to 
cytotoxicity induced by CW15337 or that there was a technical issue with the 
Annexin-V/PI labelling of this cell line. 
Therefore, to further explore this phenomenon, the raw flow 
cytometric data plots were investigated in more detail. Figure 6.2 shows a 
representative example of the collected raw data used to create the dose-
response curve shown for U266B1 in Figure 6.1. The first panel of scatter 
plots in Figure 6.2 shows the gating that was used to identify viable and 
apoptotic U266B1 cells based on their FSC-A and SSC-A profiles. The second 
panel shows the corresponding scatter plots of Annexin-V-FITC-H and PI-H 
that are used to more specifically evaluate cytotoxicity (Annexin V+/PI- (Q2-
LR) + Annexin V+/PI+ (Q2-UR) + Annexin V-/PI+ (Q1-UL)).  
Figure 6.2 highlights the inconsistency between the FSC-A and SSC-A 
profiles and the corresponding scatter plots of Annexin-V-FITC-H and PI-H 
in the U266B1 cell line following treatment with CW15337. The FSC-A and 
SSC-A profiles shown in Figure 6.2 indicate that U266B1 cells experience a 
more prominent dose-dependent increase in apoptosis induced by CW15337 
than was shown in Figure 6.1. The FSC-A and SSC-A profile for U266B1 cells 
treated with 10µM CW15337 shows that 94.1% of U266B1 cells had 
undergone FSC-A and SSC-A changes consistent with the induction of 
apoptosis. In contrast, the corresponding scatter plot of Annexin-V-FITC-H 
and PI-H in Figure 6.2 indicates that only 55.7% of U266B1 cells were 
apoptotic after 48h treatment with 10µM CW15337. 
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In conclusion, Figure 6.2 suggests that it was more likely an issue with 
the Annexin V-FITC and PI staining used to assess cell apoptosis in the 
U266B1, which resulted in an underestimation of the cytotoxicity of CW15337 
as calculated in Figure 6.1. There was no evidence to support the notion of a 
resistant sub-population of U266B1 cells. 
For this reason, the cytotoxicity of CW15337 in all MM cell lines was 
reassessed by calculating the percentage of apoptotic cells at 48h based on the 
FSC-A and SSC-A profiles measured by flow cytometry. The data used for 
calculating FSC-A and SSC-A apoptosis corresponds to the same three 
independent experiments that were used to create Figure 6.1. 
Overall, the LD50 values obtained through both the FSC-A and SSC-A 
viability method and the Annexin-V/PI positivity method were similar for 
the MM cell lines H929, RPMI8226 and JJN3 (Table 6.1). In addition, Figure 
6.3 shows that a linear regression analysis of LD50 values calculated using 
Annexin V/PI positivity and FSC-A and SSC-A apoptosis produced a 
correlation with a high linearity (r2 = 0.79). This indicates that both methods 
show strong concordance and it was appropriate to evaluate the cytotoxic 
effects if CW15337 using the FSC-A and SSC-A method. 
Therefore, Figure 6.4 shows the resulting dose-response curves plotted 
for each MM cell line using the FSC-A and SSC-A method of calculating 
apoptosis at each concentration of CW15337. Figure 6.4 shows that CW15337 
was cytotoxic in all the MM cell lines after 48h treatment in a dose-dependent 
manner. Figure 6.4 shows that in H929, U266B1, RPMI8226 and JJN3 cells, 
CW15337 induces a relatively similar maximum apoptosis at 10µM (99.5% ± 
0.1%, 94.9% ± 2.7%, 98.1% ± 0.9% and 99.5% ± 0.1%, respectively).  
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Table 6.1 Comparison between the LD50 values calculated using the FSC-A and 
SSC-A apoptosis method and the Annexin-V/PI positivity method of assessing 
apoptosis. The LD50 values for each of the two methods are shown for the H929, 
U266B1, RPMI8226 and JJN3 MM cell lines alongside 95% CI. 
 Annexin V/PI positivity FSC-A and SSC-A apoptosis  
H929 
LD50 = 1.44µM 
95% CI [1.43µM - 1.55µM] 
LD50 = 1.49µM 
95% CI [1.39µM - 1.60µM] 
U266B1 
LD50 = 1.04µM 
95% CI [877nM - 1.24µM] 
LD50 = 1.52µM 
95% CI [1.35µM - 1.71µM] 
RPMI8226 
LD50 = 1.88µM 
95% CI [1.83µM - 1.95µM] 
LD50 = 1.87µM 
95% CI [1.80µM - 1.95µM] 
JJN3 
LD50 = 2.38µM 
95% CI [2.25µM - 2.52µM] 
LD50 = 2.73µM 
95% CI [2.60µM - 2.87µM] 	  	  	  	  	  	  	  	  
   
 
Figure 6.3 Correlation of the LD50 values calculated using the Annexin-V/PI 
positivity and the FSC-A and SSC-A apoptosis method.  
The correlation between the LD50 values calculated using the Annexin-V/PI positivity 
and those calculated using the FSC-A and SSC-A apoptosis method was explored for 
the MM cell lines H929, U266B1, RPMI8226 and JJN3 using a linear regression 
analysis in Graphpad Prism 6.0. The points plotted represent the LD50 values 
calculated for each cell line using each method (n = 3). The resulting linearity (r2) is 
reported alongside the graph. 
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Figure 6.4 The cytotoxicity of CW15337 at 48h in the MM cell lines H929, U266B1, 
RPMI8226 and JJN3 when FSC-A and SSC-A are used to calculate apoptosis. 
The data shown in Figure 6.1 was re-analysed so that cell death was measured as a 
percentage of apoptotic cells at each concentration based on FSC-A and SSC-A gating. 
The percentage of apoptotic cells at each concentration of CW15337 was input into 
GraphPad Prism 6.0 and dose-response curves were constructed. LD50 values were 
interpolated and are reported for each cell line alongside 95% CI. Error bars represent 
mean ± SD, where n = 3, triplicate.	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[1.35µM - 1.71µM]) cell lines experience a relatively high sensitivity to 
apoptosis induced by CW15337 whereas the RPMI8226 cell line (LD50 = 
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apoptosis induced by CW15337. The LD50 value shown in Figure 6.4 for the 
JJN3 cell line (LD50 = 2.73µM, 95% CI [2.60µM - 2.87µM]) suggests that this 
MM cell line is the most resistant to apoptosis induced by CW15337.  
The relative sensitivity of each MM cell line to CW15337 is 
summarised in Figure 6.5, which shows the mean LD50 values alongside 95% 
CI generated using FSC-A and SSC-A method of calculating apoptosis for 
each MM cell line. In addition, a one-way ANOVA followed by a Tukey’s 
multiple comparison test was performed on the data to investigate the 
statistical difference between the LD50 values calculated for each MM cell 
line. Figure 6.5 shows that H929 and U266B1 cells do not experience a 
significantly different sensitivity to apoptosis induced by CW15337 (p = 
0.921). Furthermore, the LD50 value interpolated for the RPMI8226 cell line 
compared to that of the U266B1 cell line was also not significantly different (p 
= 0.125). However, Figure 6.5 also shows that the LD50 value calculated for 
the JJN3 cell line is significantly higher than the LD 50 value of the RPMI8226 
cell line in response to CW15337 treatment (p = 0.023). 
In conclusion, CW15337 was cytotoxic at 48h in all MM cell lines 
tested. For the MM cell lines H929, RPMI8226 and JJN3, the level of apoptosis 
calculated by both Annexin V-FITC and PI staining (Figure 6.1) and FSC-A 
and SSC-A profiles (Figure 6.4) showed a strong correlation (r2 = 0.84) (Figure 
6.3). However, Figure 6.1, 6.2 and 6.4 indicate that there was an issue with the 
Annexin V-FITC and PI staining used to calculate the cytotoxicity specifically 
in the U266B1 cell line in response to CW15337. To more accurately assess the 
cytotoxicity of the NIK inhibitor in U266B1 cells, and to more reliably 
compare the relative cytotoxic effects on the four cell lines, the FSC-A and 
SSC-A profiles were used to calculate apoptosis. By this method it was 
revealed that the H929, U266B1 and RPMI8226 MM cell lines shared a similar 
sensitivity to apoptosis induced by CW15337 (Figure 6.4 and Figure 6.5). 
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Figure 6.5 A summary of the relative sensitivity of each MM cell line to apoptosis 
induced by CW15337. 
The mean LD50 values generated through the FSC-A and SSC-A method of assessing 
apoptosis are shown for the MM cell lines H929, U266B1, RPMI8226 and JJN3 in 
response to increasing concentration of CW15337 for 48h. The results shown were 
interpolated using the dose-response curves in Figure 6.4 using Graphpad Prism 6.0. 
The values reported represent mean LD50 values ± 95% CI (µM) where n = 3, triplicate. 
A one-way ANOVA followed by a Tukey’s multiple comparison test was performed 
using Graphpad Prism 6.0 software to investigate the significant difference between 
the LD50 values calculated for the indicated cell lines. 
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6.2. CW15337 regulation of Mcl-1 expression in MM cell lines 
In myeloma cells, Mcl-1 expression plays a critical role in maintaining 
cell viability (Derenne et al. 2002; Zhang et al. 2002). Furthermore, high 
expression of Mcl-1 in cancer cell lines has been linked to constitutively high 
NF-κB activity (Liu et al. 2014). In addition, previous studies have 
demonstrated that inhibition of NF-κB activity is accompanied by the down 
regulation of Mcl-1 expression in MM cell lines and may precede the 
activation of apoptotic pathways (Meinel et al. 2010). Therefore, Mcl-1 
expression was quantified in MM cell lines after 4h incubation (prior to any 
evidence of apoptosis induction) with increasing concentrations of the NIK 
inhibitor, CW15337 to investigate whether NIK inhibition modulated the 
expression of Mcl-1 in the MM cell lines. 
MM cells from the MM cell lines H929, U266B1, RPMI8226 and JJN3 
were treated with CW15337 at concentrations of 0.5µM, 1µM, 2.5µM and 5µM. 
At 4h, cells from each MM cell line were harvested and then fixated and 
permeabilised before staining with an anti-Mcl-1-IgG1 antibody (Santa Cruz 
Biotechnology) followed by secondary labelling with a goat anti-mouse IgG1-
FITC antibody (Santa Cruz Biotechnology). The stained cells were then 
analysed using flow cytometry to quantify the intracellular Mcl-1 expression 
at each concentration of CW15337 in each MM cell line. 
A gating strategy was applied to the collected flow cytometric data to 
ensure that only viable, single MM cells were analysed. The serially gated 
MM cell populations were then assessed for Mcl-1 expression (MFI values) at 
each concentration of CW15337. Figure 6.6 shows the representative overlay 
histograms of Mcl-1 expression in each MM cell line for the untreated and 
5µM CW15337 treated MM cells at 4h. Figure 6.6 shows that all of the MM 
cell lines used have a relatively high baseline level of Mcl-1 expression. 
Moreover, all MM cell lines experience a similar decrease in Mcl-1 expression 
following 4h incubation with 5µM CW15337 relative to the untreated baseline 
level. 
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As all MM cell lines have a high expression of Mcl-1, the relationship 
between the specific baseline Mcl-1 expression and sensitivity to apoptosis 
induced by CW15337 treatment was investigated in each MM cell line. The 
aim of this was to evaluate whether baseline Mcl-1 expression could be a 
predictor of a MM cell lines response to NIK inhibition. The Mcl-1-FITC MFI 
in untreated MM cells was calculated and plotted against the mean LD50 
value interpolated for each MM cell line. A linear regression analysis was 
performed and the results are shown in Figure 6.7.  
Figure 6.7 shows that the H929 cell line possesses the highest average 
level of baseline Mcl-1 expression compared to the other three cell lines, 
although the error calculated was large. Figure 6.7 also shows that U266B1 
cells have the second highest level of average Mcl-1 expression that is 
relatively more similar to Mcl-1 expression in the H929 cell line. The 
RPMI8226 and JJN3 cell lines relatively have lower levels of average Mcl-1 
expression in untreated cells. Overall, the RPMI8226 cell line has the lowest 
baseline Mcl-1 expression of all the MM cell lines. The linear regression 
analysis indicates that there is a low negative correlation between the average 
baseline Mcl-1 expression and the calculated LD50 value in response to 
CW15337 for each MM cell line (r2 = 0.21), which indicates that baseline Mcl-1 
expression weakly determines MM cell line sensitivity to apoptosis induced 
through NIK inhibition. 
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Figure 6.6 Representative overlay histograms of Mcl-1 expression in MM cell lines 
after 4h exposure to the NIK inhibitor CW15337. 
Mcl-1 expression was investigated in H929, U266B1, RPMI8226 and JJN3 cells after 
treatment with increasing concentrations of CW15337. At 4h, intracellular Mcl-1 
expression was investigated by staining cells with an anti-Mcl-1-FITC conjugated 
antibody and the average MFI was measured by flow cytometry. To gain an accurate 
MFI for each cell surface marker, gating was applied to gate viable myeloma cells 
(P1) and exclude any doublets (P2). The resultant gating was used to create overlay 
histograms from which the MFI of Mcl-1 expression at each concentration could be 
determined. A representative overlay histogram is shown for each MM cell line after 
4h treatment with 5µM CW15337 (untreated = n, 5µM CW15337 = n). 
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Figure 6.7 Correlation between baseline Mcl-1 expression and the LD50 values 
calculated for apoptosis induced by CW15337 in each MM cell line.  
The relationship between the specific baseline Mcl-1 expression and sensitivity to 
apoptosis induced by CW15337 treatment was investigated in each MM cell line. The 
points plotted represent Mcl-1-FITC expression (MFI) (mean ± SD) against the LD50 
values calculated for apoptosis induced by CW15337 (LD50 value ± 95% CI) for each 
MM cell line (n = 3). A linear regression analysis was performed in Graphpad Prism 6 
and the resulting linearity (r2) is reported alongside the graph. 
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most consistent dose-dependent down-regulation of Mcl-1 expression 
compared to the other cell lines.  
Figure 6.8 shows that both U266B1 and JJN3 MM cells underwent a 
dose-dependent down-regulation of Mcl-1 expression, although this decrease 
was not significant when the highest concentration of CW15337 (5µM) was 
compared to untreated MM cells (p = 0.124 and p = 0.105, respectively). The 
dose-dependent decrease in Mcl-1 expression induced by CW15337 in JJN3 
cells is shown in Figure 6.8 to plateau following exposure to 2.5µM and 5µM 
CW15337 (58.6% ± 6.8% and 58.1% ± 6.4%, respectively) relative to untreated 
JJN3 cells. Figure 6.8 also indicates that the U266B1 cell line experienced a 
maximum decrease in Mcl-1 expression at 5µM similar to that of the JJN3 cell 
line, when compared to untreated Mcl-1 expression in each cell line (57.4% ± 
13.2% and 58.1% ± 6.4%, respectively). 
In conclusion, the NIK inhibitor significantly down-regulated Mcl-1 
expression in a dose-dependent manner in the MM cell lines H929 and 
RPMI8226 after 4h treatment. Moreover, the normalised change in overall 
Mcl-1 expression measured at 5µM CW15337 was relatively similar for each 
of the four MM cell lines. Therefore, Figure 6.6 and 6.8 suggest that NF-κB 
activity may be inhibited by CW15337 in each MM cell line at 4h in a dose-
dependent manner. 
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Figure 6.8 The dose-dependent regulation of Mcl-1 expression in MM cell lines 
after 4h treatment with CW15337. 
Mcl-1 expression was investigated in the H929, U266B1, RPMI8226 and JJN3 cell lines 
after treatment with increasing concentrations of CW15337 ranging from 0µM to 5µM. 
At 4h, intracellular Mcl-1 expression was investigated by staining cells with an anti-
Mcl-1-FITC conjugated antibody following fixation and permeabilisation. The Mcl-1-
FITC MFI at each concentration of SU compound was measured using an Accuri flow 
cytometer and normalised to the untreated control. A one-tailed unpaired t-test was 
performed using Graphpad Prism 6.0 software to investigate the statistical 
significance values between 0µM to 5µM of CW15337 in each MM cell line at 4h (n = 3, 
duplicates averaged). The results are reported above the graph (NS = not significant, p 
> 0.05).. Error bars represent SD where n = 3, duplicate and experimental duplicates 
are shown. 
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6.3. Inhibition of NF-κB activity by CW15337 
The association between cytotoxicity and the inhibition of constitutive 
NF-κB activity induced by CW15337 was investigated in more detail using an 
ELISA detecting the active NF-κB subunits p65, p50, p52 and RelB. These four 
subunits were specifically chosen because they would provide information as 
to whether NIK inhibition was effecting canonical or non-canonical 
generated NF-κB activity. The RPMI8226 MM cell line was used for these 
experiments because it had an intermediate level of constitutive NF-κB 
activity and also possessed a bi-allelic mutation in TRAF3 resulting in NIK 
activation. 
RPMI8226 cells were incubated with the NIK inhibitor at 
concentrations of 1µM, 2.5µM and 5µM. At 4h, RPMI8226 cells from each 
concentration of CW15337 were harvested and converted to nuclear extracts. 
1µg of RPMI8226 nuclear extract protein was assayed using the NF-κB family 
ELISA kit (Active Motif), as per the manufacturers instructions. Standard 
curves were generated alongside the assay using know quantities of 
recombinant p65 protein (r2 > 0.99) and recombinant p50 protein (r2 > 0.96) to 
allow NF-κB subunit quantification in nanograms per microgram of nuclear 
extract protein.  
Figure 6.9 shows the quantities of active p65, p50, p52 and RelB NF-κB 
subunit proteins in RPMI8226 cells following 4h treatment with CW15337 at 
concentrations of 1µM, 2.5µM and 5µM. The data shown consists of the 
collated data from three separate experiments where the individual nuclear 
extract samples were assayed in duplicate.  
Figure 6.9 shows that both the p52 and RelB subunits experienced a 
dose-dependent inhibition across all increasing concentrations of CW15337 in 
RPMI8226 cells, although only the RelB subunit experienced a significant 
decrease by 5µM CW15337 when compared to the untreated samples (p = 
0.002). 
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Conversely, the p65 and p50 NF-κB subunits did not show a 
significant change in nuclear protein levels following 5µM CW15337 relative 
to the untreated group (p = 0.269 and p = 0.224, respectively). Furthermore, 
no dose-dependent regulation of p65 and p50 was observed.  
Overall, Figure 6.9 demonstrates that 5µM CW15337 preferentially 
decreased the levels of p52 and RelB NF-κB subunits in a dose-dependent 
manner in RPMI8226 cells. The specific dose-dependent decrease of these 
subunits suggests that CW15337 predominantly inhibited the non-canonical 
NF-κB signalling pathway. 
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Figure 6.9 Effect of CW15337 on NF-κB activity in RPMI8226 MM cells at 4h. 
RPMI8226 cells were exposed to increasing concentrations of CW15337 for 4h. 
RPMI8226 cells were then harvested and used to generate nuclear extract samples. 
The MM cell line was then assayed at 1µg/well of nuclear extract protein using 
ELISAs detecting the active NF-κB subunits p50, p65, p52 and RelB. A one-tailed 
unpaired t-test was performed using Graphpad Prism 6.0 software to investigate the 
statistical significance values between 0µM to 5µM for CW15337 in RPMI8226 cells for 
each NF-κB subunit (n = 3, duplicates averaged). The results are reported above the 
graph (NS = not significant, p > 0.05). Values reported are mean ± SD produced from 
duplicate measurements where n = 3, experimental duplicates shown. 	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6.4. Gene expression following CW15337 treatment using qRT-
PCR 
NIK mainly regulates NF-κB activity through the activation of IKKα, 
which subsequently activates the non-canonical signalling pathway (Ling et 
al. 1998; Senftleben et al. 2001). Therefore, the effect of the NIK inhibitor on 
previously validated IKKα-regulated genes was compared with the IKKα 
inhibitory SU compounds using qRT-PCR analysis.  
The genes analysed included those identified as significantly altered 
following exposure to the SU compounds in the previous chapter (TRAF6, 
RIPK1, POLA2, SRSF7, POLR2A, SRSF6, OFD1, PRKCI, UBA2 and NSUN2). 
The effect of CW15337 (2.5µM) on specific gene transcription was assessed in 
RPMI8226 cells and the results compared with those obtained with SU1257, 
SU1053, SU1411, SU1438 and SU1349.  
Briefly, RPMI8226 cells were incubated alone and in the presence of 
2.5µM of CW15337. At 4h, cells were harvested from untreated and 2.5µM 
treated conditions to generate TRIzol® lysates that were subsequently 
processed to RNA extracts using an RNeasy mini kit (Qiagen), according to 
the manufacturers instructions. The eluted RNA was reverse transcribed into 
cDNA using a high capacity cDNA reverse transcription kit (Applied 
Biosystems). A reaction master mix was prepared for each primer pair 
containing the cDNA, primer pairs and SYBR® Green I dye and this was 
loaded into the wells of a 96-well reaction plate. The reaction plate was then 
analysed using ViiA™ 7 Real-Time PCR System (Applied BioSystems). The 
qRT-PCR results were used to generate the relative fold change in each target 
gene using the 2-ΔΔCt method (Livak a Schmittgen 2001) where the 
endogenous control gene was RSP14. 
The 2-ΔΔCt fold change for each of the 10 genes analysed using qRT-
PCR following treatment with 2.5µM CW15337 for 4h in RPMI8226 cells are 
shown in the heatmap in Figure 6.10. The results are shown alongside the 
qRT-PCR data previously produced for the SU compounds SU1257, 
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SU1053, SU1438, SU1411 and SU1349 in RPMI8226 cells to allow for a side-
by-side comparison of the effect of each compound on specific gene 
regulation. The results shown for the NIK inhibitor represent three separate 
experiments that were analysed in duplicate in the qRT-PCR.  
Figure 6.10 shows that CW15337 has a regulatory profile that 
possesses the most similarities with the three most cytotoxic SU compounds 
(SU1438, SU1411 and SU1349). Moreover, CW15337 appeared to encompass a 
combination of all three of the SU compounds’ regulatory profiles. For this 
reason, the statistical significance values were investigated using a Two-way 
ANOVA to compare the fold change in gene transcription that CW15337 
treatment induced with the fold changes induced by SU1438, SU1411 and 
SU1349 treatment for each of the 10 genes measured using qRT-PCR. Table 
6.2 displays the results of this analysis. 
Figure 6.10 shows that CW15337 treatment caused a similar down 
regulation in RIPK1, POLA2, SRSF7 and SRSF6 as that induced by SU1349. 
However, the average fold change in RIPK1, POLA2 and SRSF6 induced by 
CW15337 (-9.6 ± 3.2, -18.3 ± 8.1 and -10.7 ± 2.8, respectively) was relatively 
higher than that induced by SU1349 (-7.1 ± 6.0, -11.1 ± 12.2 and -6.1 ± 1.5, 
respectively), although Table 6.2 shows that only POLA2 was significantly (p 
= 0.0031) altered by CW15337 compared to SU1349. In contrast, CW15337 
induced significantly less change in the transcription of SRSF7 when 
compared to SU1349 down regulation (-5.8 ± 2.5 and -13.7 ± 13.3, 
respectively, p = 0.0009). However, this could be due to the relatively large 
variation in SU1349 qRT-PCR replicate samples skewing the average fold 
change. Moreover, TRAF6 gene transcription was most markedly decreased 
following treatment with SU1349 (-6.3 ± 1.7), although this was not 
significantly different when compared to CW15337 (p = 0.74). Moreover, the 
changes in TRAF6 induced by CW15337 were more similar to the fold change 
observed with SU1438 (-3.7 ± 0.5 and -3.8 ± 1.2, respectively, p > 0.99). 
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Table 6.2 Two-way ANOVA comparing the fold change in the transcription of each 
gene induced by CW15337 with fold change induced by SU1438, SU1411 and 
SU1349. 
A two-way ANOVA followed by Tukey’s multiple comparisons test was performed 
in Graphpad Prism to investigate the statistical significance values between the fold 
change in gene transcription that CW15337 treatment induced compared with the fold 
changes induced by SU1438, SU1411 and SU1349 as measured using qRT-PCR (n = 3). 
The adjusted p value and the resulting significance summary (p ≤ 0.05 = *, p ≤ 0.01 = 
**, p ≤ 0.001 = *** and p ≤ 0.0001 = ****) are reported for each comparison. 
  Adjusted p value Summary 
TRAF6 
CW15337 vs. SU1438 > 0.9999 ns 
CW15337 vs. SU1411 0.9668 ns 
CW15337 vs. SU1349 0.7393 ns 
 
RIPK1 
CW15337 vs. SU1438 0.1936 ns 
CW15337 vs. SU1411 0.0016 ** 
CW15337 vs. SU1349 0.7476 ns 
 
POLA2 
CW15337 vs. SU1438 < 0.0001 **** 
CW15337 vs. SU1411 < 0.0001 **** 
CW15337 vs. SU1349 0.0031 ** 
 
SRSF7 
CW15337 vs. SU1438 0.9963 ns 
CW15337 vs. SU1411 0.9516 ns 
CW15337 vs. SU1349 0.0009 *** 
 
POLR2A 
CW15337 vs. SU1438 0.8916 ns 
CW15337 vs. SU1411 0.174 ns 
CW15337 vs. SU1349 0.906 ns 
 
SRSF6 
CW15337 vs. SU1438 0.0653 ns 
CW15337 vs. SU1411 0.0032 ** 
CW15337 vs. SU1349 0.1596 ns 
 
OFD1 
CW15337 vs. SU1438 0.9753 ns 
CW15337 vs. SU1411 > 0.9999 ns 
CW15337 vs. SU1349 > 0.9999 ns 
 
PRKCI 
CW15337 vs. SU1438 0.9158 ns 
CW15337 vs. SU1411 0.7417 ns 
CW15337 vs. SU1349 0.6092 ns 
 
UBA2 
CW15337 vs. SU1438 0.9995 ns 
CW15337 vs. SU1411 > 0.9999 ns 
CW15337 vs. SU1349 0.9998 ns 
 
NSUN2 
CW15337 vs. SU1438 0.9994 ns 
CW15337 vs. SU1411 > 0.9999 ns 
CW15337 vs. SU1349 0.7418 ns 
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In addition, Figure 6.10 shows that CW15337 decreased the expression 
of POLR2A, OFD1, PRKCI, UBA2 and NSUN2, which were previously found 
to be genes that were repressed by treatment with SU1438 and SU1411. 
Moreover, Table 6.2 shows that the magnitude of the fold changes induced 
by CW15337 in these five genes was not significantly different to those 
induced by SU1438 and SU1411 gene regulation. The fold change in POLR2A 
that CW15337 induced (-7.02 ± 2.2) was marginally higher than that induced 
by SU1438 (-5.0 ± 2.3) and SU1411 (-2.6 ± 0.4) in RPMI8226 cells. The average 
fold change of OFD1, UBA2 and NSUN2 genes induced by CW15337 (-3.0 ± 
0.8, -3.4 ± 0.8 and -5.0 ± 1.4, respectively) were more similar to those caused 
by treatment with SU1411 (-3.3 ± 0.8, -3.6 ± 0.3 and -5.1 ± 0.9, respectively). 
The relative transcription of PRKCI showed an average fold change in 
response to CW15337 (-4.4 ± 2.1) that was relatively smaller than that induced 
by both SU1438 (-6.3 ± 3.9) and SU1411 (-7.0 ± 2.2). 
In conclusion, Figure 6.10 suggests that CW15337 is a potent regulator 
of the 10 SU compound associated genes. The CW15337 down regulated both 
SU1349 and SU1438/SU1411 associated genes and for the RIPK1, POLA2, 
POLR2A and SRSF6 genes the down regulation measured was relatively 
more pronounced. Taken together, these data indicate that CW15337 has a 
similar effect on the transcriptional programme of a selected subset of genes 
in RPMI8226 cells when compared with the IKKα inhibitors SU1438, SU1411 
and SU1349. 
6.5. Discussion 
The use of a novel NIK inhibitor, CW15337 was evaluated in four MM 
cell lines, each representing different NF-κB signatures due to the lack or 
presence of genetic abnormalities effecting NIK. Cytotoxicity was first 
assessed in all MM cell lines after 48h incubation with increasing 
concentrations of CW15337. The U266B1, RPMI8226 and JJN3 MM cell lines 
manifest constitutive NF-κB activity and possess increased expression of 
NIK, either due to activating mutations of NIK itself or due to the loss of a 
TRAF3 binding domain. Consequently, it was hypothesised that these three 
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MM cell lines may be more susceptible to cytotoxicity induced by NIK 
inhibition. 
CW15337 was cytotoxic in all four MM cell lines at 48h in a 
concentration-dependent manner, although the sensitivity to apoptosis 
induced by the NIK inhibitor was heterogeneous between the MM cell lines. 
Contrary to the proposed hypothesis, the H929 cell line was the most 
sensitive to the cytotoxic effects of the NIK inhibitor CW15337 whereas the 
JJN3 cell line was relatively more resistant. The U266B1 and RPMI8226 cell 
lines showed intermediate sensitivity to CW15337-induced apoptosis. 
Overall, this indicates that those MM cell lines containing TRAF3 inactivating 
or NIK activating mutations, which give rise to NIK dependency, were 
comparatively more resistant to cytotoxicity induced by CW15337 NIK 
inhibition. Moreover, NIK inhibition is more cytotoxic in the NIK 
independent MM cell line H929. 
This correlates with the study by Demchenko et al. who also showed 
that NIK inhibition by two novel NIK inhibitors in MM cell lines possessing 
more NIK protein were less sensitive to cytotoxicity induced by NIK 
inhibition compared to those MM cell lines that contained less NIK protein 
(Demchenko et al. 2014). In contrast, the same study demonstrated that NIK 
independent MM cell lines, such as H929, did not experience a decrease in 
viability in response to NIK inhibition. In addition, the cytotoxicity results for 
CW15337 also contrast with those obtained by Annunziata et al. who 
determined that NIK silencing in the NIK dependent MM cell line JJN3 was 
cytotoxic but did not induce cytotoxicity in the H929 MM cell line 
(Annunziata et al. 2007). Therefore, the finding that H929 was the most 
sensitive MM cell line to cytotoxicity induced by the NIK inhibitor is contrary 
to previous studies. However, the dichotomy between the data in this thesis 
and the existing literature may be a consequence of the off-target effects of 
CW15337. For example, the kinome screening data shown in Appendix 
Figure XV demonstrates that CW15337 has many kinase targets, including 
JAK2 and MAP4K2.  
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The results in Chapter 3 revealed that H929 had the lowest 
constitutive level of NF-κB activity, whereas U266B1 and RPMI8226 
possessed intermediate levels although U266B1 cells showed NF-κB activity 
closer to that of the H929 cell line. The JJN3 cell line possessed the highest 
level of NF-κB activity of the four cell lines and was the most resistant to the 
effects of CW15337. Therefore, the pattern of CW15337 cytotoxicity was 
inversely correlated with the level of NF-κB activity possessed by each MM 
cell line. An explanation for this could relate to the function of NF-κB because 
the transcription factor regulates genes involved in anti-apoptosis (Gilmore 
2007; Demchenko a Kuehl 2010). Therefore, cells with more NF-κB activity 
may be able to resist the inhibition caused by CW15337 by first depleting its 
increased reserves that act to buffer the induced cell death. However, this 
does not fully explain why the results for H929 differ from previous findings. 
To begin exploring the effect of NIK inhibition on NF-κB activity, the 
CW15337 dose-dependent regulation of Mcl-1 expression at 4h was 
quantified in each MM cell line. Mcl-1 is an anti-apoptotic protein that must 
be maintained in MM cells to sustain viability (Derenne et al. 2002; Zhang et 
al. 2002). In addition, inhibition of NF-κB activity is accompanied by the 
down-regulation of Mcl-1 expression and may contribute to the activation of 
apoptotic pathways (Meinel et al. 2010).  
The baseline Mcl-1 expression was quantified in the MM cell lines and 
was shown to be expressed in all four cell lines. This was consistent with each 
MM cell line possessing a constitutive level of NF-κB activity (Liu et al. 2014). 
Moreover, all MM cell lines experienced a dose-dependent decrease in Mcl-1 
expression relative to untreated myeloma cells in response to 4h incubation 
with CW15337. This was accompanied by a highly significant decrease in 
Mcl-1 expression in the H929 and RPMI8226 MM cell lines at the highest 
concentration of CW15337 (5µM) relative to the untreated control. However, 
the percentage of change in Mcl-1 expression at 5µM was relatively similar 
between the MM cell lines and did not correlate with the cell line specific 
pattern of sensitivity to apoptosis induced by CW15337. Nevertheless, linear 
regression analysis revealed a weak negative correlation between baseline 
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Mcl-1 expression and LD50 value calculated through apoptosis induced by 
CW15337 in the MM cell lines. This suggests that baseline Mcl-1 expression 
may be a predictor of cytotoxic sensitivity to NIK inhibition, although more 
data would be required to make a robust conclusion, preferably in primary 
MM cells rather than cell lines. 
The levels of other anti-apoptotic proteins, such as Bcl-XL, have also 
been shown to correlate with constitutive NF-κB activity induced by NIK 
overexpression in B cells (Sasaki et al. 2008). Similar to the results obtained 
for Mcl-1 in response to CW15337, Bcl-XL was down regulated by NIK 
inhibition in MM cell lines and this corresponded with apoptosis and a 
decrease in NF-κB activity (Takeda et al. 2016). Bcl-XL expression was not 
measured in this present study so it remains unclear whether CW15337 also 
induces a decrease in the expression of this anti-apoptotic protein. However, 
the significant dose-dependent decrease in Mcl-1 expression observed 
suggests that CW15337 NIK inhibition may correspond with a decrease in 
NF-κB activity in the MM cell lines tested, which may contribute to the 
cytotoxicity of CW15337. 
For this reason, the dose-dependent effect of CW15337 on NF-κB 
activity was investigated in more detail using an ELISA detecting the active 
NF-κB subunits p65, p50, p52 and RelB in the MM cell line RPMI8226. The 
results demonstrated that only the non-canonical NF-κB pathway 
experienced a concentration-dependent decrease, although only the RelB 
subunit was significantly affected by NIK inhibition by CW15337. However, 
as already discussed, the ELISA possessed caveats that meant that it might 
not have been an appropriate tool to quantify CW15337 inhibition of NF-κB 
activity. Therefore, western blotting could have been used as an additional 
tool to fully characterise the effect that CW15337 induced on NF-κB 
pathway processing in RPMI8226 cells. More specifically, by quantifying 
phosphorylated p100, and total p100 and p52 proteins following treatment 
with CW15337, this technique could have provided definitive proof of non-
canonical pathway inhibition because p100 functions as both the precursor 
of p52 and a RelB-specific inhibitor.  
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NIK mainly regulates the activation of the non-canonical NF-κB 
pathway (Ling et al. 1998; He et al. 2006) so it is consistent that only p52 and 
RelB subunits would be down regulated by NIK inhibition. On the other 
hand, it has been suggested that NIK silencing or inhibition decreases the 
level of overall NF-κB activity generated through both canonical and non-
canonical signalling (Annunziata et al. 2007; Demchenko et al. 2014). At least 
in the RPMI8226 MM cell line used in this study, CW15337 did not 
significantly effect the canonical NF-κB pathway because the levels of p65 
and p50 are not significantly altered by NIK inhibition. 
Several studies have shown that the non-canonical pathway is the 
main NF-κB pathway that regulates anti-apoptotic pathways (He et al. 2006; 
Xie et al. 2007; Gardam et al. 2008). Therefore, it seems possible that 
CW15337-mediated inhibition of NIK, and hence the depletion of non-
canonical NF-κB signalling, may contribute to the induction of apoptosis in 
the MM cell lines. 
NIK is responsible for phosphorylating IKKα to activate the non-
canonical NF-κB pathway (Ling et al. 1998; Senftleben et al. 2001). Given that 
CW15337 inhibited only non-canonical NF-κB pathway activity, it was 
hypothesised that CW15337 may share mechanistic similarities with the SU 
compounds explored in this thesis, as they also inhibit non-canonical 
signalling through IKKα inhibition. To investigate this, the transcriptional 
inhibition pattern caused by exposure to the SU compounds were compared 
with CW15337 using qRT-PCR analysis. The qRT-PCR analysis suggested 
that CW15337 was also a potent regulator of the 10 SU compound associated 
genes. Furthermore, the gene expression profile for CW15337 was most 
similar to the three most cytotoxic SU compounds, SU1349, SU1411 and 
SU1438. However, four of the SU compound differentially regulated genes 
experienced a more marked down regulation in response to CW15337 
compared to their associated SU compounds. These genes included the 
SU1349 associated genes RIPK1 and POLA2 and also differentially expressed 
genes POLR2A and SRSF6 that are differentially regulated by both SU1349 
and SU1438.  
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To maintain experimental consistency and allow adequate 
comparison, gene expression was investigated in the RPMI8226 cell line 
following 4h 2.5µM CW15337. This concentration was chosen based on the 
average LD50 values obtained for the SU compounds in the RPMI8226, which 
were comparatively less cytotoxic than CW15337. This may contribute to the 
relatively more potent down regulation of the four genes observed following 
treatment with CW15337 but this is unlikely as other genes, such as TRAF6, 
SRSF7 and PRKCI, experienced a smaller fold change than that the gene 
associated SU compound. 
Overall, the comparison of CW15337 regulated gene expression with 
that of the SU compounds suggests that CW15337 had a similar gene 
expression profile to SU1349, SU1411 and SU1438. These were the three most 
cytotoxic SU compounds tested in this series and so this could suggest that 
all the pharmacological agents regulated similar pathways that contributed 
to their cytotoxic nature. However, CW15337 had a quantitatively distinct 
pattern of gene regulation to the SU compounds, suggesting that its 
mechanism of action may differ slightly from that of the IKKα inhibitors.  
The aim of this chapter was to investigate the use of a novel NIK 
inhibitor, CW15337, in four MM cell lines with different clinical features of 
MM to evaluate the potential of a NIK inhibitor as a therapeutic agent. This 
chapter has successfully shown that CW15337 was potently, and dose-
dependently, cytotoxic in all the MM cell lines tested and this was coupled 
with a dose-dependent down-regulation of the expression of the anti-
apoptotic protein Mcl-1. CW15337 dose-dependently inhibited only the non-
canonical NF-κB pathway, which likely contributes to the cytotoxic effect of 
the pharmacological agent.  
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Chapter 7 – Conclusions and final discussion 
7.1. Summary of key findings 
1. The commercially available non-specific NF-κB inhibitor BAY 11-7082 
was cytotoxic in all four MM cell lines tested, H929, U266B1, RPMI8226 
and JJN3, and the cytotoxicity of this agent was associated with 
inhibition of both the canonical and non-canonical NF-κB pathways. 
2. Most of the novel IKKα inhibitory SU compounds were dose-
dependently cytotoxic in RPMI8226 cells but their potency was not 
obviously related to either the inhibition of NF-κB or the down-
regulation of the anti-apoptotic protein Mcl-1. 
3. Characterisation of the SU compounds, excluding SU1257, showed that 
the effects induced by these agents could not be entirely explained by 
their kinase inhibitory profiles for IKKα, IKKβ and CDK9. 
4. Microarray analysis revealed qualitative and quantitative changes in 
gene expression induced by the individual SU compounds. Some of the 
genes affected were common to all the SU compounds tested and some 
were unique to individual SU compounds.  
5. 10 genes that were altered by treatment with the SU compounds were 
selected for qRT-PCR validation. 9/10 of the genes showed the same 
pattern of expression as that observed in the microarray analysis. 
6. The NIK inhibitor, CW15337, was dose-dependently cytotoxic in all four 
MM cell lines, although the apoptotic responses were heterogeneous. 
Cytotoxicity of CW15337 correlated with a dose-dependent decrease in 
both Mcl-1 expression and non-canonical NF-κB pathway in MM cell 
lines. Gene expression analysis using qRT-PCR showed that CW15337 
had a similar gene expression profile to the SU1349, SU1411 and SU1438 
IKKα inhibitory SU compounds, suggesting the possibility of a shared 
mechanism of action. 
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7.2. Final discussion 
7.2.1. Characterisation of NF-κB inhibitors in MM cell lines  
The work carried out in this thesis was the first project within our 
research group to use the four MM cell lines H929, U266B1, RPMI8226 and 
JJN3. Therefore, the initial step of this project involved characterisation of the 
MM cell lines in terms of growth characteristics, cell surface phenotype and 
NF-κB activity profiling. The aim was to gain an understanding of the 
individual characteristics of each MM cell line to allow planning of future 
experiments using these cell lines. The main finding of this section of work 
was that heterogeneity was observed between the four MM cell lines in all 
the characteristics evaluated; this was important as it reflected the 
heterogeneity that is commonly observed in MM.  
The key aim of this thesis was to characterise NF-κB inhibitors in the 
MM cell lines with a view to evaluate their use as therapeutic agents in this 
hematological malignancy. To achieve this, over the course of this thesis, a 
workflow was developed for characterising potential NF-κB inhibitors in MM 
cell lines. This workflow included assessment of cytotoxicity, NF-κB activity, 
the expression of the survival protein Mcl-1 and selected gene expression 
changes by qRT-PCR. A key step in this workflow was the investigation of a 
possible correlation between cytotoxicity and NF-κB activity. Using this 
workflow, the following inhibitors were investigated: the commercial non-
specific NF-κB inhibitor BAY 11-7082; a series of first-in-class IKKα inhibitors; 
and a novel NIK inhibitor in MM cell lines.  
8. When looked at together, this work supports the concept of NF-κB 
as a promising therapeutic target in MM. The non-specific NF-κB inhibitor 
BAY 11-7082, NIK inhibitor CW15337 and most of the SU compounds 
induced dose-dependent cytotoxicity in the MM cell lines. For BAY 11-7082 
and CW15337, the cytotoxicity correlated with significant and dose-
dependent changes in NF-κB activity. With respect to BAY 11-7082, a 
significant negative correlation existed between inhibition of all five nuclear 
NF-κB subunits and the induction of apoptosis, suggesting that inhibition of 
both the canonical and the non-canonical NF-κB pathways may contribute to 
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the apoptotic effect induced by BAY 11-7082 in the MM cell lines. However, it 
is more than likely that off-target inhibitory effects are responsible for the 
dose-dependent cytotoxicity of this agent as opposed to NF-κB inhibition 
(Lee et al. 2012; Rauert-Wunderlich et al. 2013; Strickson et al. 2013). By way 
of contrast, the NIK inhibitor, CW15337, significantly and dose-dependently 
down-regulated non-canonical NF-κB subunit activity in RPMI8226 cells, 
whereas canonical NF-κB subunits were not significantly affected by NIK 
inhibition. In addition, the apoptosis induced by CW15337 was accompanied 
by a dose-dependent decrease in Mcl-1 expression in all four MM cell lines. 
An interesting finding was that sensitivity of the MM cell lines to apoptosis 
induced by both BAY 11-7082 and CW15337 was heterogeneous, and was 
inversely associated with the baseline level of overall constitutive NF-κB 
activity that each MM cell line possessed. 
9. Characterisation of the SU compounds in the MM cell line 
RPMI8226 suggested that, unlike BAY 11-7082 and CW15337, the cytotoxicity 
of these agents did not correlate with the dose-dependent down-regulation of 
NF-κB activity or expression of the anti-apoptotic protein Mcl-1. 
Furthermore, the cytotoxicity of each compound could not be completely 
explained by their respective inhibitory profiles with regards to IKKα, IKKβ 
and CDK9 inhibition. For example, an interesting finding was that SU 
compounds that appeared to have comparable kinase inhibitory profiles, 
such as the potent IKKα inhibitors SU1053 and SU1349, were shown in 
Chapter 4 to induce contrasting levels of cytotoxicity in RPMI8226 cells. This 
suggested that the SU compounds, especially those with higher potency, 
inhibited other molecular targets, which contributed to their cytotoxicity. 
Moreover, the fact that SU1053 was one of the least cytotoxic SU compounds, 
despite its potency as an IKKα inhibitor, may suggest that targeting IKKα 
alone may not be sufficient for the effective treatment of MM. 
10. Therefore, to gain a deeper understanding of the mode of action of 
the SU compounds, global gene expression was investigated using an 
Affymetrix GeneChip® HTA 2.0 gene chips. The microarray analysis of the 
SU compounds tested revealed qualitative and quantitative changes in gene 
221
	  	  
expression. Some of the genes affected were common to all compounds and 
others were unique to each SU agent. Another key finding was that the 
number of genes that were differentially regulated by SU1349 was 
significantly much higher than the number regulated individually by 
SU1053, SU1438 and SU1411. Moreover, the pattern that emerged was that an 
increase in the number of differentially regulated genes correlated with the 
cytotoxicity of that SU agent in RPMI8226 cells. Therefore, it seems likely that 
the relatively increased cytotoxicity of some of the SU compounds, similar to 
BAY 11-7082 (Lee et al. 2012; Rauert-Wunderlich et al. 2013; Strickson et al. 
2013), is likely to arise as a consequence of off-target inhibitory effects.  
11. A selection of 10 genes were chosen based on their biological 
regulation by the SU compounds in RPMI8226 cells. These genes were used 
to successfully validate the microarray data using qRT-PCR and were also 
used to assess the relative effects of CW15337 in the same cell line. 
Comparative analysis of these 10 genes showed that CW15337 had a similar 
effect to SU1349, SU1411 and SU1438, which were the three more cytotoxic 
SU compounds. However, CW15337 had a quantitatively distinct pattern of 
gene regulation when compared to the SU compounds, suggesting that its 
mechanism of action may differ slightly from that of the IKKα inhibitors. This 
was confirmed by the fact that CW15337 only inhibited the non-canonical 
pathway signalling, whereas the SU compounds inhibited both the canonical 
and non-canonical NF-κB pathways. On the other hand, Supplementary 
Figure XV demonstrates that CW15337 has many kinase targets, including 
JAK2 and MAP4K2, which may contribute to the comparatively different 
regulation of the 10 genes selected from the microarray analysis. For this 
reason, a genome-wide investigation of the effects of CW15337 is merited to 
investigate whether, similar to BAY 11-7082 (Lee et al. 2012; Rauert-
Wunderlich et al. 2013; Strickson et al. 2013) and SU1349, more off-target 
inhibition is evident. 
12. Overall, the data in this thesis shows that the novel NIK inhibitor 
CW15337 was comparatively more potent at inducing cytotoxicity in the MM 
cell lines when compared to the non-specific pan IKK inhibitor BAY 11-7082 
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and the novel IKKα inhibitors evaluated in this project. Moreover, relative to 
the SU compounds, CW15337 was a more potent inhibitor of Mcl-1 
expression and induced more selective inhibition of the non-canonical NF-κB 
pathway in MM cell lines, which likely contributes to the apoptotic effect of 
this agent. Therefore, the data presented in this thesis would suggest that 
NIK inhibition represents a promising therapeutic strategy for targeting MM. 
7.2.2. Limitations of this study and suggested future work 
The initial hypothesis for the work surrounding the evaluation of NF-
κB inhibitors in MM, was that the MM cell lines that possessed a high-level of 
NF-κB activity would be inherently more dependent on these signalling 
pathways for survival. Therefore, NF-κB inhibition would selectively target 
MM cells that relied more heavily on constitutive NF-κB activity. This is 
sometimes referred to as oncogene addiction (Torti a Trusolino 2011). An 
interesting finding of this thesis was that MM cell lines that possessed a 
relatively high level of constitutive NF-κB activity were comparatively more 
resistant to apoptosis induced by the non-specific NF-κB inhibitor BAY 11-
7082 and the NIK inhibitor CW15337. This could potentially present a flaw in 
the rationale for targeting MM using specific NF-κB inhibitors and may 
indicate that cells that possess lower levels of NF-κB activity, such as non-
malignant cells, may be sensitive to NF-κB inhibition, resulting in adverse 
toxicity. For this reason, one of the next steps for this work would be to 
evaluate the use of the novel SU compounds and CW15337 in normal B-cells 
to determine whether a positive therapeutic index exists between malignant 
cells and normal cells. 
A more complete structure activity analysis would also be important; 
this was not possible in the present study as the chemical structures of the 
individual SU compounds were not divulged due to outstanding intellectual 
property issues. Furthermore, the kinase inhibitory profile data, kindly 
provided by Prof. Simon Mackay, only included information on IKKα, IKKβ 
and CDK9. This means that it is possible that these agents may potently 
inhibit other targets, including other kinases, which might explain the 
findings reported in this thesis.  
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A critique of the work carried in this thesis would be the dominant use 
of MM cell lines as opposed to primary material. Initially, I planned to use 
primary MM cells derived from patients to provide a more realistic 
evaluation of the NF-κB inhibitors. However, it became apparent in the 
earlier stages of this project that the experiments used to characterise the NF-
κB inhibitors used a relatively large number of cells, which made routine use 
of clinical samples impossible.  
Consequently, the RPMI8226 cell line was used for the characterisation 
of the SU compounds. I would have liked to also evaluate the SU compounds 
in the other MM cell lines to allow a comparison of their sensitivity and to 
investigate whether, like BAY 11-7082 and CW15337, the sensitivity to 
apoptosis induced by the SU compounds varied between these cell lines. 
However, the time constraints of this project pressed me into selecting a 
‘representative’ MM cell line to allow appropriate evaluation of the nine 
novel SU compounds. RPMI8226 was chosen because this cell line was found 
to possess an intermediate level of constitutive NF-κB activity (Chapter 3) 
and possessed genetic abnormalities associated with constitutive non-
canonical NF-κB signalling (Annunziata et al. 2007; Keats et al. 2007; 
Demchenko et al. 2010). Another reason why the RPMI8226 cell line was 
chosen for the SU compound characterisation was that this MM cell line was 
found to express CD40, and CD40L stimulation induced a significant increase 
in both the canonical and non-canonical NF-κB activity. Interaction of 
malignant plasma cells with the BMM provides a supportive tumour 
environment, and CD40L stimulation is one factor that contributes to this 
effect in vivo (Coope et al. 2002; Tai et al. 2003; Hauer et al. 2005). Therefore, 
further work could include investigating the role that prior CD40L 
stimulation has on the sensitivity of the RPMI8226 cell line to apoptosis 
induced by the NF-κB inhibitors evaluated throughout this thesis. This 
would address the question as to whether increased NF-κB activity could 
increase the resistance of this cell line to cytotoxicity induced by the NF-κB 
inhibitors, and may highlight the role of the tumour microenvironment in 
protecting MM cells from potential therapies targeting the NF-κB pathway. 
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Another limitation of the work carried out in this thesis is the 
dependence on the techniques EMSA and ELISA to characterise NF-κB 
activity in the four MM cell lines, and the dependence mainly on ELISA to 
quantify the effect of the NF-κB inhibitors in the MM cell line RPMI8226. As 
discussed throughout this thesis, the ELISA potentially possessed caveats 
that meant that the sole use of this technique might not have been 
appropriate to fully answer the research questions posed. As shown briefly in 
Chapter 4, by using the right combination of antibodies (p-p100, p100, p52, 
IκBα and p-p65), western blotting could have provided more in depth 
information about specific NF-κB pathway processing. For this reason, it 
would have been more appropriate to have used western blotting as an 
additional or replacement technique for more definitively determining both 
canonical and non-canonical NF-κB pathway processing in the MM cell lines 
at baseline, and following treatment with the NF-κB inhibitors.  
Despite the limitations already described, this study produced the first 
genome-wide microarray dataset analysing the use of novel IKKα inhibitors 
in MM. The analysis performed in this thesis focused on the DE gene 
expression induced by the SU compounds. Therefore, many other parts of the 
dataset could be analysed including alternate splicing events, various 
microRNA and more analysis of the pathways indicated by regulation of DE 
genes. This would potentially allow a greater understanding of the effects of 
the SU compounds in MM.  
7.2.3. The future of NF-κB targeting in the treatment of MM 
Overall, my final thoughts are that targeting the NF-κB pathways in 
MM could be described as a double-edged sword. Although targeting NF-κB 
may provide a promising therapeutic strategy for the treatment of MM due 
to the reliance that this disease has on NF-κB activation, NF-κB is involved in 
the regulation of a number of biological processes and global inhibition of 
NF-κB has been shown to induce a number of toxicities related to immune 
suppression and inflammation (DiDonato et al. 2012). Therefore, the 
development of NF-κB inhibitors that selectively target specific components 
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of the NF-κB pathway could potentially minimise the serious toxicities that 
are associated with global inhibition.  
In keeping with this concept, multiple IKKβ inhibitors have been 
shown to be moderately successful in targeting MM (Hideshima et al. 2002; 
Bharti et al. 2003; Hideshima et al. 2006; Annunziata et al. 2007; Jourdan et al. 
2007; Hideshima et al. 2009). However, concerns over their safety profiles has 
prevented further development of these specific agents (Li et al. 1999a; Li et 
al. 1999b; Tanaka et al. 1999; Greten et al. 2007; Vallabhapurapu a Karin 2009; 
Hsu et al. 2011). For this reason, specific inhibition of the non-canonical NF-
κB pathway may provide an alternative method for therapeutically targeting 
MM.  
On the other hand, this thesis indicates that targeting IKKα alone may 
not provide a suitable treatment for MM, and instead inhibiting the non-
canonical NF-κB pathway using specific NIK inhibitors, such as CW15337, 
may be more beneficial. However, more work is required to understand the 
effects that NIK inhibition may have on non-malignant cells, to avoid adverse 
toxicities, and explore the protective role that the tumour microenvironment 
may play in protecting MM cells from the anti-tumour effects of NIK 
inhibition. Due to the heterogenic nature of MM, the use of NIK inhibitors 
should be evaluated in a larger selection of MM cell lines and MM patient 
samples to determine the range of responses to NIK inhibition. This could 
help to identify patient characteristics, stage and/or genetic abnormalities 
that identify patients who might benefit from frontline treatment with a NIK 
inhibiting agent. This would be particularly beneficial if NIK inhibition was 
found to be effective in the high-risk MM patient group because in this 
patient population progression-free survival is limited (Kumar et al. 2008; 
Naymagon a Abdul-Hay 2016). 
Further to the above, the use of a both IKKα and NIK inhibitors should 
be explored in combination with the current MM treatments such as 
bortezomib, pomalidomide and dexamethasone, all of which have been 
suggested to act synergistically with specific NF-κB inhibitors (Keifer et al. 
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2001; Mitsiades et al. 2002a; Mitsiades et al. 2002c). Bortezomib and IKKα or 
NIK inhibitors would be particularly interesting combinations to investigate 
in MM because Bortezomib has been shown to induce some of its therapeutic 
activity through the inhibition of the canonical NF-κB signalling pathway 
(Hideshima et al. 2001; Hideshima et al. 2002). Therefore, this combination 
may inhibit global NF-κB inhibition in MM to induce the most extreme anti-
cancer effects while providing the potential to minimise adverse events. This 
may provide the most efficacious treatment combination to eradicate MM 
cells and prevent the emergence of treatment resistant sub-clonal populations 
in MM, which usually leads to patient relapse or refractory disease (Egan et 
al. 2012; Magrangeas et al. 2013).  
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Table I Down-regulated DE genes unique to the UT vs. SU1349 contrast. 
The genes represented in this list correspond to the 419 DE genes referred to in Figure 
5.7. 
ADSS CASP2 DHX57 GNL2 
AHCTF1 CASP3 DIMT1 GOLPH3L 
AIMP2 CCDC101 DNAJA1 GPAM 
AKAP9 CCDC117 DNAJB1 GPATCH1 
AKTIP CCDC138 DOLK GPR135 
ALAS1 CCNE2 DOLPP1 GRWD1 
AMD1 CCNF DPH2 GTF2A1 
ANKRD10-IT1 CCP110 DYNC1LI1 GTPBP8 
ANKRD13C CCR2 E2F6 GXYLT1 
ANKRD32 CDC23 E2F7 H3F3B 
ANLN CDC25A E2F8 HCFC2 
APEX2 CDC40 EEA1 HCP5 
ARHGAP11A CDC5L EFNA4 HEATR6 
ARHGAP11B CDC6 EIF2AK3 HELB 
ARL13B CDC7 EPC2 HEXIM1 
ASNSD1 CDCA7 ERRFI1 HMGCR 
ASTE1 CDK12 ESF1 HMGCS1 
ASXL2 CDK17 ETAA1 HSF2 
ASXL3 CDS1 EXO1 HSPA1A 
ATG14 CEBPZ F8A2 HSPA1B 
ATMIN CENPC1 FAM111B HSPA8 
ATP6V1B2 CEP152 FAM116A ICT1 
AURKA CEP350 FAM122A ID2 
B4GALT5 CEP85 FAM54A ID2B 
BAG2 CHD1 FAM59A IKZF5 
BCAS2 CHKA FAM72A IMP3 
BIRC3 CHML FAM72B INTS6 
BLZF1 CKAP2L FAM72C INTS7 
BORA CKS2 FAM72D ISCA1P1 
BRCA2 CLSPN FANCL IVNS1ABP 
BRWD1 CNTRL FANCM JMY 
C11orf82 COIL FASTKD1 KAT7 
C12orf29 COMMD2 FASTKD2 KBTBD8 
C12orf35 CREB1 FBXL3 KCNQ5-IT1 
C12orf4 CRNKL1 FBXO21 KCTD12 
C14orf135 CRY1 FBXO32 KDM4A 
C15orf23 CRYBG3 FERMT1 KIAA1731 
C15orf42 CXCR4 FIGNL1 KIF11 
C16orf70 DBR1 FLJ27352 KIF18A 
C18orf54 DCLRE1A FTSJ3 KIF20B 
C1orf135 DDX10 GCLC KIF21A 
C21orf91 DDX20 GDPGP1 KIF23 
C2orf44 DDX3X GEN1 KIF2C 
C2orf69 DDX52 GLMN KIF5B 
C7orf26 DENND4C GMNN KLHL11 
CAMSAP2 DHX36 GMPS KLHL12 
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KLHL20 MTERFD1 PRDM4 SMEK1 
KRIT1 MTF2 PRIM1 SMG8 
LDLR MTIF2 PRPF39 SMURF2 
LEO1 MYB PRRG4 SMYD5 
LMTK2 MYNN PTCD2 SNORA81 
LOC100190986 NABP1 RAD17 SNORD1B 
LOC100288842 NBN RBBP5 SNORD75 
LOC100506294 NBPF1 RBL1 SPAST 
LOC643837 NBPF16 RBM25 SPOPL 
LONRF1 NBPF24 RBM28 SPTLC3 
LRIF1 NBPF8 RBM34 SRSF7 
LRIG2 NBPF9 RFWD3 STAG3L4 
LRIG3 NDUFAF4 RIOK1 STAM2 
LSG1 NKAP RIPK1 STIL 
MADD NLK RIPK2 SUCNR1 
MALT1 NOC3L RN5S82 SYNJ1 
MAP3K1 NOL11 RND3 SYNRG 
MARS2 NPAT RNF122 TACO1 
MAT2A NR1D1 RNU7-40P TADA1 
MB21D1 NRARP ROCK2 TAF1A 
MED19 NT5DC3 RPAP3 TAF4B 
MED21 NUAK2 RPF1 TAF5 
MED8 NUFIP1 RPF2 TAGAP 
MEPCE NUP153 RPP40 TDG 
METTL1 ORC5 RRP15 TFB2M 
METTL13 OSBPL11 RSBN1L TFRC 
METTL14 PANX1 RUNX1-IT1 TGFBR2 
METTL18 PAPOLG RYBP THOC1 
MGA PDP2 SAP130 THUMPD2 
MGC27345 PELI1 SASS6 TIMM22 
MGC57346 PGBD4 SELRC1 TIPIN 
MIER3 PHAX SETDB2 TLR4 
MINA PHLPP2 SGOL1 TMCO7 
MIR1184-1 PI4K2A SH2D4A TMEM138 
MIR1184-2 PIGA SHQ1 TMEM184C 
MIR1281 PIK3CB SIRT1 TMEM185B 
MIR186 PIK3R1 SKIL TMEM39A 
MIR4427 PLEKHA3 SLC19A2 TMEM60 
MIR4659A PLK4 SLC20A1 TMTC3 
MIR4737 PNRC2 SLC25A19 TNFRSF1B 
MIS18BP1 POC5 SLC25A33 TRAF6 
MLLT10 POGK SLC29A3 TRAFD1 
MORC3 POLA2 SLC35A1 TRIM59 
MOSPD1 POLR1B SLC35A5 TSC22D2 
MPV17L2 POLR1E SLC38A2 TTF1 
MRPL39 POLR3B SLC4A1AP TTK 
MSANTD4 POLR3C SLK TTPAL 
MSH6 PPIF SMARCAD1 TUBB4B 
MSMO1 PPWD1 PTCD2 SNORA81 
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MT1X PRAMEF2 RAD17 SNORD1B 
TUBD1 VANGL1 ZBTB41 ZNF518A 
TULP3 VEZF1 ZCCHC10 ZNF556 
UPF3B WDR47 ZCCHC8 ZNF600 
URB2 WDR76 ZFP36L2 ZNF614 
USP1 WDR89 ZNF10 ZNF770 
USP12 WEE1 ZNF184 ZNF776 
USP31 WSB1 ZNF280C ZNF93 
UTP11L YARS2 ZNF322 ZNHIT6 
UTP15 YEATS4 ZNF322P1 ZRANB1 
UTP18 ZBTB40 ZNF468 ZNF518A 	  	  	  	  	  	  	  	  	  	  
Table II Up-regulated DE genes unique to the UT vs. SU1349 contrast. 
The genes represented in this list correspond to the 83 DE genes referred to in Figure 
5.7. 
ACOT12 CSAD LAMB2P1 NEXN-AS1 
ACRC CTLA4 LAMB4 NPR3 
ADAM20P1 DDR2 LHFPL3-AS2 OMG 
ARL9 DIO2 LOC100128288 OOEP 
AVIL EFCAB8 LOC100506606 OR11H12 
BAAT EPHX3 LOC100506855 OR2AE1 
BCAR4 ERP27 LOC200726 OR2K2 
BCL2L10 FGF7 LOC339894 OR9A1P 
BTLA FNDC7 LOC348120 OR9A3P 
C12orf5 GOLGA6C LOC93432 PLAC8L1 
C14orf178 HMP19 LRGUK PLCL2-AS1 
C1orf138 HTR1D LRRTM2 PNLDC1 
C1orf162 ICOS LY6G5B PYGM 
C1orf189 IDI2 MGAM RFPL3-AS1 
C5orf47 IDI2-AS1 MGARP SERPINC1 
CASS4 IGKV4-1 MICALCL SLC22A1 
CCDC62 IGKV5-2 MIR4514 SLC23A1 
CDKL2 ITGA1 MSH4 SLC9C2 
COL14A1 ITGB1BP2 MSTN TMED6 
CPB2 KIAA0825 MYO5C VHLL 
CPLX4 KLRAP1 NEB  
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Table III Alternate DE genes for the UT vs. SU1349 contrast where Log2 (FC) ≥ 1.5 in 
both directions, and p ≤ 0.05. 
The genes represented in this list correspond to the 92 DE genes used in the Enrichr 
analysis for the UT vs. SU1349 contrast. The 58 down regulated DE genes (Log2 (FC) ≤ 
-1.5 and p ≤ 0.05) are shown on the left and the 34 up regulated DE genes (Log2 (FC) ≥ 
1.5 and p ≤ 0.05) are shown on the right.	  
Log2 (FC) ≤ -1.5 Log2 (FC) ≥ 1.5 
BLZF1 MED21 ACOT12 PLCL2-AS1 
C15orf42 MIER3 ACRC PNLDC1 
C2orf44 MIR4500 ADAM20P1 SLC10A5 
CCNE2 MIR4737 ARL9 TMED6 
CEP85 MTF2 BAAT VHLL 
CHKA MYNN C12orf5  
CKAP2L PAPOLG C1orf162  
CLSPN PIK3R1 C1orf189  
DIMT1 POC5 C5orf47  
DNAJB1 POLA2 CASS4  
EFNA4 POLR3B CPB2  
EPC2 RFXAP CPLX4  
EXO1 RIOK1 CTLA4  
FAM111B RIPK1 ERP27  
FAM72D RND3 ICOS  
GDPGP1 RPF2 IDI2-AS1  
HEATR3 RPP40 ITGA1  
HEATR6 SAP130 LHFPL3-AS2  
HELB SIRT1 LOC100128288  
HMGCR SLC25A19 LOC100506606  
HMGCS1 SLC38A2 LOC100506855  
HSPA1B SRSF7 LOC339894  
INTS7 TAF5 LRRTM2  
KCNQ5-IT1 TMEM185B MGAM  
KDM4A TRAF6 MSH4  
KIF20B VEZF1 MSTN  
KIF23 ZNF280C OMG  
LDLR ZNF322 OR11H1  
MB21D1 ZNF322P1 OR9A3P  
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     SU1438 
 
 
     SU1411 
 
 
     SU1349 
 
 
Figure II The number of DE genes associated with each GO category for the 
comparisons UT vs. SU1438, UT vs. SU1411 and UT vs. SU1349. 
The DE gene lists for UT vs. SU1438 and UT vs. SU1411 (Log2 (FC) ≥ 1 and p ≤ 0.05.) 
and UT vs. SU1349 (Log2 (FC) ≥ 1.5 and p ≤ 0.05.) were inserted into Enrichr separately 
to retrieve a list of GO terms associated with each list of DE genes. The GO terms were 
sorted into GO categories using R Studio and the number of DE genes appearing in 
each GO category is shown for each SU compound in the bar graphs. 
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Table VII The resulting DE gene lists for SU1438, SU1411 and SU1349 contrasts 
based on their GO category relevance. 
The 21, 25 and 41 selected DE genes selected based on their enrichment analysis result 
for GO category for SU1438, SU1411 and SU1349. A DE gene for SU1438 and SU1411 
is Log2 (FC) ≥ 1 and p ≤ 0.05, whereas for SU1349 it is Log2 (FC) ≥ 1.5 and p ≤ 0.05.	  
UT vs. SU1438 UT vs. SU1411 UT vs. SU1349 
ANXA1 UBR5 SIRT1 
ATP7A RASA1 ITGA1 
PRKCI PRKCI HMGCR 
RASA1 ATRX PIK3R1 
CMYA5 UBR2 RIPK1 
GCNT4 RGS2 TRAF6 
OFD1 ATP7A CLSPN 
SRSF6 PDE5A EXO1 
BCL9 OFD1 KDM4A 
BCLAF1 IQGAP2 KIF23 
CLPX CMYA5 LDLR 
POLR2A SOX30 MSH4 
SOX30 CLPX MTF2 
DAAM1 BCLAF1 CPB2 
CTNND1 SMEK2 DNAJB1 
NOL8 NOL8 POLA2 
SLC20A1 NSUN2 POLR3B 
UBA2 CTNND1 CTLA4 
ARL17A AKAP5 EPC2 
METTL4 UBA2 HMGCS1 
STAG1 IGF2BP3 INTS7 
 CSE1L KIF20B 
 PDS5B LRRTM2 
 NUF2 MSTN 
 ARL17A OMG 
  HELB 
  SAP130 
  SRSF7 
  TAF5 
  VEZF1 
  BLZF1 
  MB21D1 
  RND3 
  CPLX4 
  DIMT1 
  EFNA4 
  ERP27 
  SLC38A2 
  CCNE2 
  CASS4 
  ARL9 
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Table XI The quantitative expression data UT vs. SU1438 (p ≤ 0.05, Log2FC ≥ 1) 
selected DE genes based on the pathway enrichment analysis results. 
The table presents the Log2 expression (mean ± SEM), Log2 (FC) and the adjusted p 
value where n = 3 of the 8 DE genes selected based on pathway enrichment analysis 
results for UT vs. SU1438. Down regulated DE genes are shown in red and up 
regulated are in green. 
  
 RMA normalised 
Log2 expression 
Log2 (FC) 
Adjusted p 
value 
PRKCI 
UT 7.98 ± 0.14 
-1.332 4.79×10-4 
SU1438 6.65 ± 0.01 
 
OFD1 
UT 7.32 ± 0.18 
-1.151 1.02×10-3 
SU1438 6.17 ± 0.25 
 
SRSF6 
UT 8.92 ± 0.12 
-1.006 5.40×10-4 
SU1438 7.91 ± 0.05 
 
BCL9 
UT 6.94 ± 0.25 
-1.005 1.05×10-2 
SU1438 5.94 ± 0.12 
 
POLR2A 
UT 8.79 ± 0.04 
-1.137 1.61×10-3 
SU1438 7.65 ± 0.05 
 
UBA2 
UT 8.34 ± 0.11 
-1.057 9.87×10-4 
SU1438 7.28 ± 0.08 
 
STAG1 
UT 7.17 ± 0.16 
-1.018 5.28×10-3 
SU1438 6.15 ± 0.07 
 
DAAM1 
UT 5.15 ± 0.23 
-1.156 8.19×10-4 
SU1438 4.00 ± 0.07 
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Table XII The quantitative expression data UT v.s. SU1411 (p ≤ 0.05, Log2FC ≥ 1) 
selected DE genes based on the pathway enrichment analysis results. 
The table presents the Log2 expression (mean ± SEM), Log2 (FC) and the adjusted p 
value where n = 3 of the 6 DE genes selected based on pathway enrichment analysis 
results for UT vs. SU1411. Down regulated DE genes are shown in red and up 
regulated are in green. 
  
 RMA normalised 
Log2 expression 
Log2 (FC) 
Adjusted p 
value 
PRKCI 
UT 7.98 ± 0.11 -1.797 3.58×10-5 
SU1411 6.18 ± 0.17 
 
OFD1 
UT 7.32 ± 0.15 -1.096 1.58×10-3 
SU1411 6.23 ± 0.13 
 
UBA2 
UT 8.34 ± 0.11 
-1.201 3.71×10-4 
SU1411 7.14 ± 0.12 
 
PDS5B 
UT 6.88 ± 0.17 -1.170 6.01×10-3 
SU1411 5.71 ± 0.14 
 
NUF2 
UT 6.63 ± 0.34 -1.227 4.88×10-2 
SU1411 5.40 ± 0.16 
 
NSUN2 
UT 7.64 ± 0.03 
-1.124 1.54×10-4 
SU1411 6.52 ± 0.13 
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Table XIII The quantitative expression data UT v.s. SU1349 (p ≤ 0.05, Log2FC ≥ 1.5) 
selected DE genes based on the pathway enrichment analysis results. 
The table presents the Log2 expression (mean ± SEM), Log2 (FC) and the adjusted p 
value where n = 3 of the 9 DE genes selected based on pathway enrichment analysis 
results for UT vs. SU1349. Down regulated DE genes are shown in red and up 
regulated are in green. 
  
 RMA normalised 
Log2 expression 
Log2 (FC) 
Adjusted p 
value 
PIK3R1 
UT 6.11 ± 0.16 
-1.556 1.73×10-6 
SU1349 4.56 ± 0.19 
 
TRAF6 
UT 6.53 ± 0.08 
-1.537 1.06×10-7 
SU1349 5.00 ± 0.23 
 
RIPK1 
UT 7.27 ± 0.06 
-1.568 1.80×10-8 
SU1349 5.70 ± 0.13 
 
CLSPN 
UT 7.25 ± 0.10 
-1.771 2.87×10-5 
SU1349 5.48 ± 0.36 
 
POLA2 
UT 8.33 ± 0.10 
-1.629 8.35×10-5 
SU1349 6.70 ± 0.37 
 
POLR3B 
UT 6.74 ± 0.05 
-1.567 2.46×10-7 
SU1349 5.17 ± 0.14 
 
SRSF7 
UT 7.53 ± 0.07 
-1.707 3.18×10-6 
SU1349 5.82 ± 0.18 
 
TAF5 
UT 6.05 ± 0.16 
-1.876 2.12×10-7 
SU1349 4.17 ± 0.11 
 
CCNE2 
UT 5.86 ± 0.06 
-1.817 4.72×10-7 
SU1349 4.04 ± 0.03 
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RPS14 
A  
	  
B 
	  	  
Figure III Representative examples of a melting curve and an amplification plot 
produced when the RPS14 primer pair is used in qRT-PCR as an endogenous 
control.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
RPS14 was used as an endogenous control gene in all qRT-PCR experiments. 
Representative examples of a RPS14 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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TRAF6 
A  
	  
 
B 
	  	  
Figure IV Representative examples of a melting curve and an amplification plot 
produced when the TRAF6 primer pair was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
TRAF6 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a TRAF6 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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RIPK1 
A  
	  
 
B 
	  	  
Figure V Representative examples of a melting curve and an amplification plot 
produced when the RIPK1 primer pair was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
RIPK1 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a RIPK1 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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POLA2 
A  
	  
 
B 
	  	  
Figure VI Representative examples of a melting curve and an amplification plot 
produced when the POLA2 primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
POLA2 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a POLA2 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n).The data shown represents n = 3, duplicate. 
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SRSF7 
A  
	  
 
B 
	  	  
Figure VII Representative examples of a melting curve and an amplification plot 
produced when the SRSF7 primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
SRSF7 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a SRSF7 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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POLR2A 
A  
	  
 
B 
	  	  
Figure VIII Representative examples of a melting curve and an amplification plot 
produced when the POLR2A primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
POLR2A was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a POLR2A melting curve (A) and amplification plot (B) 
are shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
280
	  	  
SRSF6 
A  
	  
 
B 
	  	  
Figure IX Representative examples of a melting curve and an amplification plot 
produced when the SRSF6 primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
SRSF6 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a SRSF6 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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PRKCI 
A  
	  
 
B 
	  	  
Figure X Representative examples of a melting curve and an amplification plot 
produced when the PRKCI primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
PRKCI was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a PRKCI melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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OFD1 
A  
	  
 
B 
	  	  
Figure XI Representative examples of a melting curve and an amplification plot 
produced when the OFD1 primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
OFD1 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a OFD1 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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UBA2 
A  
	  
 
B 
	  	  
Figure XII Representative examples of a melting curve and an amplification plot 
produced when the UBA2 primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
UBA2 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a UBA2 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
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NSUN2 
A  
	  
 
B 
	  	  
Figure XIII Representative examples of a melting curve and an amplification plot 
produced when the NSUN2 primer was used in qRT-PCR.  
qRT-PCR was used to validate the DE genes identified through microarray analysis. 
NSUN2 was one of those DE genes validated using qRT-QPCR experiments. 
Representative examples of a NSUN2 melting curve (A) and amplification plot (B) are 
shown for untreated RPMI8226 cells (n) and RPMI8226 cells treated for 4h with 
SU1411 (n). The data shown represents n = 3, duplicate. 
285
	  	  
   
   
   
   
   
   
U
T 
1 
 
   
   
   
   
   
  R
IN
: 1
0	  
   
   
  U
T 
2 
 
   
   
  R
IN
: 9
.9
	  
U
T 
3 
 
R
IN
: 1
0	  
	  
	  
   
   
   
   
   
   
SU
12
57
 1
 
   
   
   
   
   
   
R
IN
: 1
0	  
   
   
  S
U
12
57
 2
 
   
   
   
R
IN
: 1
0	  
SU
12
57
 3
 
R
IN
: 9
.8
	  
	  
	  
   
   
   
   
   
  S
U
10
53
 1
 
   
   
   
   
   
  R
IN
: 1
0	  
   
   
  S
U
10
53
 2
 
   
   
   
R
IN
: 1
0	  
SU
10
53
 3
 
R
IN
: 1
0	  
	  
286
	   
   
   
   
   
   
   
 S
U
14
38
 1
  
   
   
   
   
   
   
R
IN
: 9
.7
	  
   
   
  S
U
14
38
 2
  
   
   
  R
IN
: 1
0	  
SU
14
38
 3
  
R
IN
: 9
.9
	  
	  
	  
   
   
   
   
   
   
SU
14
11
 1
 
   
   
   
   
   
  R
IN
: 1
0	  
   
   
  S
U
14
11
 2
 
   
   
  R
IN
: 1
0	  
SU
14
11
 3
 
R
IN
: 9
.9
	  
	  
	  
	  
   
   
   
   
   
  S
U
13
49
 1
 
   
   
   
   
   
 R
IN
: 1
0	  
   
   
  S
U
13
49
 2
 
   
   
  R
IN
: 1
0	  
SU
13
49
 3
 
R
IN
: 1
0	  
	  
Fi
gu
re
 X
IV
 T
h
e 
R
N
A
 in
te
gr
it
y 
n
u
m
b
er
 o
f 
th
e 
q
R
T
-P
C
R
 R
N
A
 e
xt
ra
ct
s 
u
se
d
 f
or
 v
al
id
at
io
n
 o
f 
th
e 
m
ic
ro
ar
ra
y.
 
T
he
 q
ua
lit
y 
of
 th
e 
R
N
A
 g
en
er
at
ed
 fo
r 
th
e 
qR
T
-P
C
R
 to
 v
al
id
at
e 
th
e 
m
ic
ro
ar
ra
y 
d
at
a 
w
as
 te
st
ed
 b
y 
m
ea
su
ri
ng
 th
e 
R
N
A
 in
te
gr
it
y 
nu
m
be
r 
(R
IN
) u
si
ng
 
an
 A
gi
le
nt
 2
10
0 
B
io
an
al
yz
er
 S
ys
te
m
. 
T
he
 e
le
ct
ro
ph
er
og
ra
m
s 
fo
r 
ea
ch
 s
am
pl
e 
w
er
e 
us
ed
 t
o 
ca
lc
ul
at
e 
R
IN
 a
nd
 c
le
ar
ly
 s
ho
w
 t
he
 t
w
o 
m
ai
n 
pe
ak
s 
co
rr
es
po
nd
in
g 
to
 1
8S
 a
nd
 2
8S
 r
ib
os
om
al
 R
N
A
, r
es
pe
ct
iv
el
y.
 A
n 
R
IN
 th
re
sh
ol
d
 o
f 6
 w
as
 s
et
 a
nd
 s
am
pl
es
 w
er
e 
on
ly
 p
ro
ce
ss
ed
 to
 c
D
N
A
 if
 R
IN
 >
 6
. 
287
	   	  
	   Figu
re
 X
V
 T
h
e 
k
in
om
e 
sc
re
en
in
g 
d
at
a 
fo
r 
C
W
15
33
7 
at
 a
 c
on
ce
n
tr
at
io
n
 o
f 
1µ
M
.  
T
hi
s 
fi
gu
re
 w
as
 p
ro
vi
d
ed
 b
y 
Pr
of
. 
Si
m
on
 M
ac
K
ay
 a
t 
th
e 
U
ni
ve
rs
it
y 
of
 S
tr
at
hc
ly
d
e.
 T
he
 p
er
ce
nt
ag
e 
of
 i
nh
ib
it
io
n 
is
 s
ho
w
n 
fo
r 
ea
ch
 k
in
as
e 
w
he
n 
C
W
15
33
7 
is
 u
se
d
 a
t a
 c
on
ce
nt
ra
ti
on
 o
f 1
µM
. 
288
	  	  
 	  
